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Abstract 
The G1uN3 subunits of the NMDA receptor are thought to reduce the Ca 2+ permeability 
and Mg2+ sensitivity of NMDA receptors. cRNA for rat NMDA receptor subunits were 
injected into Xenopus oocytes and responses were recorded using two electrode voltage 
clamp at 
-100, -75 and -50 mV. G1uN1-1a/2A, GluN1-1a/2A/3A and G1uN1-1a/2A/3B 
containing receptors were characterised using Mgz+, memantine, philanthotoxin-343, 
methoctramine and MK-801. IC50 values were calculated and generally showed significant 
increases between those containing G1uN1-1a/2A/3 subunits and G1uN1-1a/2A, while 
those with G1uN3B were found to be significantly higher than G1uN3A. Activity was also 
typically shown to be partially restored with mutations at the N and N+1 site asparagines 
of G1uN3A. As the ICS0 was only partially restored the changes cannot be attributed to 
the loss of the N-site alone. Further differences may be due to a constricted threonine 
ring within the M3 vestibule region, or due to continued reduced flux through the 
channel. Another possibility is that to restore block it may require both the double N and 
N+1 mutation at the N-site. 
Multi-target-directed ligands combine two pharmacophores to produce drugs which 
retain the properties of the constituents. Memantine has been approved for use in 
Alzheimer's disease and there is a search for drugs that have similar actions. A range of 
multi-target compounds were tested to determine if NMDA receptor blockade activity 
was obtained. The pharmacophores explored were tacrine, donepezil, lipoic acid 
carvedilol and dimebon. The most promising compounds were carbacrine(3) (tacrine and 
carvedilol) and lipocrine (lipoic acid and tacrine), and it was found that the former was 
equipotent and the latter more potent than memantine. Potency was likely due to the 
a 
tacrine moiety. These compounds should be further categorised to determine if they 
retain the kinetics that gives memantine its favourable side effect profile. 
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Introduction 
Glutamate is the main excitatory transmitter in the nervous system and two classes of 
receptor activated by it are known, ionotropic (ion channel) and metabotropic (G-protein 
coupled). The ionotropic receptors can be split into three classes N-methyl-D-aspartic 
acid (NMDA), a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and 
kainate, and are termed according to the synthetic agonist that preferentially activates 
them (Rang et al., 2007). The NMDA receptor family is further split into subtypes, 
G1uN1 which has eight spice variants; G1uN2, which has four subtypes A-D and G1uN3 
(formerly NMDAR-L or x; ' and x2) which has two subtypes A and B (see Paoletti and 
Neyton, 2006). Four subunits come together to form a functional receptor that are 
mainly comprised of two pairs of G1uN1 /2 dimers in a1 /2/ 1 /2 formation creating a 
pore that is highly Ca2+ permeable (Sobolevsky et al., 2009). It is thought that the G1uN3 
subunit is rapidly incorporated into receptor assemblies, but its stoichometry is unknown 
(Tong et al., 2007). 
The GluN3 subunits of the NMDA receptor are the most recently discovered and what 
effect its presence has on the ion channel is currently unknown, although due to amino 
acid changes in the pore it is thought to reduce Mg2+ sensitivity and Ca 2+ permeability 
(see Paoletti and Neyton, 2006). With these changing properties and the fact that 
expression peaks during development it has led to the suggestion that the G1uN3 
subunits protect neurones from excitotoxicity, or help produce mature synapses (see 
Henson et al. 2010). Another suggestion has been that the G1uN3 subunit tags receptors 
for removal as they have been shown to allow rapid endocytosis from the membrane 
(Perez-Otano et al., 2006). Although the expression patterns in rat seem to suggest a link 
to development, in situ hybridisation studies in human show expression of G1uN3A and 
G1uN3B throughout adulthood (Nilsson et al., 2007, Henson et al., 2008, Bendel et al., 
2005, Chatterton et al., 2002, Wee et al., 2008). Further complicating any interpretation of 
function has been the reports of NMDA receptors that consisted only of G1uN1 and 
G1uN3 subunits where the GluN2 was not present which could be gated by glycine 
alone, although there has been little evidence to support their existence in vivo (Das et al., 
1998, Chatterton et al., 2002, Tong et al., 2007). Without having fully established the 
properties of open channel block (endogenous or exogenous) and identifying the residues 
involved, together with the glycine-gated complications, it has been difficult for 
researchers to conclusively state what effect the subunit has on activity of NMDA 
receptors, and what function the subunit has. 
As the GluN3 subunit has aG instead of an R at the Mg2+ binding site potency should be 
lost when the subunit is present (Wollmuth et al., 1998a, Wollmuth et al., 1998b). 
Although the effect of Mg2+ has been explored in some transgenic neuronal cultures, it 
has not been fully tested in recombinant expression systems and a full study will be 
carried out (Sasaki et al., 2002, Tong et al., 2007). Residues involved in the binding of 
memantine and MK-801 have been located in the pore region of G1uN1 /2 NMDA 
receptors (Kashiwagi et al., 2002, Chen and Upton, 2005). Therefore, these compounds 
can be tested at GluN3 containing receptors, and if their activity is impaired, residues that 
have already been implicated may help identify regions where the structure of the pore is 
altered. Furthermore, polyamine open-channel blockers such as the philanthotoxin 
(PhTX) group derived from the wasp Philanthus triangulum have been shown to block the 
AMPA ionotropic glutamate receptor, and are of interest to our group. Philanthotoxins 
show reduced block if there is an R residue at the equivalent of the NMDA receptor N- 
site within the pore of the AMPA receptor (Andersen et al., 2006). G1uN1/2 NMDA 
2 
receptors have an N at this position, but the G1uN3 subunits have aG then an R, 
therefore the PhTX compounds may have the ability to selectively antagonise NMDA 
receptors that do not contain a G1uN3 subunit. 
The current study aimed to address some of the issues outlined by carrying out a 
comprehensive categorisation of the activity of open-channel blockers at GluN3 
containing receptors. Such information will be useful in determining what changes occur 
in the pore region, and can be used to interpret what possible function the subunit may 
have in vivo. There was also the possibility that PhTX compounds may be subunit 
selective for GluNI/2 over GluN3 receptors similar to the effect of the R residue on the 
G1uA2 subunit of the AMPA receptor, and if such a molecule is discovered it would be 
useful pharmacological tool. 
The second part of the study exploited the mechanism of block by memantine to test 
new multi-target directed ligands (MTDL) for the treatment of Alzheimer's disease. In 
collaboration with the University of Bologna these new compounds were designed to 
have multiple targets and the study determined their ability to block the NMDA receptor. 
Compounds based on the acetylcholine esterases tacrine and donepezil where combined 
with compounds that had anti-oxidant activity lipocrine and the ß-blocker carvedilol to 
create new pharmacological entities. Furthermore, compounds based on dimebon a 
potential Alzheimer's disease drug, were explored to determine their NMDA receptor 
activity. Although this group of multi-target compounds were not specifically designed to 
be active at NMDA receptors tacrine, donepezil and dimebon have previously been 
shown to have this property (Wang et al., 1999, Wu et al., 2008). The ability to block 
NMDA receptors would be in any case useful in an Alzheimer's disease compound as 
that is the mechanism by which memantine has been approved for use in the disease. The 
3 
study aimed to determine if such an effect was retained by tacrine, donepezil and 
dimebon within the MTDL compound structure. 
1.1 Glutamate Receptor Classes 
The first indication that glutamate acted as a transmitter in the central nervous system 
was when its injection into the motor cortex of dogs was shown to cause convulsions 
(Hayashi, 1954). Later, ionophoretic delivery of glutamate to the spinal cord of the cat 
was found to produce similar effects (Curtis et al., 1959). Even though glutamate was 
found in very high concentrations, it was not thought that an amino acid could have a 
major role in the nervous system. It was known that other amino acids such as aspartate 
had similar effects when delivered in the same manner to the spinal cord, and it was 
thought that a non-specific amino acid receptor was involved. 
Modifications to the structure of glutamate allowed stereoselective evidence to be 
obtained that led to a specific receptor being identified (see Watkins and Jane, 2006) 
(Table 1). Glutamate did not show stereoselectivity so bulky substitutions of other amino 
acids were made to engineer this. NMDA, an aspartate analogue, was found to be a more 
potent agonist compared to the L enantiomer of the aspartate analogue providing 
evidence for the existence of a specific membrane receptor. Other glutamatergic 
receptors were also identified using chemical means. AMPA, a modification of ibotenic 
acid, was generated in the search for a more stable glutamate agonist (Krogsgaard-Larsen 
et al., 1980). Kainic acid, a glutamate analogue, was isolated from digenea simplex, a marine 
red alga and was found to potentiate L-glutamate induced depolarisation of the crayfish 
opener neuromuscular junction (Shinozaki and Shibuya, 1974b). These same researchers 
showed that quisqualic acid from the seeds ofQuisqualis indica activated the same areas of 
the crayfish opener muscle as L-glutamate (Shinozaki and Shibuya, 1974a). 
4 
Structure Name 
H, 
N 
L-glutamate 
H02C C02H 
H3 
H 
NH 
MD 
>'2ý, C02H N A HO2C 
O 
NH2 O 
H NH N Quisqualate y H02C" 
0 
H2N 
H,,. OH 
HO2C AMPA 
H3C O, 
, --C02H (I Kainate 
-co2H 
H 
Table 1: Agonists of the glutamate receptors. Shown are the endogenous agonist 
glutamate and the synthetic agonists which were selective between the receptor types NMDA, 
AMPA and Kainate. Quisqualate was originally used instead of AMPA until the latter proved 
more selective. Adapted from Watkins and Jane, (2006). 
When these compounds were tested in various experimental preparations differing 
patterns of activity were found. For instance, it was found that kainate and NMDA had 
different effects on spinal interneurones and Renshaw cells (McCulloch et al., 1974). It 
was also shown in recordings from frog spinal cord that only responses elicited by 
NMDA were inhibited by Mgt+, but not those of AMPA or kainate (Evans et al., 1979). 
In addition, a subpopulation in spinal cord preparations was found to respond more to 
kainate than AMPA or NMDA (Evans et al., 1982). Such evidence suggested that there 
5 
were different subtypes of glutamate receptor, with differing regional expression and 
differing properties. 
Although classifying the receptors based on their agonist profiles proved useful, there 
was still a subset of glutamatergic responses that were not activated by any of the agonists 
shown in table 1. When DNA sequencing became available this shed light on two 
separate classes of glutamate receptor. The first, ion channels, were found to be the class 
that responded to the synthetic agonists, and the second class were found to be G- 
protein coupled receptors (Figure 1). Those that responded to AMPA were found to be 
the subset that mediated fast excitatory transmission in the central nervous system 
(Boulter et al., 1990, Cull-Candy et al., 2006). They are constructed from four subunits 
G1uA1-4 which are encoded by the genes GRL41-4. AMPA receptors come together as a 
group of four subunits and those that lack the GluA2 subunit are permeable to Ca 2+ (see 
Isaac et al., 2007). Ion selectivity is mediated by the RNA editing of glutamine to arginine 
(the Q/R switch, equivalent to the NMDA receptor N-site) in the pore region causing 
receptors containing the subunit to be impermeable to Cat+. The predominant form of 
the AMPA receptor contains the GluA2 subunit while the G1uA2 lacking form is though 
to be expressed mainly through development possibly mediating plasticity (see Isaac et 
al., 2007). 
The receptors that responded to kainate were found using low stringency hybridisation 
probes to the AMPA sequence, and subunits in this class are termed G1uK1-5 (see 
Pinheiro and Mulle, 2006). G1uK1, G1uK2 and G1uK3 can form functional homomeric 
channels that are termed low affinity subunits due to their low affinity to kainate. G1uK4 
and G1uK5 show a high affinity but cannot form functional channels alone. They show 
less than 40% homology to the AMPA receptor subunits, and do not form channels with 
6 
G1uA1-4. G1uK1 and GluK2 also contain the Q/R switch that is found in AMPA 
receptors to reduce Ca 2+ permeability (see Pinheiro and Mulle, 2006). G1uK2 has two 
further amino acid substitutions in the first transmembrane region, isoleucine/valine 
(I/V) and a tyrosine/cysteine (Y/C), also leading to a reduction in Ca 2+ permeability. No 
regions of RNA editing have been found for the G1uK4 and G1uK5 subtypes. 
Glutamate Receptors 
lonotropic 
NMDA AMPA Kainate 
II 
GIuN1 GIuN2 GIuN3 GIuA GluK 
(8 Splice (A-D) (A-B) (1-4) (1-5) 
variants) 
Metabotropic 
Group I Group II Group III 
(PLC 1) (ACt) (ACI) 
mGlula-d mGIu2 mGlu4a, b 
mGlu5a, b mGIu3 mGIu6 
mGlu7a, b 
mGlu8a, b 
Figure 1: Glutamate receptors and their subtypes. The left branch shows the ionotropic 
glutamate receptors, followed by their agonist then the subunits. The right branch shows the 
metabotropic receptors followed by their effects on phospholipase C (PLC) and adenyl 
cyclase (AC) with the last branch showing the subunits that are involved. Adapted from 
Watkins and Jane, 2006. 
The NMDA receptor is the ionotropic glutamate receptor whose agonist is the 
compound from which it takes its name. As well as glutamate binding to the G1uN2 
subunit, NMDA receptors also require the co-agonist glycine to bind to the GluN1 
subunit for activation (lüeckner and Dingledine, 1988). In addition, at resting membrane 
potentials, there is an endogenous voltage-dependent block by Mg2+ of the NMDA 
receptor (Evans et al., 1979). Depolarisation of the membrane removes block allowing 
the channel to open. These features makes the NMDA receptor unique amongst the 
ionotropic glutamate receptors as they only respond when glutamate is present, glycine is 
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present and if the membrane is depolarised to a level which removes Mg" block. This 
means that the receptor acts as a coincidence detector which reduces temporal jitter, 
spontaneous activity and integrates the status of the input events (see Dingledine et. al. 
1999). The NMDA receptor is highly permeable to Ca" and may help trigger evens such 
as LTP (Mayer and Westbrook, 1987, Malenka and Bear, 2004). The GluN3 subunits are 
gated by glycine and there are two subtypes G1uN3A and G1uN3B (Yao and Mayer, 
2006). The presence of a G1uN3 subunit is thought to act in a dominant-negative 
manner, reducing the amplitude of inward currents, reducing Ca2+ entry and decreasing 
Mg2+ sensitivity (Yamakura et al., 2005, Tong et al., 2007). 
1.2 Receptor Structure 
1.2.1 AMPA Receptor 
The complete crystal structure for the AMPA receptor has been reported and is closely 
related to the NMDA receptor (Sobolevsky et al., 2009). The AMPA receptor is shaped 
like a capital Y with the N-terminal domain at the top and the ion channel at the bottom. 
The ligand binding domain is at the intersection of the lines of the Y, positioned like a 
block over the ion channel, occluding it when closed. The extracellular region has a two- 
fold rotational symmetry vertically down its centre with the N-terminal domain rotated 
- 
24° and the ligand binding domain rotated -19° from this axis. AMPA receptors come 
together in a dimer of dimers that are lettered A-D (Figure 2A). Dimer A/B comes 
together with dimer C/D giving an orientation that terms A/C proximal and B/D distal 
to the axis of two-fold symmetry, although referring to dimer pairs is less descriptive as 
they swap pairings across domains. At the N-terminal domain subunit A and B form a 
dimer pair; however, at the ligand binding the domains swap over so that subunit A 
forms a dimer pair with dimer C and vice versa. A/C also has extensive contacts between 
8 
the N-terminal domain and the ligand binding domain which are not present in the B/D 
dimer 
AB 
istal 
NTD 
LI< 
L2 
Dl 
LBD < 
s D2 
Figure 2: AMPA receptor composition. (A) Stoichometry of subunits. A/C are termed 
proximal, and B/D are termed the distal, to the overall two-fold axis of symmetry. (B) Cartoon 
representation of a subunit of the AMPA receptor. Adapted from Sobolevsky et al., (2009). 
At the N-terminal domain is a bilobar clamshell with the upper lobe termed L1 and the 
lower L2, the latter of which has extensive contacts across the distal subunits B and D 
(Sobolevsky et al., 2009) (Figure 2A). The contacts between the dimers A/B and C/D, as 
well as crossover contacts between the distal subunits B/D, contribute to the stability in 
N-terminal domain. At the ligand binding domain the majority of connections exist 
diagonally across the receptor structure so that the local dimer pairs would be considered 
A/C and B/D, proximal and distal to the origin of four-fold rotational symmetry. Again, 
the ligand binding domain is a clamshell structure which has an upper domain D1 and 
the lower domain D2. The AMPA receptor was crystallised in the presence of the AMPA 
receptor competitive antagonist ZK 200775 and was shown to bind within this region, 
indicating antagonism occurs within a subunit unlike, for example, the acetylcholine 
receptor (Czajkowski and Karlin, 1995, Sobolevsky et al., 2009). 
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Proximal 
At the transmembrane domain the four AMPA receptor subunits come together to form 
a pore with four-fold rotational symmetry (Sobolevsky et al., 2009). There are the four 
transmembrane segments M1, M3 and M4 and the M2 pore region which contains a pore 
lining loop. Starting at the S1 region of the ligand binding domain, pre-M1 extends and 
turns 90° so it runs parallel to the membrane (Figure 2B). Pre-Ml region has contacts 
with the amino and carboxyl end of M3 and M4 and forms a collar around the ligand 
binding domain linker regions to the membrane regions and may be involved channel 
opening. 
The Ml region lies outside the ion channel while the M2 region forms the pore that has a 
central cavity above where the Q/R site is located (Sobolevsky et al., 2009). This site is 
the Q/R switch in AMPA receptors, the `N-site' of G1uN1 and the N+1 site of GluN2 
(Wollmuth et al., 1998a, Wollmuth et al., 1998b, Sobolevsky et al., 2009). The M3 regions 
are crossed over at the level of pre-M1 at the conserved SYTANLAAF motif when the 
channel is closed, and forms the ion channel gate (Sobolevsky et al., 2009) (Figure 3 and 
Figure 4). The M3 a-helix was also shown to be longer in the A/C subunits than the 
B/D subunit. There is also further occlusion of the ion channel by M629 of the A/C 
subunits which resides above the SYTANLAAF glutamatergic ion channel conserved 
motif and may be involved in desensitisation. M3 then returns to form part of the 
ABD 
which then returns to the pore to start M4. It lies outside the ion channel and has 
significant interactions between adjacent subunits contributing to overall structure and 
function. From here this region leads to the C-terminus. 
10 
Cl) 
O 
O 
O 
O 
O 
O 
N 
O 
O 
O 
O 
O 
O 
O 
O 
O 
O 
O 
O 
O 
O 
O 
O 
O 
O 
O 
i 
Q. 
rV-NN 
1D lL ýD ýD 
HMH [il yý 
Fa 
HH 
0x cf) Z Z. 
>äzää 
HHH C4 C4 
aaxaa 
U) U7 FFF 
aCF at -- 
U) vl 0UU 
aaxxx 
n. aan na E4 azm 
H uaxx 
cW7 
ä ~q 
CI 
UH> ly 
C7 U to E E- 
7 co v) Zaa 
oaZZ C7 C: EawE. w 
a>aa 
33r 
cn cn 
.]VU E. a>a 
- 1-1 11 C14 ci) 
3R`ý( 
Q 
W 
tU) V' 
rill 
C/) Cl) 
HaHwN DFFL. 
L/ U G. [a. L. ., 
W <Cn> > 
Zoa, x 
FWUZ C7 
In Wxaa 
wW CL ZZ 
m 
Cal Cal 
01 1I b( dig 
FIII 
WII1 
aII1 
11 
WWx 
wZ 
WiZ 
Fxan. z 6- [ 
W> Cv 
L. LL [, X k% Zxr33 
noww 
>awa"r 
aa>aa 
wNýFF 
>ý>>ääl 
>>>FF 
xasx 
r>aaa 
uaxCD(D 
[7F V) E. U) 
YnQ33 
< Ol Cn 22 Cl) 
Unv)aaa 
N 0) OO 
Ln -. v 
0QQ G1 
NýN ("1 t"1 
77777 
C9 C7 C7 C9 C7 
N 
c.. 
c 
Cl CD 
Co r- rcorrna 
ýarwý 
>miii 
cn az (f) (1) 
Cz00. 
wrzrr 
w. 
-. 
a oa 
xwww 
F>>F rS cL U) V) co V) co 
0 V) 0 tf) m 
co 0Zww 
o aL a pG 3 
F E. F 
ýD <uu 
0oM 
I U) 
m 
Iaa Fza 
aaaa 
xawa Unaxr aa 
m cn s 
L 
u C9 
WL 
co 
F co 
.. 
>aa 
CL aaww 
mw0wm 
>w>a"w 
EaG. ri E. 
aawxV 
womwa 
>a0 cý 0 
m co E. cn 
Hr4U> 
NCQO 
. --1 C-M^ ýo ýo ýo r 
m N (N Nmm 
77777 
C. 7 L7 ý7 C7 L 
ri 
v 
d 
ä 
m a 
zwö 
awýH 
v] ED C7 (7 
awaEE 
Eaaa 
co aa 
> 
cn ZZ 
Q co `. L fn 
ii 
a2 
ZaFýi 
>+ 1 
tý aa ýmýnxx 
N>7 
E- FF 
JJ 
--a aa 
.a I 
L ýG 
DD 
M 
0 (n 
a 
(D H .. 
wýww 
rwrrr 
wzo0 
zaaaa HQam 
woýýö 
a3rýý 
>. 
wwww 
ý: YY Y' Y 
SO f- NN 
SNO. - 
lu ¢mm NýNM rn 
77777 
L C7 C9 C7 U' 
0 0 
7ST 
mmm Oý a 
co 
coxaca- 
a3aa 
xxrxr 
rrý. >w 
vFt aH> 
a L-, ý-+ Ha a E. U) 
äa- äF 
- nä 
aQaam 
>aUU 
a>aa. 
-. 
c /O Nrr 
01 a, CD CD 
r ao r rn 
maam N 
7777 
C7 C2 (2 C7 (7 
c 
m0 öL 
ýpoco 
-ýcrn 
>. 0C a, 
c3 
cl) Qo 
.-p cCD 
0 LZC 
ma 
y 
= CCU 
ÖQ"C 
wdw CL vý. o 
a0) 
ZLUy 
L=CD 
!'OL 
c 
a, L3 
ýaaiy0 
03ö 
CoN 
ßt=X (ß 
w f0 NN- LO 
NNY 
(A 
COO> 
NNi ý-*+ OO 
o L'. N 
OO .ý 
t= (ý Ü (0 
wOýN 
0 CIO (Y) C Z i_ CO OC 
,ON CD 
VOC 
a) IV Co EN 
oQNE0 
aM OE 
CD Zy 
-7 ýi fC 
00VUL C ch V 
V4NE 
cc 0 
Q. 0 
' a, a, 
NMÜ L- Cu 
'C N 'O 
tjýU) U)Q 
C (n U) -c 
EöZ 
-0 
0 
(; o0 O 
0 LLL 
Y 
LL COL. 
0 
11 
M2 
Figure 4: Transmembrane domain of the AMPA receptor. M1 is orange, M2 is green, M3 
is purple and M4 is blue. (A) is viewed above the axis of four-fold symmetry and (B) is viewed 
parallel to the membrane (Sobolevsky et al., 2009). 
By superimposing the crystal structure of a desensitised mutant (S729C) onto the AMPA 
receptor crystal structure a model of channel gating can be proposed (Sobolevsky et al., 
2009). Agonist binds to the ligand binding domain clamshell pushing D2 toward Dl by a 
- 
25° rotation while competitive antagonists keep it open. Binding separates the 
transmembrane domains by 
-20 A pulling apart the M3 region which opens the channel. 
The M3-S2 linker in the proximal A/C dimer moves less than the distal subunits B/D; 
therefore, the proximal subunits may play a lesser role in gating. To examine 
desensitisation, the D2 lobes of the ligand binding domain of a desensitised-like mutant 
receptor with bound glutamate was superimposed on antagonist bound AMPA receptor 
crystal and showed few differences in structure (Sobolevsky et al., 2009). Therefore, it is 
thought that for the desensitised receptor, the ligand binding domains twist back around 
into the position they took in the closed state, but while glutamate is still bound. 
1.2.2 NMDA Receptor 
The NMDA receptor also consists of a large extracellular N-terminal domain, a ligand 
binding domain, transmembrane regions containing a re-entrant pore loop and a 
intracellular C-terminus (see Paoletti and Neyton, 2006). The N-terminal domain has a 
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more important role in NMDA receptors binding allosteric modulators such as Znz+ and 
polyamines. It is bilobar, similar to a leucine/isoleucine/valine binding protein, and it 
oscillates spontaneously between open and closed states affecting open probability of the 
channel (Gielen et al., 2009). Chimeras of the NTD have also been shown to transfer 
glutamate potency which is higher at G1uN2D than at G1uN2A (Yuan et al., 2009). 
Receptors containing chimeric GluN2D-(G1uN2A NTD) subunits decreased glutamate 
potency toward G1uN2A compared with GluN2D wild-type. The same study showed 
that the G1uN2A-(G1uN2D NTD) chimera increased potency toward the levels of 
G1uN2D wild-type. The crystal structure of the N-terminal region has also been reported, 
confirming Zn 2+ binding in the cleft between the two lobes promoting the closed 
conformation (Karakas et al., 2009). The structure also showed that the lobes are twisted 
-45° to 54° degrees away from each other compared with the AMPA and kainate 
receptor subunits. The same study showed that this region had Na' and Cl- binding sites 
although their physiological role is unclear. 
The second extracellular domain is the ligand binding domain which is formed by the 
pre-transmembrane Ml region and M3-4 loop (Mayer, 2006). The ligand binding domain 
shows homology with bacterial periplasmic proteins, but with a substructure that is 
increased in size and complexity. G1uN1 and G1uN3 binds glycine and G1uN2 binds 
glutamate. The glutamate binding region of the G1uN2 subunit consists of an S1 region 
which is N terminal to the M1 domain and the S2 region, which occurs between M3 and 
M4 (Furukawa et al., 2005). Selectivity for NMDA over AMPA and kainate is due to an 
aspartate residue in the binding pocket which is shorter than the glutamate found in the 
other ionotropic glutamate receptors. It is suggested that the changed residue leaves 
space for the N-methyl group of NMDA to enter. After agonist has bound there is 
rotation of the ligand binding domain region leading to channel opening (Furukawa et al., 
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2005). As it is the movement of the ligand binding domain lobes that allow the channel 
to open, it is thought that the partial agonist homoquinolinate may mediate its effects by 
reducing stability for the closed conformation due to increased motion in the binding 
pocket, or through conformational changes that occur after binding (Erreger et al., 
2005b). 
The glycine binding domain of GluN1 has a similar bilobar clamshell structure to the 
glutamate binding domain of G1uN2, and the agonist binding residues were in the same 
position when they were superimposed over G1uN2 (Furukawa and Gouaux, 2003). 
However, G1uN1 may exclude glutamate through steric effects as well as through a local 
hydrophobic environment meaning only glycine can enter. Similar to GluN2, the 
presence of an agonist keeps the lobes of the binding domain in the open configuration. 
G1uN3 subunits have been shown to have a higher affinity for glycine than G1uN1 even 
though they have similar binding residues, positions and domain rotation after binding 
(Yao et al., 2008). There may be a different hydrogen bonding network in G1uN3 which 
increases the stability of the closed state by producing more constrained amino acid 
interactions. Such a mechanism would be the opposite to how homoquinolinate reduces 
stability of the closed conformation. In the binding pocket there is also the loss of a T731 
which is M in G1uN3A and G1uN3B. This residue has been shown to interact with the 
Cl" of 5,7-DCKA, as 5-DCKA showed no difference in affinity between G1uN3A and 
G1uN3B (Yao and Mayer, 2006). 
Similar to the AMPA receptor, agonist binding to the NMDA receptor is thought to 
result in the ligand binding domain closing disrupting the linkers to the transmembrane 
region which opens the channel (Mayer, 2006). Ml, M3 and M4 are directly linked to the 
ligand binding domains and it is known that the M3 region plays the most important role 
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in gating (Sobolevsky et al., 2009). Like AMPA receptors, NMDA receptors also have a 
conserved region with the sequence SYTANLAAF in the M3 region and the crossing 
over between subunits of this area is thought to be the channel gate (Figure 3). 
Supporting this is the evidence that mutations between S645 and 1655 of M3 resulted in 
constitutively open channels (Chang and Kuo, 2008). It is thought that open channel 
blockers such as MK-801 may bind in a manner with high affinity that they can become 
trapped when the channel is closed (Qian and Johnson, 2002). Substituted cysteines 
accessibility showed that of those residues mutated from the M3 to the M2 loop where 
the N-site resides were accessible, with or without glutamate binding, meaning the M3 
region may be exposed to the extracellular region in NMDA receptors even in the closed 
state, questioning the location of the gate (Sobolevsky et al., 2002a). The M3 segments 
from the G1uN1 and GluN2B and G1uN2C subunits were shown to be staggered relative 
to each other in the vertical axis probably indicating a differential role in gating 
(Sobolevsky et al., 2002b, Kashiwagi et al., 2007). 
In G1uN1, C-terminal to the M3 region is an amino acid sequence DRPEER in the ligand 
binding domain/transmembrane domain linker (Figure 3) (Watanabe et al., 2002). The 
study showed that mutations of the DRPEER motif, as well as those in the conserved 
asparagine of the M3 region, resulted in reduced Ca2+ current. It is thought that it 
increases current by binding Cat' and excluding monovalent ions from the pore. The 
DRPEER sequence is not present in G1uN3, which may account for the reduction in 
Ca 2+ current when the subunit is present (Figure 3). However, the DRPEER sequence is 
not present in the G1uN2, and may not account completely for the reduction in Ca" 
permeability seen with G1uN3 unless a GluN1 subunit is replaced. 
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G1uN1 /G1uN2A receptors expressed in HEK-293 cells showed a shift in the reversal 
potential in the presence of 1 mM and 10 mM Ca 2+ of 
-11.5 mV (Perez-Otano et al., 
2001). With the addition of GluN3A, together with GluN1 /G1uN2A, there was a 
reduction of the shift to 
-5.93 mV indicating reduced Ca 2+ permeability of the channel. In 
hippocampal neurones from transgenic mice overexpressing GIuN3A it was shown that 
there was a three-fold reduction in Ca 2+ permeability compared with wild-type controls 
(Tong et al., 2007). Expressing G1uN3B together with GluN1 /GluN2A in HEK-293 
cells, but using 1 mM and 20 mM external Ca 2+ concentrations, showed a two-fold 
reduction in calcium permeability compared with controls (Matsuda et al., 2002). 
Expression of the G1uN3B subunit in cultured mouse hippocampal neurones led to a 
four-fold reduction in Ca 2+ permeability (Matsuda et al., 2003). 
The intracellular C-terminal end of the NMDA receptors contains sites that can be 
phosphorylated by PKA, PKC, protein tyrosine kinase (PTK) and CaMKII (Chen and 
Roche, 2007). Interactions with these proteins can affect signalling, trafficking and gating 
properties. G1uN3A has a molecular weight of -125 kDa indicating that it is the most 
heavily glycosylated of the NMDA receptor subunits, affecting the gating properties of 
the receptor (Ciabarra and Sevarino, 1997). G1uN3A also has also been shown to interact 
with PACSINI /syndapinl which is involved in mediating endocytosis of the receptor 
(Perez-Otano et al., 2006). 
1.3 Subunit Stoichiomet 
Unravelling the subunit stoichiometry of the NMDA receptor has produced competing 
studies showing differing arrangements around the pore. Truncation of the G1uN1 and 
G1uN2 subunits before M4 was shown to form functional channels when expressed 
together with a separate M4 region (Schorge and Colquhoun, 2003). Doing this 
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supposedly allowed the N and C-terminals to reside on the same side of the membrane 
and these could be linked together to form subunit tandems. The subunits present and 
their orientation could be constrained depending on the truncated subunits that were 
linked together. Those tandems which forced an alternating orientation around the pore 
were either non-functional or showed rapid desensitisation. Those tandems which forced 
a 1-1-2-2 orientation produced functional channels with similar properties to wild-type, 
indicating it was the preferred orientation. 
The structural data from the AMPA receptor crystal was used to determine the 
stoichometry of the NMDA receptor as cysteine substitutions in the ligand binding 
domain were made to determine regions that were in close proximity, as they would 
cross-link (Sobolevsky et al., 2009). These showed that only one residue of the ligand 
binding domain of G1uN1 was required to link the NMDA receptor subunits, E699. It 
was deduced that the only way E699 could orientate around the NMDA receptor is by 
forming a diagonal pair around the pore with the G1uN1 subunit in the proximal position 
and the GluN2 subunit in the distal position. The AMPA receptor structure was also 
used to explore the pore of the NMDA receptor. Cysteine mutations in the M3 region at 
M629 in AMPA led to cross-linking due to the proximity of these amino acids 
(Sobolevsky et al., 2009). In the NMDA receptor if there is an alternating subunit 
arrangement around the pore then the equivalent mutations in M3 of G1uN1(P661) 
would be close enough to show cross-linking with cysteine mutations, but those of 
GluN2 (P631) would not, which is what was found (Figure 5). GluN2 and G1uN3A 
dimers were shown to only form functional receptors when a G1uN 1 subunit was 
present, and GluN3 could not form a dimer with another GluN3 subunit (Furukawa et 
al., 2005, Schuler et al., 2008, Yao et al., 2008). Therefore, how a G1uN3 containing 
triheteromeric assembly is formed still remains unknown. 
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G 
!A 
Figure 5: Subunit arrangement of the pore region of the NMDA receptor. Shown are the 
positions of the cysteine substitutions at P661 and F631 (Sobolevsky et al. 2009). 
1.4 NMDA Receptor Subunits 
I. 4. I GIuN I 
The G1uN 1 subunit was cloned in 1991 and was shown to require glycine as an agonist, 
confirmed later by mutagenesis of the binding site (Moriyoshi et al., 1991, Kuryatov et al., 
1994). A screen of a rat forebrain library with probes for the transmembrane region of 
G1uN 1 found multiple genes with similar sequences (Hollmann et al., 1993). Eight 
different G1uN1 splice variants were identified and these were arranged into four 
categories depending on the splice cassettes present (Figure 6). In rats, the gene for 
G1uN1 Grin1 is located at 3p13, contains 22 exons and has eight functional splice variants 
of pre mRNA from two regions of alternative splicing (Figure 6). The splice cassette at 
the 5' end it termed the N1 cassette (exon 5,63 basepairs (bp)) and occurs at position 
516 if it is present. At the 3' end there are C1 (exon 21,111bp, between positions 2536 
and 2646) and C2 (exon 22,356bp, between positions 2647 and 3002) cassettes 
(Hollmann et al., 1993, Dingledine et al., 1999, Zarain-Herzberg et al., 2005, Del Valle- 
Pinero et a1., 2007). The C2 cassette is followed by a C2' cassette, but is only translated 
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when C2 is not present. This removes the original stop codon allowing expression of a 22 
amino acid C2' region which has its own alternative stop codon. There is one further 
splice acceptor site in exon 3 which is a 150 nucleotide open reading frame containing an 
alternative stop codon, but is not thought to be functional (Sugihara et al., 1992). 
A 
NI Cl) (C2* 
B 
Splice Variant Exons Alternative 
stop codon? 
EBML 
GIuN1-1a C1, C2 No U08261 
GIuN1-1b N1, C1, C2 No U08263 
GIuN1-2a C2 No U08262 
GIuN1-2b N1, C2 No U08264 
GIuN1-3a C1 Yes U08265 
GIuN1-3b N1, C1 Yes U08266 
GIuN1-4a n/a Yes U08267 
GIuN1-4b N1 Yes U08268 
Figure 6: Alternative splicing of the GluN1 receptor. (A) White boxes represent exons of 
the sequence which are alternatively spliced: the N1 cassette (exon 5), C1 (exon 21) and C2 (exon 22). The black box represents the C2' region with an alternative stop codon. 
*represents stop codons in the sequence. (B) Combinations of splice cassettes that make up 
the GIuN1 receptors adapted from Rollmann et al., (1993) and Yamakura and Shimoji, (1999). 
The G1uN1 subunits are classed 1 `a' and `b' to 4 `a' and W. The `a' form does not 
contain the Ni cassette, and the increasing number indicates differing combinations of 
the Cl and C2 cassettes (Figure 6). The Cl cassette contains an endoplasmic reticulum 
(ER) retention signal meaning that the `1' and `3' forms have reduced expression in 
Xenopus oocytes (Cavara et al., 2009). For the 3 form, it may be less important as the C2' 
region contains a post synaptic density protein (PDZ) domain. The gene encoding 
human G1uN1, glutamate receptor ionotropic (GRIN1), is located at 9q34.3 and 
comprises of 21 exons (exon 3 from the rat is not present) of which exons 4 (N1), 20 
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(Cl) and 21 (C2) are alternatively spliced and these have the same sequence as those in 
the rat (Zimmer et al., 1995). 
1.4.2 GIuN2 
The G1uN2 subunit was also cloned in the early 90's and has four subtypes A-D which 
bind glutamate (Table 2) (Moriyoshi et al., 1991, Cull-Candy et al., 2001). Rat G1uN2C 
(Grin2C) can be alternatively spliced resulting in truncation after the first transmembrane 
region (Ml) or M3 region (Rafiki et al., 2000). G1uN2D (Grin2D) also has a region of 
alternative splicing at the c-terminus which consists of a 33 amino acid insert in rats that 
either has a deletion (GluN2D-1) or does not (G1uN2D-2) (Monyer et al., 1994). 
However, it is unclear if there are any functional characteristics associated with these 
splice variants. 
Human Rat 
Subunit Chromosome 
Accession 
Number 
Accession 
Number 
GIuN2A 16 13 U09002 D13211 
GIuN2B 12 12 U88963 U11419 
GIuN2C 17q25 BC031077 U08259 
GIuN2D 19g13.1-qter U77783 U08260 
Table 2: GIuN2 subunits and their locus positions in humans. Shown are the 
chromosome positions on human, human accession numbers and rat accession numbers for 
GIuN2A-2D. Adapted from Dingledine et al., (1999), Schmidt and Hollmann, (2008) and 
Collingridge et al., (2009). 
1.4.3 GIuN3 
G1uN3 has two subtypes G1uN3A and G1uN3B (formerly NMDAR-L or x' and 3B x) 
which are activated by glycine (Table 3) (see Cull-Candy et al., 2001, Yao and Mayer, 
2006). G1uN3A was cloned in 1995 and consists of 1115 amino acids in the rat (Grin3A) 
(Ciabarra et al., 1995, Sucher et al., 1995). There is also a splice-variant in rat that results 
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in a 60 bp insert at the C-terminal termed G1uN3A-l (Sun et al., 1998, Cull-Candy et al., 
2001). Human G1uN3A (GRIN3A) has 9 exons and is located on chromosome 9 
(Eriksson et al., 2002). It consists of 3345 bases translating to 1115 amino acids. The 
mature peptide contains 1089 amino acids leaving a signal peptide of 26 amino acids. 
There is no evidence of alternative splicing of GRIN3A in humans. 
Rat G1uN3B (Grin3B) contains 1003 amino acids and shares 62% nucleotide homology to 
GluN3A (Matsuda et al., 2002). The human GluN3B (GRIN3B) gene has an open 
reading frame of 3129 bases which translates to 1043 amino acids and contains 9 exons 
and exon 9 is elongated at the carboxyl end in humans (Bendel et al., 2005). It has also 
been described as having 2703 bases translating to 901 amino acids (Andersson et al., 
2001). Human G1uN3B is polymorphic with 10% of the European/American population 
homozygous for a 4bp insertion in exon 3 (Niemann et al., 2007). The protein is 
truncated causing the removal of its membrane binding domains and is a null mutant. 
The C-terminal region of G1uN3B contains an ER retention signal which must be 
masked before receptors can be trafficked to the surface (Matsuda et al., 2003). Deletion 
of amino acids in the C-terminal region of G1uN3B distal to amino acids 914, and distal 
to 953, led to no surface expression when co-expressed with G1uN1-1 a. Deletions distal 
to position 986 led to normal cell surface expression. The amino acids between 952 and 
985 may mask the G1uN 1-1 a ER retention signal. However, a recent study has found the 
opposite, with the removal of this region in G1uN3B reducing cell-surface expression 
(Wee et a1., 2010). 
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Human Rat 
Accession Accession Subunit Chromosome 
Number Number 
GIuN3A 9g31.1 BC132866 U29873 L34938 
GIuN3A-1 AF061945 
AF073379.1 
GIuN3B 19p13.3 AY507107.1 AF440691 
Table 3: GIuN3 subunits and their locus positions in humans. Shown are the 
chromosome positions on human, human accession numbers and rat accession numbers for 
GIuN3A-3B. Only the accession number for rat GIuN3-I is shown as a human variant has not 
been described. Adapted from Adapted from Dingledine et al., (1999), Schmidt and Hollmann, 
(2008) and Collingridge et al., (2009). 
1.5 NMDA Receptor Single Channels 
Like most ion channels the NMDA receptor has multiple conductance states, but this 
differs with the G1uN2 subunit that is expressed in the tetramer. G1uN2A and G1uN2B 
are similar, having a main 50 pS opening with a brief 40 pS sublevel (Stern et al., 1992). 
G1uN2C has a 36 pS and 19 pS conductance which both occur with similar brief 
durations. G1uN2D has similar conductance levels to G1uN2C, but they differ in the 
transitions between the states, and the mean open time for the low conductance state is 
longer (Wyllie et al., 1996). Single channel open probability is also altered according to 
the G1uN2 subunit that is expressed. Within an `activation' G1uN2A has a higher open 
probability (0.5) than G1uN2B (0.12) (Erreger et al., 2005a). G1uN2C has a lower open 
probability (0.011) than G1uN2B, and G1uN2D has an open probability of 0.04 (Wyllie et 
al., 1998, Dravid et al., 2008). These differences are controlled by the closing of the N- 
terminal domain, and its linker to the ligand binding domain, leading to a lower open 
probability (Gielen et al., 2009, Yuan et al., 2009). 
Single channel studies in HEK-293 cells expressing G1uN1, G1uN2A and G1uN3A had 
one conductance level of 47 pS similar to G1uN1 /G1uN2A receptor, and another 
conductance of 29 pS (Perez-Otano et a1., 2001). The latter was not a subconductance 
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state as there were no direct transitions. Single channels studies from Xenopus oocytes 
injected with G1uN1 /2A/3A also showed two conductance states of 75 pS and 35 pS 
(Sasaki et al., 2002). It was shown that only the larger conduction state was blocked by 
Mg". The abundance of the lower state depended on the ratio of GluN3A injected. 
Again, no direct transitions were observed between states and may suggest two different 
populations of channel. However, if there is a subpopulation of G1uNI-1a/2A receptors 
then there would be at a minimum two sublevels, one of which would have a direct 
transition, which was not found. Outside-out patches from disassociated P8 
cerebrocortical neurones also showed two conductances with no direct transitions (Das 
et al., 1998). The lower conductance may be attributed to the G1uN3 subunit as it was 
not present in G1uN3A-1" mice. However, with two populations, superimpositions could 
be expected to be found, and there was no mention of this in any of the studies outlined. 
1.6 Agonists and Competitive Antagonism 
1.6.1 Glutamate 
The half-maximal effective concentration (EC50) for L-glutamate alters depending on the 
GluN2 subunit that is expressed. G1uN2A has the highest EC50 (-3. tM) and GluN2D 
has the lowest (-0.5 µM) (Erreger et al., 2007). G1uN2B (EC50 -2.86 µM) and G1uN2C 
(ECO 
-1.68 µM) have intermediate potencies between these two extremes. The ECG for 
the D-glutamate enantiomer has a 100-fold higher EC50 and shows the same pattern with 
differing GluN2 subunits. It also shows a small increase in efficacy at G1uN2B, 2C and 
2D receptors. NMDA is less potent overall than L-glutamate (Figure 7). It has the highest 
ECG at G1uN2A (EC50 
- 
94 µM) and the lowest at G1uN2D (EC50 - 7.30 µ1V1) (Erreger 
et al., 2007). G1uN2B (EC50 
- 
29 µM) and G1uN2C (EC50 - 21 . tM) again have 
intermediate potencies. NMDA shows reduced efficacy at the differing GluN2 NMDA 
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receptor subunit combination compared with glutamate. G1uN2B has the lowest efficacy 
(78%) and increases for G1uN2C (86%), G1uN2D (92%) and G1uN2D (93%). 
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Figure 7: Competitive antagonists for the GIuN2 subunit of the NMDA receptor. Shown 
are glutamate and how the extended backbone and the phosphate group led to competitive 
antagonists in the case of R-AP5 and R-AP7 (see Monaghan and Jane, 2009). Modifications 
that added a piperazine ring led to the antagonists CPP. Lastly shown the compound NVP- 
AAM077 which was shown not to be the GIuN2A specific agonist that it was thought to be 
(Neyton and Paoletti, 2006). 
Competitive antagonists at the ligand binding domains of the GluN2 subunits were 
originally produced by extension of the glutamate backbone (see Monaghan and Jane, 
2009). Increased potency was found with R-AP5 which was produced by extending and 
adding a w-phosphoric group (Figure 7). Increasing the alkyl chain by one decreased 
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potency, but increasing one more to seven restored it (D-AP7). Incorporating the AP7 
structure into a piperazine ring produced the compound CPP which is a potent (K; 0.04 
µM) competitive antagonist at the NMDA receptor (Figure 7). These compounds show 
some selectivity between the G1uN2 subunits, but not for them to be considered selective 
antagonists (see Paoletti and Neyton, 2006). 
There was hope that the quinoxaline-2,3-dione based antagonist NVP-AAM077 was a 
selective antagonist for G1uN2A containing receptors (Figure 7). The half-maximal 
inhibitory concentration (IC50) for NVP-AAM077 was found to be 14 nM at G1uN2A 
receptors, and 1800 nM at G1uN2B receptors (Liu et al., 2004). However, the glutamate 
concentration was not varied in order to reflect the true EC50value at the differing 
G1uN2 subunits, which would be required when exploring competitive antagonism 
(Neyton and Paoletti, 2006). Therefore, when the glutamate concentration was adjusted 
to the true EC50 values it was found that the compound was not selective. Although it 
remained quite a potent compound at G1uN2A receptors (K; 0.006 µM) there was only 
around a 10-fold difference between the other G1uN2 subunits. 
1.6.2 Gl rye 
Similar to glutamate, the potency of glycine at G1uN1 depends on the G1uN2 subunit 
that is co-expressed. Glycine has a lower ECso at G1uN1 with G1uN2D (ECS - 0.13 µM) 
than GluN2A (ECG 
- 
1.31 µM), with G1uN2B and GluN2C having intermediate glycine 
potencies (Chen et al., 2008). The same study showed that this was mediated by the S2 
region of the ligand binding domain, as the mutation of L719 and '1735 in the S2 region 
of G1uN2A to that of G1uN2D transferred the EC50 of glycine. As well as glycine, D- 
alanine is an agonist at G1uN1, as is D-serine, the latter being more potent in G1uN2A 
containing receptors (Chen et al., 2008). The same study has shown that the L- 
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enantiomer of these amino acids have a 100-fold increase in EC50with a similar pattern 
across the G1uN2 subunits. Chimeras of the GluN2 N-terminal domain and their linker 
domains may also transfer the differences in glycine EC5o, but has not been explored. The 
absence of the C-terminal cassettes has been shown to increase the potency of glycine, 
but the N1 cassette had no influence (Schmidt and Hollmann, 2009). 
Kynurenic acid was the first G1uN1 glycine site antagonist to be found (see Monaghan 
and Jane, 2009). It was modified mainly by the addition of Cl to produce compounds 
such as 5,7-dichlorokynurenic acid, L-683344, L-689560, L-701324 and MDL-299591 
which had increased potency (Figure 8) (Leeson et al., 1991, Leeson et al., 1992, 
Kulagowski et al., 1994, Salituro et al., 1992). The AMPA receptor antagonists CNQX 
and DNQX were also found to be active here, but modifications carried out to increase 
potency were not water soluble and hence had limited use as therapeutics (Cai et al., 
1997). Spermine has also been shown to decrease glycine dissociation leading to a 3-fold 
increase in affinity, and is termed glycine dependent potentiation (Benveniste and Mayer, 
1993). It is only found when G1uN1 is expressed with G1uN2A and G1uN2B, but not 
G1uN2C and G1uN2D, and is not affected by the differing G1uN1 splice variants 
(Williams, 1997). 
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Figure 8: Glycine site agonists, partial agonists and antagonists. Shown are the amino 
acid agonists glycine D-serine and D-analine for the GIuN1 subunit of the NMDA receptor 
(Chen et al., 2008). CNQX and DNQX were AMPA receptor antagonists that were also shown 
to be active here (see Monaghan and Jane, 2009). Kynurenic Acid was the fist glycine site 
antagonist to be found and this was modified to produce the compounds with similar modes of 
action 5,7-dichlorokynurenic acid, L-683344, L-689560, L-701324 and MDL-299591 (see 
Monaghan and Jane, 2009). 
Both G1uN1 and G1uN3 bind glycine; however, the ligand binding domains of the 
G1uN3 subunits have different properties. Glycine binds to G1uN3A with a high affinity, 
having a 650-fold lower KD than G1uN1, as well as binding glutamate with a low affinity 
(Yao and Mayer, 2006, Neyton and Paoletti, 2006). The partial agonist ACBC has a 65- 
fold higher affinity at G1uN3A than G1uN1 (Yao et al., 2008). For the antagonists, 
CNQX has a similar dissociation constant at G1uN1 and GluN3A; however, CGP-78608, 
5,7-DCKA, L-689560 and L-701324 show selectivity for GluN1 over G1uN3A (Figure 8) 
(Yao and Mayer, 2006). L689560 and 5,7-DCKA can be considered the best selective 
compounds for this purpose as they have affinities in the nM range for G1uN1 and 100 
µM range for GluN3A. 
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1.7 Modulation of the NMDA Receptor 
Zn2+ is released at many glutamatergic synapses and it may act as an endogenous allosteric 
modulator (see Frederickson et al., 2000). It binds to the cleft of the N-terminal domain 
of G1uN2 subunits promoting closure, which then interferes with the ligand binding 
domain through its linkers causing desensitisation (Gielen et al., 2009). Zn 2+ inhibits 
NMDA receptor currents in a manner that is 100-fold more selective for receptors 
containing G1uN2A (IC50 - 15 nM) than G1uN2B (IC50 -1 µM) while having a low 
affinity for G1uN2C (ICS - 20 µM) and G1uN2D (IC50 - 10 µM) (see Mony et al., 2009a, 
Rachline et al., 2005). G1uN1 alternative splicing has also been shown to influence Zn 2+ 
inhibition, such that those that contained NI and the full length C2 were shown to have 
a 3-fold and 10-fold increase in IC50 at G1uN2A and G1uN2B containing receptors 
respectively (Traynelis et al., 1998). Zn 2+ has been shown to mediate its effects by 
reducing mean open time open probability (Erreger and Traynelis, 2008). 
Ifenprodil also acts at the N-terminal domain producing selective inhibition of the 
G1uN2B subunit (Williams, 1993, Williams, 1995) (Figure 9). It is 1000-fold more potent 
here than at the GluN2A subunit, and shows little affinity to GluN2C and GluN2D 
(Williams, 1993). Its binding has also been shown to be competitive with Zn 2+ indicating 
that it binds at the same site (Perin-Dureau et al., 2002, Rachline et al., 2005). Ifenprodil 
is thought to bind to both lobes of the N-terminal domain encouraging its closure hence 
reducing open probability in a similar manner to Zn 2+ (Gielen et al., 2009, Mony et al., 
2009b). A large range of compounds similar to ifenprodil have been produced to increase 
selectivity and potency. Ro 25,6981 and CP 101,606 (traxoprodil) are around 10-fold 
more potent than ifenprodil, and have a similar structure and similar binding sites (Figure 
9) (see Gogas, 2006). 
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Figure 9: Ifenprodil and related compounds. These compounds block at the N-terminal 
domain of the GIuN2B subunit similar to where Zn 2+ binds (see Gogas, 2006). 
Sensitivity to Zn2+ and ifenprodil can alter in tri-heteromeric NMDA receptor assemblies. 
GluN1 /2A/2B receptors have been found in the cortex and hippocampus with 
GluN1 /2A/2C (or 2D) in the cerebellum (Cull-Candy and Leszkiewicz, 2004). In tri- 
heteromeric receptors, even though G1uN2A and GluN2B can be present, it was found 
that there was reduced efficacy of ifenprodil although affinity remained the same (Hatton 
and Paoletti, 2005). The G1uN2C subunit also was also shown to have a similar high 
affinity with low efficacy. Therefore, the absence of GluN2B does not always follow 
from a lack of activity of ifenprodil; however, such a claim could be made if Zn 2+ 
inhibition was also low. There was no loss in ifenprodil efficacy with GluNl-la/2B/3A 
receptors, therefore the triheteromeric properties are related to GluN2 subunit 
expression (Smothers and Woodward, 2003). 
NMDA receptors are inhibited by protons in a non-competitive voltage-independent 
manner. Inhibition is dependent on the G1uN2 subunit expressed, with GluN2B and 
G1uN2D being the most sensitive with an IC_5- pH 7.4 and G1uN2C having the lowest 
pH IC50 at - pH 6.5 (Low et al., 2003). G1uN1-la/G1uN2A receptors show intermediate 
inhibition with an IC50 of - pH 6.9. G1uN2B and G1uN2D are therefore inhibited by 
50% at physiological pH, highlighting an important role for protons in the gating of 
NMDA receptors. G1uN1 alternative splicing has also been shown to affect proton 
sensitivity. Inclusion of the N1 cassette in GluN1-1b together with G1uN2A or G1uN2B 
was shown reduce the IC,, to - pH 6.7 (Traynelis et al., 1995). 
The exact site of proton inhibition is unknown; however, mutations in the linkers 
between M2, M3 and the S2 region leading to the ligand binding domain were shown to 
reduce pH sensitivity in the G1uN1 subunit (Low et al., 2003). For G1uN2A, the same 
study found that mutations in the S2 to M4 linker domain also led to a reduction in pH 
sensitivity, and that a combination of S2-M3 in both G1uN1 and G1uN2A led to a 145- 
fold decrease in the ICS. In addition, mutations that lead to open channels in the 
conserved SYTANLAAF motif of M3 have also been shown to influence proton 
sensitivity (Low et al., 2003). The results of these mutations indicate a close relationship 
between channel gating and protons, possibly promoting the shut conformation of the 
channel as shown by increased shut times in single channel studies (Banke et al., 2005). 
Modulation of the NMDA receptor by N-terminal may therefore mediate their effects by 
shifting the pKa of the putative proton sensor. 
As well as inhibition of NMDA receptors, modulation of the N-terminal domain can 
potentiate responses. Spermine could potentiate currents, but was limited to the G1uN2B 
subunit (see Mony et al., 2009a). It has an EC50 - 150 pM at pH 7.3 and can potentiate 
responses up to a maximum of 3-fold (Benveniste and Mayer, 1993). Two mechanisms of 
potentiation by spermine have been proposed, as many mutations across the extracellular 
domain of G1uN1 and GluN2B inhibit the potentiation (see Mony et al., 2009a). The first 
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proposes that spermine binds at the ligand binding domain across a dimer pair keeping 
the region in the open conformation and inhibiting disruption of the N-terminal domain. 
Supporting this is evidence that has shown that spermine and spermidine bind to the 
SIS2 regions of the ABD (Stoll et al., 2007). A second model proposes binding occurs in 
the N-terminal domain, but rather than holding the N-terminal domain open by binding 
at the cleft where ifenprodil binds, spermine binds together the bottom lobes of the 
dimer pair. Ifenprodil and spermine have been shown to bind at distinct sites in a 
negative allosteric manner, hence a modified model is required (Han et al., 2008). 
1.8 Open Channel Block 
Mg2+ is the endogenous open channel blocker of the NMDA receptor. It occludes the 
channel pore region after opening and acts in a voltage-dependent manner (Mayer et al., 
1984, Nowak et al., 1984). A single mutation at the `N-site' asparagine site at the tip of 
the pore loop of the G1uN 1 subunit was found to reduce Mg2+ sensitivity (Sakurada et al., 
1993). The N-site of the GluN1 is the binding site for intracellular Mg2+ (Wollmuth et al., 
1998b). Similarly, the N-site and the adjacent asparagine (N+1 site) in G1uN2A was 
shown to bind extracellular Mg2+ (Wollmuth et al., 1998a). The sensitivity to Mg2+ is 
altered according to the G1uN2 subunit that is expressed. The biggest difference is 
between G1uN2A and G1uN2B, which have the lowest ICS values and G1uN2C and 
G1uN2D containing receptors which have the highest (Kuner and Schoepfer, 1996, 
Wrighton et al., 2007). The largest difference in Mg2+ sensitivity is found between 
G1uN2A and GluN2D (34 and 91 tM respectively). Chimeras where the M1, M2 and M3 
regions from G1uN2D were transferred to G1uN2A showed a 10-fold increase in the IC50 
for Mg2+ compared with wild-type GluN2A, and a 3-fold higher IC50 than G1uN2D 
containing receptors (Wrighton et al., 2007). The same study showed that the chimera of 
the Sl S2 domain of G1uN2D transferred to G1uN2A had an IC50 for Mg2+ that was lower 
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than wild-type GluN2A. The study showed that the transmembrane regions, and the 
SIS2 region of the ligand binding domain, play differing roles in mediating Mg2+ 
sensitivity. 
The G1uN3A and G1uN3B subunits are thought to reduce Mg" sensitivity as the `N-site' 
residue which has been shown to bind the ion is G in these subunits (Wollmuth et al., 
1998a). Some review articles made this claim, but evidence was weak as no full study had 
been carried out on the activity of Mg2+ (Petrenko et al., 2003, Paoletti and Neyton, 
2006). Inhibition by Mg`" was not significantly different when GluN3B was present in 
GluN1 /2A and G1uN1 /2B receptors expressed in Xenopus oocytes (Yamakura et al., 
2005). The same study showed that mutations at the N-site and N+1 site in G1uN3B did 
not alter Mg2+ sensitivity. However, the authors only applied two concentrations of Mg2+ 
at 
-75 mV and compared percent inhibition with a t-test. This is not a valid comparison 
as percentage data must be arcsin transformed to normalise the error distribution. The 
percentage must be divided by 100, then the square root taken and then the inverse sin is 
taken to get a value in degrees. The value can then be analysed using parametric statistics. 
Expression of G1uN3B has also been shown to have no effect on Mg" sensitivity when 
expressed with G1uN1/2A in HEK-293 cells (Nishi et al., 2001). The authors tested 1 
mM Mg2+, producing an I/V curve that showed inhibition by Mg2+ at voltages less than 
- 
50 mV, and it was not altered by the presence of G1uN3B. However, the converse has 
also been shown, with GluN1 /2B/3A receptors expressed in HEK-293 resistant to block 
by 1 mM and 10 mM Mg 2+ at negative voltages (Sasaki et al., 2002). The sensitivity of 
Mg 2+ was tested in hippocampal neurones from transgenic mice overexpressing G1uN3A 
and the IC_, for Mg 2+ in wild-type (WT) neurones was found to be 9.9 µM, and was 
significantly increased to 133.8 µM (Tong et al., 2007). These results suggest that the loss 
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of Mg2+ sensitivity in the presence of GluN3 subunits may not be as dramatic as that 
suggested by the N-site changes. 
Memantine (1-amino-3,5-dimethyl-adamantane) is a highly selective open-channel 
blocker of the NMDA receptor (Chen et al., 1992, Chen and Lipton, 1997). It is a 
derivative of amantadine, an anti-influenza drug, which was serendipitously found to be 
effective against the symptoms of Parkinson's disease. The two methyl side groups of 
memantine help prolong dwell time compared with amantadine which slows the off-rate 
and increases affinity for to the channel (Figure 10). It has a higher affinity and slower 
off-rate than Mgt+, as well as showing less voltage-dependence (Danysz and Parsons, 
2003). Memantine has a ko that depends on memantine concentration, but a ko ff that is 
independent, giving the compound the same off-rate at clinically relevant concentrations 
(Chen and Upton, 1997). It was shown to bind preferentially to the GluNl Mg2+ site (the 
`intracellular' Mg2+ binding site) and showed electrostatic interactions at the N and N+1 
on G1uN2 (Chen and Upton, 2005). The same study located a second more superficial, 
low affinity, less voltage-dependent binding site at L651 of the M3 region of GluN1. It is 
similar to where hexamethonium, the acetylcholine receptor blocker, was shown to bind 
(Chen and Upton, 2005). It is thought that the superficial site is where memantine can 
unbind without agonist being present, contributing towards its `partial trapping' property 
(see below) (Kotermanski et al., 2009). Further residues involved in memantine binding 
are found on the M1, M2 and M3 regions and these are shown in (Figure 11). 
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Figure 10: Structure of amantadine and memantine. Amantadine was an influenza drug 
that was modified with the amino group to produce the more potent compound memantine 
(Chen et at., 1992). 
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Figure 11: Binding sites of the pore region of the NMDA receptor. N shows the N site of 
GIuNI and GIuN2, as well as the N+1 site of GIuN2. Circles 1-4 show residues involved in 
MK-801 and memantine binding, with the circles 5-12 showing further residues involved in 
binding MK-801 (Kashiwagi et al., 2002). Circle 13 shows the superficial memantine binding 
site (Chen and Lipton, 2005). Quaternary structure adapted from AMPA crystal in the closed 
configuration (Sobolevsky et al., 2009). Amino acid positions should be considered 
diagrammatic. 
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(IuN1 ® GIuN2 
Memantine is considered a `partial trapping' compound as a proportion of agonist- 
induced response can be recovered immediately after a quick wash out, an effect which is 
not found present in fully trapping compounds such as ketamine and MK-801 (Blanpied 
et al., 1997, Kotermanski et al., 2009). One possible mechanism is that memantine 
escapes up and out of the channel when it closes, but as memantine unbinding is slower 
than agonist unbinding then it would have to hold the channel open by a foot-in-the- 
door type mechanism. If this was the case, then there should be a related tail current 
when memantine was released, but this was not found (Benveniste and Mayer, 1995, 
Blanpied et al., 1997). As the off-rate of memantine increases with membrane 
depolarisation, if the compound is escaping up and out the open channel then a 
depolarisation jump after application of agonist is stopped should leave an increased 
proportion of NMDA current with a second application of agonist (Blanpied et al., 
1997). However, no significant differences were found in the proportion of inward 
current after the second application of agonist, providing further evidence that 
memantine does not escape out of open channels (Kotermanski et al., 2009). 
It has been suggested that the deep and superficial memantine binding sites are 
competitive. As the superficial site is less voltage-dependent, depolarisation would push 
binding toward it rather than the deep site. This would be shown by increased 
proportional recovery after a second agonist application and this was found to be the 
case (Kotermanski et al., 2009). Furthermore, a mutation at the `N-site' in G1uN2A 
significantly increased fractional recovery after a second agonist application, indicating 
that the mutation in the deep binding site may have pushed memantine binding toward 
the superficial site. Unlike Mgt+, memantine is more potent at G1uN2D (0.29 µM) 
containing NMDA receptors than G1uN2A (0.86 µM), but chimeras transferring the Ml, 
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M2 and M3 regions from G1uN2D to G1uN2A did not alter memantine potency 
(Wrighton et at, 2007). 
Memantine (ebixia) is currently the only clinically approved drug that targets 
glutamatergic transmission (Chen and Upton, 2006). A tolerated NMDA receptor 
antagonist has to block excessive activity of the NMDA receptor without blocking 
normal signalling. Memantine was found to block only around 15% of the late 
component of synaptic transmission (which is mediated by NMDA receptors), whereas 
MK-801 completely blocked this (Chen et al., 1992). Memantine has been shown to 
block LTP in the CA1 region of the hippocampus but did not inhibit memory as 
measured by the Morris water maze task (Chen et al., 1998). This showed that normal 
functions were unaffected. Memantine was also shown to be an ineffectual blocker when 
low concentrations of NMDA are used, but if the agonist concentration was increased it 
was shown to become more effective (Chen et al., 1992). Therefore, memantine could be 
considered more useful with excessive glutamate levels, providing a further property that 
which spares normal glutamatergic transmission. 
MK-801, PCP and ketamine (Figure 12) are not as useful as memantine as they have high 
affinity and can become trapped within the channel which seem to produce symptoms 
similar to schizophrenia and are also thought to cause acute pathomorphological changes 
termed Olney's lesions (Olney et al., 1989, Krystal et al., 2003). MK-801 (dizocilpine) is a 
high-affinity open channel blocker of the NMDA receptor that is considered fully 
trapping (Dingledine et al., 1999). It has a large dwell time due to its high affinity, and the 
N-site mutations on G1uN1 and G1uN2B as well as N+1 on the latter showed reduced 
affinity for MK-801 highlighting a potential binding site in this region (Kashiwagi et al., 
2002). MK-801 is also considered fully trapping meaning that the M3 region can close 
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and due to its high affinity it becomes trapped in the pore. Further residues involved in 
MK-801 binding are found on the Ml, M2 and M3 regions and these are shown in Figure 
11. The dissociative anaesthetics ketamine and phencyclidine are also considered fully 
trapping blockers of the NMDA receptor (Figure 12). These act in a similar manner to 
MK-801 producing schizophrenia-like effects that limit their use as therapeutics (Mealing 
et al., 1999, Krystal et al., 2003). 
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Figure 12: Structure of fully trapping blockers of the NMDA receptor. MK-801, 
phencyclidine (PCP) and ketamine are all though to be fully trapping compounds, meaning 
that they remain in the channel after the gate has closed due to their high affinity (Krystal et 
al., 2003). 
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1.9 Polyamines as Open channel Blockers 
Endogenous polyamines such as spermine, spermidine and putrescine (Figure 13) are 
present in most living cells and have a wide variety of essential functions (Childs et al., 
2003). They are involved in processes such as regulating nucleic acid packaging, DNA 
and RNA synthesis, apoptosis, transcription and translation. They can also act as 
electrostatic bridges between phosphate groups on nucleic acids, as well as interacting 
with other chain like molecules such as actin and microtubules. It has also been shown 
that polyamines can interact with ion channels such as inwardly rectifying potassium 
channels and ionotropic glutamate receptors (see Williams, 1997). 
As well as potentiation of the NMDA receptor, intracellular spermine can block the 
outward rectification of Ca 2+ permeable (without edited GluA2) AMPA receptors in a 
voltage-dependent manner that is prevented by the positively charged R at the Q/R site 
(Bowie and Mayer, 1995). Therefore receptors without GluA2 are inwardly rectifying due 
block by endogenous polyamines. As well as potentiating NMDA channels, extracellular 
spermine has also been shown to block them in a voltage-dependent manner suggesting 
open-channel block (Benveniste and Mayer, 1993). It is more potent at G1uN2A and 
G1uN2B than G1uN2C and G1uN2D, similar to Mg" (Williams et al., 1994, Williams, 
1995). Mutations at the N-site were shown to reduce the voltage-dependent block by 
spermine (Kashiwagi et al., 1997). At potentials less than 
-60 mV spermine can dissociate 
from its blocking site and permeate through the channel (Araneda et al., 1999). As 
spermine was a weak blocker of the NMDA receptor pore, improvements in potency 
were made by adding a bulky headgroup as seen in N'-Dansylspermine, (Chao et al., 
1997) (Figure 13). 
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Figure 13: Spermine and related compounds. The endogenous polyamines spermidine 
and spermine were modified to produce the more potent glutamate receptor blocking 
compound N1-Dansylspermine (Bowie and Mayer, 1995, Chao et al., 1997). 
1.9.1 PhTX 
Polyamine toxins with a similar structure to spermine are found in the venom of the 
parasitic wasp Philanthus triangulum, commonly known as the European beewolf (Piek, 
1986). The wasp attacks its prey by injecting venom at the head and the thorax causing 
paralysis. Although adults feed mainly on nectar and pollen, the female hunts honey bees 
to feed its larvae. The venom from Philanthur triangulum belongs to a group of related 
compounds known as the polyamine toxins. It was first shown to be active at 
quisqualate-sensitive glutamate receptors (qGluR) in the locust (May and Piek, 1979). Its 
most active constituent is Philanthotoxin-433 (PhTX-433) and its structure consists of a 
tyrosine head group with a butyryl side chain attached to a thermospermine moiety 
(Figure 14) (Williams, 1997). It is numbered according to the number of methylene 
groups between the amine groups on the polyamine chain. PhTX-433 was synthesised in 
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conjunction with the isomers PhTX-334 and PhTX-343 which were easier to produce 
(Eldefrawi et al., 1988). 
At muscle type nicotinic acetylcholine receptors (nAChR) in TE671 cells, PhTX-343 was 
shown to inhibit responses in a voltage-dependent manner (Mellor et al., 2003). PhTX- 
343 was shown to cause a large reduction in mean open time at nAChR and this, coupled 
with its voltage-dependence, indicated that it acted as an open channel blocker (Brier et 
al., 2003). Also, the same study showed that pre-application of PhTX-343 gave a voltage- 
independent block that may have been due to binding to the closed conformation of the 
channel, thereby enhancing desensitisation after agonist is bound. PhTX-343 has also 
been shown to block neuronal nAChR in a voltage-dependent manner when measured in 
PC12 cells (Liu et al., 1997). Adding an ether group into the polyamine chain also 
increased potency at nAChR and was optimal with 4-oxa-PhTX-83 (Figure 14). The 
potency of the PhTX compounds was also dependent on the length of the polyamine 
chain, as when it was reduced, potency decreased. Replacing amines with methylene 
groups increased potency and of these new structures PhTX-12 (Figure 14), which had 
12 methylene groups between the head group and the terminal amine, was the most 
potent (Brier et al., 2003). However, as it showed little voltage-dependence a second 
more superficial binding site was implicated. There is the possibility that the polyamine 
group folds back on itself when the polyamine amines were removed, causing the tail to 
bind to the head group (Tikhonov et al., 2004). Such a shape may stop the molecule 
entering the pore, possibly pushing it toward a more superficial binding site. 
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Figure 14: The naturally occurring PhTX-433 and synthetic analogues. PhTX-433 was 
the most active constituent of the toxin from the wasp Philanthus triangulum, but the synthetic 
agonists based on their structure were easier to produce starting with the thermospermine 
moiety (Williams, 1997). The further modifications are shown and these show differing 
patterns of activity at nAChR, AMPA and NMDA receptor (Mellor and Usherwood, 2004). 
42 
Similar to endogenous polyarnines, GluA2 lacking Ca 2+ permeable AMPA receptors are 
also blocked by PhTX-343 (Mellor et al., 2003, Andersen et al., 2006). Truncation of the 
polyamine chain reduced potency and reducing the number of amines to one (PhTX-12) 
impaired potency, but on the other hand leaving two amines (PhTX-83) produced an 
Ca2+ permeable AMPA receptor selective antagonist that was 100-fold more potent at 
these receptors than at NMDA and nACh receptors (Figure 14) (Mellor et al., 2003). 
PhTX-74 is another isomer that could be a selective for Ca2+ impermeable AMPA 
receptors as it has been shown to be selective for G1uA1 /A2 channels but not 
G1uA2/A3 receptors (Nilsen and England, 2007). However, the concentrations used (100 
and 500 µM) were high, and compared with the low IC50values found with GluA2 
lacking AMPA receptors it is not useful in vivo (Mellor et al., 2003). Furthermore, a 
recent poster presentation has indicated that the claims made in Nilsen and England 
(2007) were wrong, and that PhTX-74 may only preferentially blocked homomeric 
G1uA1 receptors, which is what could have been expected (Poulsen et al., 2010). 
A model of PhTX binding to the AMPA receptor states that two amine groups must pass 
beyond the selectivity filter so one amine can bind to the Q/R/N site and another to the 
exposed main chain oxygen at G+2 (Tikhonov et al., 2002, Andersen et al., 2006). The 
head group can then make multiple hydrogen bonds in the M3 segment of the channel. 
PhTX modifications have shown that at least a hexyl spacer is required between the 
charged amines to bind at both sites, as a larger chain reduced potency (Andersen et al., 
2006). When the amines were pushed toward the tail, as long as the chain length was 12, 
the potency could be restored. It may be that both amines were able to interact with the 
exposed oxygen of G+2 in this case. 
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NMDA responses from whole rat brain RNA expressed in Xenopus Oocytes have been 
shown to be inhibited by PhTX-343 (Mellor et al., 2003). It was less potent than at 
AMPA receptors, but more potent than at muscle nAChR. Unlike inhibition of 
recombinant AMPA receptors methylene substitutions that reduced the number of 
positive charges to two or one reduced potency, indicating at least three amine groups 
were required for optimal activity. Ether substitutions failed to produce a compound with 
more potency than PhTX-343 which may be because the negative charges in the pore 
region of the NMDA receptor could not accommodate the oxygen (Figure 14) 
(Bolshakov et al., 2000). For G1uN3 subunits of the NMDA receptor, there is a glycine at 
the N-site and a positively charged R at the N+1 site which may mean that these 
receptors are not blocked by PhTX-343 in a similar manner to GluA2 containing AMPA 
receptors which have the R at the Q/R site. 
1.9.2 Anthraquinone 
Anthraquinone (AQ) polyamines (Figure 15) are a group of open-channel blockers that 
have been shown to block the NMDA receptor (Kashiwagi et al., 2007). They are similar 
in structure to PhTX, with a polyamine tail group numbered in the same manner but with 
a different aromatic head group. Potency at the NMDA receptor is dependent on the 
number of positive charges on the chain, with the truncated AQ33 (IC50 5.6 µM) and 
AQ34 (IC50 7.1 µM) which had two positive charges showing reduced potency compared 
with AQ343 (IC50 0.39 µM) and AQ444 (IC50 0.57 µM) which had three charges 
(Kashiwagi et al., 2007). Some subunit selectivity was also found for AQ343 and AQ444 
as they had the lowest potency at G1uN1 /2C receptors Gin et al., 2007). 
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Figure 15: Structure of anthraquinone polyamines AQ343 and AQ444. These polyamines 
have a similar structure to the PhTX compounds and activity at NMDA receptors (Kashiwagi 
et al., 2007). 
Mutational studies have shown that the M3 region in G1uN1 is important for the potency 
of anthraquinone polyamines and may be involved in compound recognition (Kashiwagi 
et al., 2002). Mutations which widened the vestibule increased the potency of AQ343. 
The difference may be due to steric effects as AQ343 has a width of 8.3 A and AQ444 
has one of 6.5 A, with the latter possibly having a longer and more flattened tail group 
accounting for its smaller size. When the pore was widened AQ343 had the same 
potency. These compounds have also been shown to bind at the N-site of G1uN1, as a 
mutation to Q reduced the potency of AQ343 and AQ444 but G had no effect 
(Kashiwagi et al., 2002). At the same site in GluN2B, the Q mutation resulted in a loss of 
activity but the G mutation increased block by AQ343 (Kashiwagi et al., 2007). On 
G1uN1 the Q mutation may have inhibited the polyamine tail from entering the pore, 
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whereas expansion of the pore by G may have increased potency of AQ343 by no longer 
causing a steric hindrance. Beyond the level of the N-site a mutation in G1uN1 at E621 
which is five amino acids more intracellular reduced the potency of these compounds, 
showing that the tail group entered the pore (Kashiwagi et al., 2007). 
1.9.3 Argiotoxin 
Argiotoxin 636 (Arg636, Figure 16) is a toxin from the orb-web spider Aýgiope lobata and 
is active at insect and vertebrate ionotropic glutamate receptors (Mellor and Usherwood, 
2004). Unlike other polyamine compounds it is numbered according to its molecular 
weight. It is a voltage-dependent open channel blocker of the NMDA receptor, and is 
more potent at G1uN1 /2A (IC50 9.45 nM) and G1uN1 /2B (IC_44.5 nM) than at 
G1uN 1 /2C (IC50 460 nM) and binds in competition with Mg2+ and MK-801 (Raditsch et 
al., 1993, Raditsch et al., 1996). Mutations at the N-site to Q increased the potency of 
Arg636 
-1 0-fold at G1uN2A and G1uN2C indicating steric effects. Structural 
modifications have shown that at least three positive charges were required for optimal 
NMDA receptor antagonism similar to other polyamine compounds (Moe et al., 1998, 
Nelson et al., 2009). 
Arg636 has a similar potency at AMPA receptors and modifying the amine groups in the 
centre of the chain to methylene produced compounds that were selective between 
AMPA and NMDA receptors (Nelson et al., 2009). Modifying the central amine that 
resides toward the terminal guanidine group to methylene resulted in an 84-fold 
reduction in potency at NMDA, but no change at AMPA receptors; while altering the 
central amine group at the head end gave a -100-fold reduction in potency at AMPA, 
with no change at NMDA receptors. The same study proposed a binding model where 
an amine hydrogen bonds with the N-site in NMDA but not AMPA receptors, therefore 
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the loss of this group affects NMDA receptor potency. AMPA receptor potency is 
dependent on the terminal amine binding to the G+2 site deep in the pore (Nelson et al., 
2009) 
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Figure 16: Argiotoxin and related compounds. These compounds were isolated from the 
orb-web spider argiope lobata and depending on the number of amines were shown to be 
selective for AMPA over NMDA receptors or vice versa (Mellor and Usherwood, 2004). 
1.9.4 Methoctramine 
Methoctramine (Figure 17) is a symmetrical polyamine type molecule with a 2-methoxy 
benzyl head group at each end. It has a 686 methylene spacing between amine groups 
and a fully protonated charge of +4. It can selectively block muscarinic acetylcholine M2 
and M4 receptors and has a low affinity at M3 receptors, leaving M, receptors with an 
intermediate affinity (Melchiorre et al., 2003). It has an IC50 around 4.2 µM at nAChR's 
and increasing the number of methylenes between the inner amines increased potency 
(Bixel et al., 2000). Modifications to the compound that removed an amine, or replaced 
an amine with amide or ether, reduced potency at muscarinic, as well as nicotinic 
acetylcholine receptors. It is thought that the head group at each end of the chain binds 
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to different subunits of the nAChR with folding occurring resulting in a V-shaped chain 
whose point can bind deep in the pore (Rosini et al., 2002). Methoctramine can also 
inhibit the transient receptor potential cation channel, subfamily V, member 1 (TRPVI) 
in a non-competitive voltage dependent manner indicating open channel block (Mellor et 
at., 2004, Rosini et al., 1999). 
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Figure 17: The structure of methoctramine. Shown is the structure of methoctramine 
whose activity at recombinant NMDA receptors is currently unknown. 
1.10 Glycine-gated NMDA Receptors 
G1uN1 has been shown to form functional receptors in combination with G1uN3A or 
G1uN3B producing channels that did not respond to glutamate or NMDA, but were 
instead glycine gated (Chatterton et al., 2002). They desensitise over 10s, with 
G1uNl /G1uN3B receptors showing a rebound of increased current after glycine 
application was stopped (Madry et al., 2007). In Xenopus oocytes these channels are 
relatively insensitive to Mgt+, MK-801, memantine and APV compared with G1uN1 /2 
receptors. Also, D-serine did not activate G1uN1/3A receptors and only a small response 
was found for GluN1/3B (Chatterton et al., 2002). Mutations in the glycine binding 
domain of G1uN1 potentiated currents in response to glycine, but those in the GluN3 
glycine binding site reduced responses (Madry et al., 2007). The same study showed that 
the G1uN1 glycine site antagonist MDL-29951 potentiated glycine responses from 
G1uN1/3A and G1uN1/3B receptors. Furthermore, null mutations of the G1uN1 glycine 
binding site led to receptors that were opened by glycine binding to G1uN3 alone 
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(Awobuluyi et al., 2007). Taken together, it may be that glycine binds to G1uN3 subunits 
causing channel to open, and that binding to G1uN1 results in desensitisation. 
Zn2+ has been shown to potentiate glycine-gated currents in G1uN1 /3A receptors 
expressed in Xenopus oocytes (Madry et al., 2008). It occurred up to a maximum of 10- 
fold with 50 µM Zn 2' and 100 µM glycine. At concentrations greater than 100 µM, Zn 2+ 
was found to activate these receptors alone. In G1uN2 subunits the N-terminal domain 
binds Zn2+ as an allosteric modulator, but GluNI/3A glycine activated receptors with no 
N-terminal domain did not have altered potentiation by Zn 2+ (Madry et al., 2008). The 
same study showed that a G1uN3A mutation which abolished the glycine binding site led 
to no glycine induced current or potentiation of glycine induced current by Zn2+. A 
similar point mutation in GluN1 abolished Zn 2+ potentiation. 
It has been shown that GluN1/3A and G1uN1/3B receptors have a reversal potential 
around 
-10 mV (Madry et al., 2010). The study also showed that, whilst G1uN1/3B 
receptors had a linear I/V relationship, G1uN1 /3A showed block of inward current at 
potentials lower than 
-30 mV which was reversed by MDL-29951 and Zn2+. At -90 mV 
the effect of MDL-29951 on 3A (8-fold) was significantly more than G1uN1/3B (2-fold), 
but no difference was found at +30 mV. The I/V curve also became linear with the null 
mutation of the GluN1 glycine binding site indicating a link to desensitisation caused by 
this subunit. Furthermore, it was shown that removal of 1.8 mM Ca 2+ from the 
extracellular solution restored the linearity of the G1uN1/3A I/V curve and that 20 mM 
Ca2+ blocked the G1uN1/3A and GluN1/3B mediated current that was potentiated by 
Zn2+. Taken together, the authors claim that under physiological conditions G1uN1 /3A 
receptors are held under a Cat' block in a similar manner to Mg" block of G1uN1 /2 
receptors. 
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Using fluorescence tagged NMDA receptor subunits it has been shown that injection of 
G1uN1, GluN2 and G1uN3 into Xenopus oocytes may lead to separate populations of 
G1uN1/2 and GluN1/3 glycine activated NMDA receptors (Ulbrich and Isacoff, 2008). 
The same study also found that when GluN1, G1uN3A and G1uN3B were injected 
G1uN1/3A/3B receptors were preferentially formed over separate populations of 
G1uN1 /G1uN3A and G1uN1 /GluN3B. However, it was not tested if functional channels 
were produced and may represent the detection of dimer pairs. Co-immunoprecipitation 
of G1uN1 /3A and G1uN2B/3A was found in COS-7 cells, showing that these pairings 
can assemble together (Sasaki et al., 2002). In HEK-293 cells both G1uN1-1a and 
G1uN2A subunits were co-immunoprecipitated with hemagglutinin-tagged (HA) G1uN3B 
(Matsuda et al., 2002). Hippocampal neurones transfected with G1uN3B using the sindbis 
virus vector produced cell lysates after 24 hours that, when co-immunoprecipitated with 
anti-G1uN1 and anti-G1uN2A, were associated with G1uN3B (Matsuda et al., 2003). Brain 
membrane fractions also showed that Glut-la and G1uN2A were co-immunoprecipitated 
with G1uN3A (Das et al., 1998). It has also been shown that rat G1uN3A can associate 
with G1uN1 and G1uN2A separately in the endoplasmic reticulum of HEK-293 cells; but 
only when the receptor became a heteromer containing G1uN1 was it trafficked to the 
membrane (Perez-Otano et al., 2001). The same study showed that G1uN1/3 dimers 
could leave the ER, but required G1uN2A to produce functional channels. 
Glycine activated receptors similar to those found in Xenopus oocytes are not found in 
HEK-293 cells (Nishi et al., 2001, Perez-Otano et al., 2001). Instead, to produce similar 
channels it requires the expression of both G1uN3 subunits together with G1uN1 
(Smothers and Woodward, 2007). These G1uN1 /3A/3B receptors do not show a voltage 
dependent Mg2+ block, are not inhibited by APV, ifenprodil, memantine, MK-801 but are 
activated by D-serine (Chatterton et al., 2002, Smothers and Woodward, 2007). 
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Expression is dependent on the G1uN1 splice variant, as when it was changed more 
robust responses could be produced (Smothers and Woodward, 2009). Glycine activated 
currents were small with G1uN1-1a; but those with G1uN1-2a, G1uN1-3a and G1uN1-4a 
produced large currents indicating a role for the C-terminal in mediating surface 
expression of these channels. Differing expression dependent on splice variant 
dependent change was not found in Xenopus oocytes (Cavara et al., 2009). 
Despite the above in titnm findings, there is little evidence to support the existence of 
these channels in vivo. Glycine-gated currents were not found in hippocampal slices from 
wild-type or transgenic mice overexpressing G1uN3A (Tong et al., 2007). Single channel 
study of the same material found two distinct conductance states, 61 pS and 40 pS. These 
states had no direct transitions which may indicate two different types of receptor. As 
glycine alone did not elicit any state these may be populations of G1uN1-la/2A and 
G1uN1-1a/2A/3A. Glycine-gated currents were also not found in hippocampal cells that 
were transfected with G1uN3B (Matsuda et al., 2003). Single channel studies in parieto- 
occipital cortical neurones of eight day old mice had 56 and 26 pS conductances to 
NMDA/glycine, with no direct transitions, possibly indicating two receptor populations 
were present (Sasaki et al., 2002). Mg 2+ did not block the lower conductance, possibly 
indicating a glycine activated component, but glycine alone as agonist was not tested. 
Cultured cerebrocortical neurones were tested in the presence of strychnine (to block 
glycine receptors) and excitatory glycine responses that were blocked by D-serine have 
been found (Chatterton et al., 2002). However, these currents have also been shown to 
be present in neurones cultured from G1uN1 k/o mice, which is generally required for 
surface expression of NMDA receptors (Matsuda et al., 2003). 
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The evidence for G1uN1 /2/3 receptors in vivo is slightly more convincing. The 
transfection of G1uN3B into hippocampal neurones resulted in the subunit being 
incorporated into receptors that were already present (Matsuda et al., 2003). Neurones 
from G1uN3A overexpressing transgenic mice were less sensitive to Mg2+ and were less 
permeable to Cat+, while no glycine activated component was found (Tong et al., 2007). 
1.1 1 NMDA Receptor Distribution 
The G1uN1 subunit is required for expression of functional NMDA receptors (Okabe et 
al., 1999, Perez-Otano et al., 2001). In the rat, G1uN2B and G1uN2D are the most 
abundant in the neonate nervous system but as development progresses this shifts to 
G1uN2A and G1uN2C subunits being in the majority (Figure 18) (see Henson et al., 
2008). In the rat, G1uN3A expression follows a similar pattern to GluN2B and GluN2D, 
peaking at P8 and decreasing from P12 onward (Al-Hallaq et al., 2002, Wong et al., 
2002). In adult rats G1uN3B expression starts low and increases throughout development 
becoming ubiquitous throughout the nervous system, particularly motoneurones of the 
spinal cord and brainstem (Chatterton et al., 2002, Wee et al., 2008). However in humans, 
although expression peaks during maturation, GluN3A expression is found in all regions 
of the cerebral cortex, the subcortical forebrain, midbrain and hindbrain, with low levels 
in the spinal cord (Nilsson et al., 2007, Henson et al., 2010). Similarly In situ hybridisation 
of human adult brain slices revealed G1uN3B expression in the neuronal layers of the 
hippocampus, dentate gyrus and layer 5 of the cortex (Bendel et al., 2005). 
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Figure 18: Expression levels of NMDA receptor subunits (A) rat (B) human. Black 
indicates high levels of expression. Adapted from Henson et al., (2010). 
Although G1uN3 containing receptors can be localised to the postsynaptic density, there 
seems to be more present at perisynaptic and extrasynaptic locations (Perez-Otano et al., 
2006). These regions are active endocytotic sites and G1uN3A can be internalised by a 
PACSINI /sydapinl complex which is involved in clathrin-coated vesicle detachment 
(Kessels and Qualmann, 2002). GFP tagged GluN3A was visualised moving from the 
postsynaptic region in a manner that increased with agonist application and was 
decreased by blocking voltage-gated sodium channels (Perez-Otano et al., 2006). Such 
movement may represent transportation to a site where receptors are removed from the 
synapse ready for endocytosis, leading to the hypothesis that GluN3 subunits tag 
synapses ready for removal (see Henson et al., 2010). Excessive activity may lead to the 
receptors being replaced by mature synapses and those with limited activity could be 
removed by the PACSIN1 /sydapinl process. Supporting this is evidence that spine 
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elimination is related to takusan (Japanese adjective `many') proteins and the activity of 
these were up-regulated in G1uN3A-1- mice (Tu et al., 2007). It has been shown that 
when G1uN3A expression was forced to continue beyond its normal decay phase in the 
developing nervous system there was a reduction in plasticity, memory and the formation 
of mature synapses (Roberts et al., 2009). The impairment of development was reversible 
when the transgene system was removed, indicating that the removal of G1uN3A was the 
trigger for producing mature synapses. Another hypothesis is that the presence of GluN3 
during development increases threshold for synaptic activity to reduce excitotoxicity 
through reduced Ca 2+ permeability (see Henson et al., 2010). Once the mature synapses 
have been produced, there then may again be endocytosis allowing them to be replaced 
by mature receptors by the PACSIN 1 /sydapinl process. 
1.12 Alzheimer's Disease and the NMDA Receptor 
1.12.1 Svmatoms and Potential Causes 
It is estimated that worldwide 24.3 million people suffer from Alzheimer's disease (AD) 
and that around 4.6 million cases will be added every year (Ferri et al., 2005). It was first 
described by Alois Alzheimer whose patient Auguste Deter showed symptoms that 
included progressive cognitive impairment, confusion, mood swings, hallucinations, 
delusions and impaired memory. Post-mortem examination identified amyloid plaques, 
neurofibril tangles and arteriosclerotic changes that were later confirmed as being the 
cause of the disease that takes its discoverers' name. As Deter was 51 at the time of her 
disease her symptoms are now classified as pre-senile early onset AD (Goedert and 
Ghetti, 2007). 
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The plaques discovered by Alzheimer were found to be caused by aggregation of ß- 
amyloid protein (Aß) leading to the loss of mainly cholinergic neurones in the forebrain, 
cortex and hippocampus (Bowen et al., 1976, Glenner and Wong, 1984). Amyloid 
precursor protein (APP) is located in the plasma membrane and is processed by two 
different pathways, an amyloidogenic and a non-amyloidogenic pathway, by a family of 
secretase enzymes containing a, (3 and y subtypes (Figure 19) (LaFerla et al., 2007). In 
functional neurones non-toxic Aß,, is degraded by insulin degrading enzyme (IDE) and 
neprilysin (NEP), and an impairment in the balance between production and clearance 
may lead to an abnormal build-up (Vepsalainen et at, 2008). Alzheimer also described 
`dense bundles of fibrils' which were found to be tau, a microtubule associated protein 
(MAP) that shows an abnormal increase in phosphorylation (Grundke-Igbal et al., 1986). 
Under normal conditions it promotes the stable assembly of microtubules and regulates 
axonal transport (Konzack et al., 2007). Phosphorylation is increased 3-4 fold in AD 
which leads to reduced affinity of tau to microtubules impairing cellular transport 
(Bramblett et al., 1993). 
sAPPa APP 
P3 
retase a-secretase ýY. sec 4 7 
D C83 AIC 
sAPPO 
ß-secretase y secretase 
Aß 
C99 AICD 
Figure 19: Amyloidogenic (right) and non-amyloidogenic (left) pathways for APP 
processing. The amyloidogenic pathway takes APP which is cleaved by an a secretase to 
produce the membrane fragment C83 while releasing sAPPa. The remaining membrane 
fragment is then cleaved by y secretase releasing the fragment P3 and AICD. The non- 
amyloidogenic pathway on the right cleaves APP by ß-secretase which leaves the membrane 
fragment C99 and releases sAPP3. The membrane fragment is then cleaved by y-secretase 
to leave the membrane bound fragment AICD and releasing A. Adapted from LaFerla et al., 
(2007). 
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Familial AD is usually early onset and can be caused by mutations in the amyloid 
precursor protein gene on chromosome 21. Mutations or repetitions (such as Down's 
syndrome) can lead to an increase in the levels of Aß7.42 leading to a change in the Aß1.40: 
Aßl_42 ratio, with the latter thought to be more toxic, as well as increasing Aß generation 
and aggregation (see Tanzi and Bertram, 2005). A recent large scale genome wide study 
of AD brain tissue found a link to Apolipoprotein E (APOE), which is involved in lipid 
metabolism, and also found a link to another apolipoprotein, clusterin (Harold et al., 
2009). These proteins are also found at the blood brain barrier and may be the clearance 
mechanism for Aß out of the CNS (Zlokovic et al., 1994). Harold et al. (2009) also found 
a link to phosphatidylinositol-binding clathrin assembly protein (PICALM). It is 
expressed in all cells mediating clathrin endocytosis, and is required for intracellular 
trafficking. In AD PICALM may lead to endocytosis of APP, increasing AP release 
possibly through a link to soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor (SNARE) proteins (Yao et al., 2005, Harel et al., 2008). There is also a massive 
loss of cholinergic neurones and synapses in AD (Coyle et al., 1983). In the cortex it has 
been shown to lead to the loss of a4ß2, but not a7 homomeric acetylcholine receptors 
(AChR) (Court et al., 2001). 
There is evidence to suggest that oxidative damage plays a role in AD. It has been shown 
to occur at the greatest levels before the appearance of plaques; reducing as the disease 
progresses in human AD tissue and APP transgenic mice (Nunomura et al., 2001, Pratico 
et al., 2001). Furthermore, the binding of Cu 2+ and Fe3+ to A(3 reduced these metals 
producing the reactive oxygen species H202 by double electron transfer (Opazo et al., 
2002). H202 has also been shown to increase the levels of A 31 2 in foetal guinea pig 
neurones (Ohyagi et al., 2000). Free radicals can also open mitochondrial permeability 
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transition pores (mtPTP) which normally transport Ca2+ and proteins up to 1.5 kDa 
leading to `energy failure' (Sas et al., 2007). 
Single nucleotide polymorphisms (SNP) in G1uN3A have been linked to Alzheimer's 
disease in a Taiwanese cohort study (Liu et al., 2009). It was found that AD patients have 
a significantly higher occurrence of G compared with controls which had A at position 
3723. The residue is located in exon 9 which is C-terminal to M4 region and may interact 
with intracellular signalling proteins. A SNP in the G72/D-amino acid oxidase activator 
(DADA) gene was also linked to AD (Di Maria et al., 2009). G72 activates DADA 
increasing D-serine levels, and mutations would indirectly influence NMDA receptors at 
their glycine binding sites. SNP's in the promoter region for GRIN2B in a north Han 
Chinese cohort were also linked to AD (Jiang and Jia, 2009). 
1.12.2 The NMDA Receptor 
NMDA receptors have been shown to be implicated in AD. Aß 1-40 been shown to 
induce inward current, cause increased intracellular Ca" levels and cause cell death by 
activating NMDA and AMPA receptors (Alberdi et al., 2010). A(3 has been shown to 
reduce cell surface expression of NMDA receptors by promoting endocytosis of synaptic 
receptors in cortical neurones (Snyder et al., 2005). Injection of Aß140and A32535 into 
cultured pyramidal neurones has been shown to downregulate expression of the G1uN1 
subunit Qohansson et al., 2006). A separate study has shown that pre-treatment with Aß, 
_ 
42also significantly reduced GluN1 surface expression (Goto et al., 2006). These effects 
additionally suggest the involvement of the a7 nicotinic acetylcholine receptor (ACh) as 
the selective blockers a-bungarotoxin and methyllycaconitine were shown to block the 
reduction in cell surface expression (Snyder et al., 2005). Finally, A(3 has been shown to 
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directly enter neurones through NMDA receptors, as APV has been shown to block 
internalisation (Bi et al., 2002). 
200 nM AP, 
-, 
O was shown to inhibit NMDA responses in hippocampal neurones within 
minutes of activation (Raymond et al., 2003). The same study showed that A(3, 
_ß 
blocked 
LTP, but concentrations of MK-801 that inhibited NMDA currents by the same 
magnitude did not. It may be due to Aß having further actions downstream rather than 
directly inhibiting the channel itself. Aß142 has been shown to inhibit phosphorylation of 
cAMP response element binding (CREB) signalling through NMDA receptor activation, 
which is linked to the regulation of genes involved in neuronal survival, synapse 
formation and memory (Snyder et al., 2005). The fragment A2535 has been shown to 
displace radiolabelled glutamate and glycine in rat cortical membranes (Cowburn et al., 
1997). However, binding could have occurred at any glutamate receptor as selective 
agonists were not used. 
NMDA receptors mediate the activity of APP cleaving enzymes. Application of NMDA 
caused a shift from a-secretase to (3-secretase activity, producing `neuronal Kunitz 
protease inhibitory domain-APP' via a Cat' dependent process (Lesne et al., 2005). 
Double k/o mice for the presenelins PS1 and PS2 also caused a significant increase in 
G1uN2A expression (Aoki et al., 2009). NMDA receptor activation may promote the 
non-amyloidogenic pathway as it led to increases in C83 formation by a-secretase, with 
an attenuation of Aß, O production in cortical neurones (Hoey et al., 2009). Activation of 
NMDA receptors increased membrane trafficking of the x-secretase `a disintegrin and 
metalloproteinase domain', (ADAM) 10 (Marcello et al., 2007). 
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.i2.3 Excitotoxicity 
Even though glutamate it is the main excitatory transmitter in the nervous system, excess 
levels can be toxic to neurones (Lucas and Newhouse, 1957, Olney and Ho, 1970). There 
is 10 mM glutamate in the brain, with 0.00006 mM estimated to be extracellular (Lipton 
and Rosenberg, 1994). If the concentration increases to between 2-5 µM, damage can 
occur. Excitotoxicity can be a result of cerebral ischemia induced by stroke or cell death 
in disease states (see Hazell, 2007). There is a reduction in glutamate uptake into 
astrocytes due to the lack of blood flow because of `energy failure. ' The excess 
extracellular glutamate leads to increased levels of intracellular Ca 2+ through NMDA 
receptors resulting in apoptosis (Chen and Upton, 2006). Extracellular glutamate is 
removed quickly by high affinity amino acid transporters which can be found 
presynaptically, postsynaptically and in astrocytes (Danbolt, 2001). In glial cells glutamine 
synthase converts glutamate to glutamine, which is not toxic, and is taken up by neurones 
and converted back into glutamate 
- 
termed the glutamate-glutamine shuffle (Danbolt, 
2001). The levels of excitatory amino acid transporters in the hippocampus and gyrus 
frontalis medialis in brain tissue from AD patients is reduced, and these correlated to 
areas that contained amyloid plaques (Jacob et al., 2007). 
1.12.4 Treatment 
Memantine (Ebixa) is the only clinically tolerated NMDA antagonist approved for use in 
dementia. It fits the requirement of an antagonist that only blocks overactivity, leaving 
normal signalling intact. Memantine is a non-competitive low affinity open channel 
blocker with a fast off-rate, therefore it does not accumulate in the channel in the same 
manner as MK-801. The phase III clinical trial found that 20 mg memantine per day 
slowed the onset of AD, leading to its approval (Reisberg et al., 2003). 
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The established cholinergic role in AD led to the use of tacrine, an anticholinesterase 
inhibitor (AChEI), becoming the first drug approved for the treatment of AD (Figure 20) 
(see Rang et al., 2007). Acetylcholine esterase (AChE) is the neuronal enzyme that 
hydrolyses ACh, and is a member of the a/(3-hydrolase fold superfamily of proteins 
(Bourne et al., 1999). The main active site of AChE is centrosymmetric to the subunit 
and is located at the bottom of a narrow gorge at the rim of which is another aflosteric 
site, the peripheral anionic site. Tacrine led to improvements in memory and cognition 
for around 40% of patients; but also had cholinergic side effects such as nausea, 
abdominal cramps and hepatotoxicity. It had to be taken four times daily and patients 
had to be continually monitored for liver damage. Therefore other cholinesterase 
inhibitors were developed and these included donepezil, rivastigmine and galantamine 
(Figure 20). Donepezil is 1000-fold more selective for AChE than the peripheral choline 
esterase butyrylcholinesterase (BuChE) giving it a better side-effect profile (see Francis et 
al., 1999). 
AChEI are however not particularly effective in combating the symptoms of AD. It is 
estimated their use saves two months per year of disease progression; however, such 
outcomes may not be beneficial in a disease where quality of life is more important than 
actual life expectancy (Trinh et al., 2003). Such thinking led to a combination therapy 
approach using AChEI together with memantine treatment in order to exploit the 
beneficial effects of both compounds (Farlow, 2004). Studies have shown that 
rivastigmine, when combined with memantine, improved cognitive decline in patients 
that did not seem to improve on AChE alone (Dantoine et al., 2006, Riepe et al., 2006). 
It was also shown that donepezil and memantine treatment improved cognition (Tariot et 
al., 2004). 
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Figure 20: Structure of acetylcholine esterase inhibitors used clinically to treat AD. 
Tacrine, rivastigmine, galantamine and donepezil have all been shown to act as acetylcholine 
esterase inhibitors and have been used in the treatment of AD (Rang et al., 2007). 
1.12.5 Multi-Target Directed Ligands 
Combination therapy, although useful in a multifactorial disease such as AD, does have 
downsides. There can be an increase in side effects due to the multiple drugs involved, as 
well as unintended drug/drug interactions. Another approach would be to produce a 
single molecule with multiple biological properties that would reduce the difficulties such 
as differing pharmacokinetics/ pharmacodynamics and complex toxicological profiles. 
Producing a single molecule from differing drugs would limit optimisation to one 
compound, as toxicology is an exceedingly problematic area when moving to efficacy in 
man trials. There would be no drug/drug interactions and by its nature it would have a 
more simple treatment regime increasing compliance in patients with AD. Such an 
approach to drug design is termed multi-target directed ligands (MTDL). 
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The MTDL approach led to the production of a potential AD drug candidate memoquin 
(Figure 21) (Bolognesi et al., 2009a). The originator molecule caproctamine is an AChEI, 
and its large structure allows it to interact with both sites of the AChE enzyme. Into this 
backbone, the 1,4-benzoquinone radical scavenger moiety of CoQ (an antioxidant), was 
placed. The synthetic derivative of CoQ, idebenone, was shown in a fully randomised 
double-blind placebo controlled trial with 450 subjects to improve symptoms of AD over 
the two year study period (Gutzmann and Hadler, 1998). However, in a later similarly 
rigorous trial idebenone had no effect over the year of the study (Thal et al., 2003). In 
vitro, memoquin has been shown to retain its antioxidant and AChEI properties, inhibit 
aggregation of Aß and inhibit the ß-secretase, BACE-1 (Bolognesi et al., 2009a). Using 
the AD11 mouse model, memoquin was shown to prevent the loss of cholinergic 
neurones, inhibit Aß accumulation, reduce tau hyperphosphorylation and restore memory 
in object recognition tests, hence shows promise (Bolognesi et al., 2009a). 
Another MTDL, ladostigil, combined rivastigmine and rasagiline (Azilect, an MAO-B 
inhibitor) and is currently in phase II clinical trials (Figure 21) (Bolognesi et al., 2009b). It 
was shown to retain its AChE activity and retains MAO-B inhibition, but serendipitously 
added MAO-A activity. Inhibiting MAO reduces H202 production as well increasing 
monoamine levels, possibly giving the compound an antidepressant effect. It was also 
found to interfere with APP processing by stabilising the mitochondrial membrane 
potential, as well as inhibiting oxidative stress induced apoptosis (Bar-Am et al., 2009). 
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Figure 21: Structures of MTDL ligands and their originator molecules. CoQ and its 
synthetic derivative idebenone have been shown to act as anti-oxidants (Bolognesi et al., 
2009a). Caproctamine is an AChEI that has been shown to interact with both sites of the 
AChE enzyme. Memoquin is the MTDL that is formed by the combination of caproctamine and 
CoQ. Another MTDL is ladostigil which combines rasagiline which is an MAO-B inhibitor and 
the AChEI rivastigmine (Bolognesi et al., 2009b). Bis(7)-Tacrine is a modification of tacrine 
that allows it to bind to both sites of the AChE enzyme (Liu et al., 2008). 
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When using a MTDL approach potential candidates have to be identified with properties 
that have been shown to attenuate the effects of AD. Carvedilol is a vasodilating ß- 
blocker that acts as an antioxidant and is currently licensed for treatment of hypertension, 
angina and heart failure (Figure 22) (Lysko et al., 1998). In the streptozotocin-induced rat 
model of dementia it was shown to attenuate oxidative damage, reduce the associated 
increase in AChE activity and improve memory in the Morris water maze task when 
compared with those animals who did not receive treatment (Prakash and Kumar, 2009). 
It has also been shown to block Aß1., 0 fibril formation in a fibril-dependent immunoassay 
(Howlett et al., 1999). Although thought to be the non-toxic form Aß1.40 fibrils have been 
shown to be toxic in PC12 cells (Okada et al., 2007). However, CNS active (3-blockers 
(to which carvedilol belongs) do not impair cognition in normal subjects, but have been 
shown to impair memory retrieval in patients with AD and dementia which may limit 
their use as therapeutics (Gliebus and Lippa, 2007). Carvedilol may also be a 
neuroprotective open channel blocker of NMDA receptors as it could partially displace 
3[H]MK-801 binding with a KD that was 4,800-fold less potent than MK-801 (Lysko et al., 
1992). The same study showed that it could also reduce intracellular Ca2+ levels in 
cerebellar granule cells after exposure to NMDA and glycine. Carvedilol has also been 
shown to restore the activity of the Na+/glutamate transporter and block glutamate 
induced excitotoxicity (Lysko et al., 1994,1998). 
Lipoic acid is another potential candidate molecule suitable for the MTDL approach 
(Figure 22). It is a sulphur containing compound that is synthesised in mitochondria and 
is a co-factor for multienzyme complexes (Biewenga et al., 1997). It can also act as an 
anti-inflammatory antioxidant by modulating REDOX sensitive signalling, regenerate 
levels of other antioxidants such as glutathione, act as a carboxyl scavenger and stimulate 
glucose uptake into cells increasing energy metabolism (Biewenga et al., 1997, Holmquist 
64 
et al., 2007). Intraperitoneal injection of Aß25-35 amyloid fibrils into mice has been shown 
to increase the level of reactive oxygen species, cause lipid peroxidation, decrease 
antioxidant levels and decrease ATPase activity in hepatocytes, splenocytes and 
astrocytes; effects that were inhibited by lipoic acid Qesudason et al., 2008). Similarly 
AP2, 
-ss 
induced cell death in primary hippocampal cultures was reduced by pre-treatment 
with lipoic acid (Lovell et al., 2003). Twenty-four hour pre-treatment by lipoic acid 
inhibited glutamate induced toxicity in cultured neurones (Muller and Krieglstein, 1995). 
The reduced form of lipoic acid, dihydrolipoic acid, is required for the action of choline 
acetyl transferase and may act as a co-enzyme in the production of ACh, indicating 
further beneficial effects in AD (Haugaard and Levin, 2002). As lipoic acid can also act as 
an iron chelator and may possibly inhibit REDOX binding of metals in AD (Fonte et al., 
2001). The only published clinical trial testing the effectiveness of lipoic acid found that it 
slowed progression of the disease (Hager et al., 2007). However, it was only a basic 
cohort study that was not double-blinded, placebo controlled or randomised and AD was 
not confirmed post mortem. 
Lipoic acid has also been shown to improve memory in behavioural tasks in animal 
models of AD. Dietary supplementation in rats improved spatial memory performance in 
24.5 month old animals, pushing performance toward levels seen in 4.5 month old rats in 
the Morris water maze (Liu et al., 2002). A separate study has shown that with the 
Tg2576 mouse model of AD, animals tested at 10 months had improved performance 
when lipoic acid was added to their diet over a six months period, but the levels of Aß 
plaques in the brain post-mortem remained the same (Quinn et al., 2007). However, a 
separate study using the same model but with animals aged 6.25-11.5 months at onset, 
showed that 10 months chronic treatment had no effect on memory or levels of A(3 
measured at endpoint (Siedlak et al., 2009). 
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Figure 22: Candidate molecules for MTDL drug design approach. Shown is the ß-blocker 
carvedilol, lipoic acid and Medivations' dimebon. These compounds were all used to produce 
MTDL candidate drugs in the current study. (Biewenga et al., 1997, Lysko et al., 1998). 
The AChEI tacrine has displaced 3[H]MK-801 indicating binding at the pore of the 
NMDA receptor (Wang et al., 1999). The bis(7)-tacrine (N, N'-bis-(1,2,3,4- 
tetrahydroacridin-9-yl)heptane-1,7-diamine) form of tacrine inhibited NMDA receptor 
currents with a similar potency to memantine in rat hippocampal slices (Liu et al., 2008). 
The same study found that it had a relatively slow onset of activity and could also reduce 
the efficacy of NMDA by up to 40%. Inhibition was not voltage-dependent or 
competitive, possibly indicating an allosteric binding site or impairment of a downstream 
mechanism. At the single channel level it reduced open probability and frequency of 
opening, but had no effect on the mean open time. Block was shown to be sensitive to 
changes in pH, with the IC50 in cultured rat hippocampal neurones shifting to the right 
when pH was increased from 6.8 to 9 (Luo et al., 2007). The evidence suggests that it 
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affects proton sensing, but at a different site to spermidine as it was shown not to alter 
this inhibition. 
A further AChEI that may be useful for design of MTDL compounds is donepezil. As 
well its traditional function, it has been shown to displace 3[H]MK-801 binding but was 
shown to be less potent at doing so than tacrine (Wang et al., 1999). The blocking effect 
of donepezil was shown to have differing effects with varied concentrations. Between 1 
and 100 tM there was inhibition of NMDA currents in rat cortical neurones, but at 
higher concentrations currents were potentiated (Moriguchi et al., 2005). 
Another compound that may be useful in a MTDL drug design approach is dimebon 
(Latrepirdine) which was originally used as an anti-histamine in Russia, but fell out of use 
as more selective compounds became available (Figure 22) (Matveeva, 1983). It has been 
shown to have an IC50 (although not fitted with the Hill equation) around 100 µM when 
inhibiting NMDA induced currents in primary striatal neurones (Wu et al., 2008). In 
addition, the same study showed that pre-treatment with 50 µM dimebon blocked 
glutamate induced excitotoxicity. The group also carried out a commercial assay that 
showed activity at a-adrenergic (1A, a, B) a, D, and ate), histamine (H, and H) and 
serotonin (5-HTL, 5-HT5A, 5-HT2) receptors, with greater than 90% inhibition at 10 µM. 
At around 70-80% inhibition, receptors blocked were dopamine (D,, D2S, D3), 
imidazoline (I) as well as 5-HT2 and 5-HT2,. At 50 to 60% inhibition it blocked 
cytochrome CYP450 and 2C19 receptors, voltage-gated L-type Ca 2+ channels, dopamine 
D4.2 receptors and the 5-HT, receptor. Later radioligand binding studies also confirmed 
the compound to be a 5-HT6 receptor antagonist (Schaffhauser et al., 2009). It has also 
been shown to inhibit the opening of mtPTP pores in the mitochondria providing a 
further possible role in AD by blocking energy failure (Bachurin et al., 2003). 
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The effect of dimebon has been found using two mice models of AD to be undesirable. 
Neuroblastoma cells from mice overexpressing the Swedish mutation of APP showed a 
concentration dependent increase in extracellular Aß between 30 to 64% by dimebon 
(Steele et al., 2009). The same study showed that with TgCRND8 transgenic mice that 
had both the Swedish and Indiana mutation dimebon caused an increase in Aß1-42 in 
cortical synaptosomes. It also caused increased levels of Aß, 40in the hippocampal 
interstitial fluid of freely moving animals. However, dimebon has been shown to improve 
survival of cerebellar granule cells incubated with Aß25-35 (Urmontova et al., 2001). 
A randomised placebo controlled blinded trial for dimebon showed a significant 
improvement in the primary outcome measured by the Alzheimer's disease assessment 
scale-cognitive subscale (ADAS-cog) after 26 weeks (Doody et al., 2008). The study 
proved enough to get Pfizer interested in a partnership to carry out a global Phase III 
trial (ClinicalTrials. gov Identifier: NCT00675623). But a recent press release announced 
that the study failed to meet its primary and secondary outcomes. The global phase III 
study had the exact same protocol as the smaller study that showed promising results, 
and what could be leading to these differences is unclear. It may be that modifications 
based on its structure may lead to a more effective therapeutic. 
In support of its potential clinical use, a placebo-controlled trial of dimebon in 
Huntington disease did meet its primary outcome of clinical tolerability (Kieburtz et al., 
2010). Of the secondary outcomes, only the mini-mental state examination (MMSE) 
showed significant improvement, where the unified Huntington's disease rating scale 
(UHDRS) and ADAS-cog showed no significant differences. With such a wide range of 
targets, and its safe toxicological profile, it would be unwise to give up on dimebon too 
early. 
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1.13 Aims 
The aim of the work presented in this thesis was to determine what effects the presence 
of G1uN3A and G1uN3B subunits in NMDA receptor assemblies had on block by the 
well categorised open channel blockers Mgt+, memantine, and MK-801; as well as the 
lesser known compounds PhTX-343, PhTX-12 and methoctramine. The data was then 
used determine what changes in the pore region were brought about by the presence 
these subunits. Overall, the three main questions that were asked of the data were: was 
there an effect of subunit on the IC50 values for the blockers tested, and would this be 
restored by site-directed mutageneis. The second question that was asked was if block by 
the compounds was voltage-dependent, and if this was altered depending on the subunits 
that were expressed. The third main question that was asked of the data was how the 
potency of compounds compared to each other, and if this altered depending on the 
subunits tested. 
Furthermore, due to the G at the N-site, and the positively charged R at the N+1 site on 
the G1uN3 subunits, the polyamine toxin PhTX-343 was tested to determine if these 
amino acid changes impaired the ability to block similar to the R of the AMPA G1uA2 
subunit (Andersen et al., 2006). The ability for PhTX-12 to block G1uN3 was also tested 
to see if it had any changes in potency. As PhTX-12 is not thought to interact with the 
N-site the loss of these residues and replacement with GR may mean that block will be 
impaired less than what would be expected from PhTX-343. 
The N-site and N+1 site residues of the G1uN3A subunit were also individually mutated 
back to N to determine if the IC_, could be restored to levels found in receptors without 
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the G1uN3 subunit. Furthermore, aD mutation at the N+1 site was produced to 
determine what effect placing a negative charge at this position had on block. 
The aim of second part to the study was to test the MTDL compounds provided by Dr. 
Michela Rosini from the University of Bologna. The activity of these determined at the 
G1uN1-1a/2A containing NMDA receptors in order to establish their potential as 
therapeutics in the treatment of AD. 
The carbacrine compounds took tacrine, an acetylcholinesterase inhibitor, and combined 
it with the vasodilating ß blocker carvedilol to produce a group of compounds termed 
carbacrine (Lysko et al., 1998, Rang et al., 2007). The carbacrine group was also designed 
with increasing chain size between the pharmacophores. These compounds have a name 
as they have been previously described (Rosini et al., 2008). Compounds 1 and 2 were 
produced from donepezil, an acetylcholine esterase inhibitor, and carvedilol (Francis et 
al., 1999). Compounds 1 and 2 were numbered as they were unique entities described for 
the first time in this thesis. Compounds 3,4 and 5 were based on dimebon with differing 
linker regions between the two dimebon pharmacophores. Again these compounds were 
numbered as this is the first time they have been described. Lipocrine was produced from 
the combination of lipoic acid, an antioxidant, and tacrine, and has a name as it has been 
reported previously (Biewenga et al., 1997, Rosini et al., 2005). Compound 6 was derived 
from carvedilol and lipoic acid and takes a number as it is being first described in this 
thesis. 
The IC_, for these compounds were compared with that of memantine and, if similar, 
would hopefully show that they had promise as drug entities. Although they did not have 
specifically designed NMDA blocking pharmacophores, donepezil, tacrine and carvedilol 
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have all been shown to have some affinity toward the receptor (Wang et al., 1999, Wu et 
al., 2008). Therefore, their potency was measured to determine if these pharmacophores 
were all that would be required to produce effects similar to memantine, while retaining 
their original functions. 
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2 
Methods 
2.1 Cloning 
All the NMDA subunit clones used in the study were from the rat. JM109 E. coli were 
seeded in 5 ml of LB media (Sigma) and left overnight with vigorous shaking at 37.5 °C. 
The next day 5m1 of cells was poured into 50m1 of LB media and left for 2 hours under 
vigorous shaking at 37.5 °C in order for the cells to divide at an exponential rate. The cell 
suspension was spun at 10,000 G for 15 mins and the supernatant was removed. Cells 
were resuspended in 10m1 of chilled 0.1 M CaCl, placed on ice for 10 min and spun for 
15 min at 10,000 G. The supernatant was removed and cells were resuspended in 2 ml of 
0.1 M CaC1 and placed on ice, leaving Ca 2+ competent cells. GluN3A and G1uN3B 
(kindly gifted by Dr Zhang at the Burnham Institute California) were received on filter 
paper, extracted by adding 10 µl of DHCP water and left to soak for 5 mins. The paper 
was spun down to remove the liquid. Subsequently 2 µ1 was added to 200 µl of the 
competent cell suspension, then mixed and left on ice for 30 mins. The mixture was heat- 
shocked at 42 °C for 90 s in a water bath and placed on ice for 2 mins. To this 800µ1 of 
pre-warmed Super Optimal broth with Catabolite repression (SOC) (bacto-tryptone 20 
g/L, bacto-yeast extract 5 g/L, 10 mM NaCl, 2.5 mM KCI, 20 mM MgSO4) medium was 
added and the mixture was placed in the water bath for 45 min at 37.5 °C. 20011 of was 
then plated on 50 µg/ml ampicillin agar plates and left overnight in an incubator at 37 °C. 
The following day surviving colonies were picked and placed in 100 ml of LB media with 
50. tg/ml ampicillin and left overnight at 37 °C with 200 rpm shaking. 
Plasmid DNA was purified using the QAprep Spin mini preparation kit (Qiagen) by the 
following protocol. Cells were resuspended in 250 µl of buffer P1 and inverted five times. 
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250 µl of buffer P2 was added and the microcentrifuge tube was inverted until a 
homogeneous blue coloured suspension was achieved. 350 µl of Buffer N3 was added 
and the tube was inverted until all traces of blue had disappeared. The mixture was 
centrifuged for 10 mins at 17,000 G. Once complete, the supernatant was transferred to 
the QlAprep spin column. The column was centrifuged for 60s and the flow through 
discarded. The column was washed with 0.5 ml Buffer PB, centrifuged for 30-60s and the 
flow through discarded again. The column was further washed by adding 0.75 ml buffer 
PE and was centrifuged for 60s. The flow through was discarded and the column was 
centrifuged for a further minute to remove residual wash buffer. The column was placed 
in a new microcentrifuge tube and the plasmid was eluted by adding 50 µl of ddH2O to 
the centre of the column, left to stand for 1 min and then centrifuged for 1 min. The 
concentration of plasmid DNA was measured using a Nanodrop (Thermo Scientific). 
2.2 Sequencing 
The proposed rat GluN1-1a and G1uN2A subunits did not have vector maps so 
sequencing had to be carried out to confirm their identity. They were known to be cloned 
into a `prk7' plasmid and the sequence which was found at www. addgene. com. All DNA 
sequencing was carried out using a 3130 ABI PRISM Genetic Analyser at the Biopolymer 
Synthesis and Analysis Unit at the University of Nottingham. Sequencing was carried out 
for GluN1 using the primers SP6 and G1uN11 (Table 4). Those that were not standard 
were designed using VectorNTI to adhere around 200 bp upstream from the sequence of 
interest with the correct annealing temperature (Tm 50°C 
- 
80°C), to avoid hairpin loops 
and self hybridisation. GluN2A was cloned into the same plasmid so it was sequenced 
using SP6 and a separate primer designed upstream of the end of the insert and was 
named G1uN2_1 (Table 4). GluN3A and GluN3B were sequenced using T7 primer and 
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G1uN3A_1 and G1uN3B_1 which annealed upstream of the end of the insert. Restriction 
maps were produced using MacVector (MacVector Inc. ). 
Primer Name Sequence 
SP6 5'-GATTTAGGTGACACTATAG-3' 
T7 5'-TAATACGACTCACTATA-3' 
GIuN 11 5'-TCCTGCAACCCTCACTTTTGAGAACA-3' 
GIu N2 1 5'-CATCATATTGCTCCAGGGACAGTCG-3' 
EBV Rev 5'-GTGGTTTGTCCAAACTCATC-3' 
GIuN3A 1 5'-CTCAGAGGAGAAGAGAGCTCCCTGC-3' 
GIuN3B_1 5'-AACCTGGGGAGGCTGGCGGAGACCG-3' 
Table 4: Primers used for sequencing of the NMDA receptor subunits. SP6 and T7 are 
standard bacterial origin primers. GIuN1_I and GIuN2_1 were designed to anneal 200 bp 
from the stop codon of their respective inserts. EBV_Rev was designed to anneal within the 
plasmid. GIuN3A_1 and GIuN3B_1 were both designed to anneal 200 bp from the stop codon 
of their respective inserts. 
2.3 Restriction Digest 
Restriction digests were carried out to linearise the plasmid for mRNA production. 
Suitable restriction sites downstream of the gene of interest were identified by DNA 
sequencing and the relevant restriction enzymes were used. The total digest volume was 
20 µ1 and was carried out using the following reagents: 1 µg DNA, 1. l Restriction 
Enzyme (G1uN1-1a, BamHI; G1uN2A, EcoRI; G1uN3A, Nod and GluN3B, XbaI), 5 µl 
suitable buffer, 5 µl Bovine Serum Albumin (BSA) x 10. The mixtures were incubated 
for 1 hour and 30 µ1 of ddH2O was added then 2.5 µd of 0.5 M EDTA, 5 µl of 3M Na 
acetate and 100 
.l of ethanol. It was kept at -20 °C for an hour and spun at 17,000 G at 
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4°C for 25 min. The supernatant was removed and the microcentrifuge tube was spun at 
17,000 G at 4°C for 5 mins. The supernatant was again removed and the DNA was left 
to air dry for 5 mins, resuspended in a suitable volume of ddH2O and the concentration 
was measured using a Nanodrop (Thermo Scientific). 
2.4 Agarose Gel Electrophoresis 
Restriction digests were visualised using agarose gel electrophoresis to confirm the 
enzymes only cut once and that linearisation had occurred. 100 ml of stock 50x Tris- 
acetate-EDTA (TAE) buffer was produced (24.2 g Tris Base, 5.71 ml glacial acetic acid, 
10 ml 0.5 M EDTA). The TAE stock solution was diluted to 1x and to 50 ml 8% 
agarose was added and heated in a microwave. 10 of 1% ethidium bromide was added 
and the mixture was poured into a mould. The gel was placed in a gel electrophoresis kit 
(Bio-Rad) and 1x TAE buffer was poured in until the gel was covered. 1 kb plus ladder 
(Invitrogen) was added as well as 1 µl of the digested DNA and the gel was allowed to 
run at 100 V for 70 min. Bands were then visualised using Chemidoc XRS and quantity 
one image capture software (Bio-Rad). 
2.5 mRNA synthesis 
mRNA was produced using a mMESSAGE mMACHINE Kit (Ambion). The reaction 
assembly was the following: 10 µl NTP/CAP, 2 µl Reaction Buffer, 1 µg linear template 
DNA and 2 µl Enzyme Mix. This was incubated for 1h and the RNA was recovered 
using lithium chloride precipitation. 30 0 of nuclease free water and 30 µl of LiCI were 
added and the mixture was kept at 
-20 °C for an hour. The RNA was spun at 17,000 G at 
4°C for 15 min and the supernatant removed. The pellet was washed with 70% ethanol 
and spun for a further 15 min and the supernatant removed. The RNA was then 
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resuspended in a suitable volume of ddHZO and the concentration determined using a 
Nanodrop (Thermo Scientific). 
2.6 Mutations 
Mutations were produced using the QuikChange mutagenesis kit (Stratagene) by mixing 
together 5µl of 10 X reaction buffer, 50 ng of DNA template, 125 ng of sense primer 1, 
125 ng of antisense primer 2 (Table 6), 1 µl of dNTP mix. ddH2O was added to a final 
volume of 50 µl, to which 1 µl of PfuTurbo DNA polymerase was then placed. The 
reaction was run in a thermal cycler using the settings outlined in Table 5. 
Segment Cycles Temperature Time 
1 1 95°C 30S 
2 16 95°C 30S 
55°C 1 min 
68°C 9 min 
Table 5: Thermal cycler settings for the production of mutant DNA. The first segment 
contained only one denaturing step, while segment two was programmed to have one cycles 
as per the manufacturers instructions for one amino acid mutation. This segment contained a 
denaturing, annealing and extension step. 
The PCR reaction was digested with Dpnl restriction enzyme for 1h at 37°C. The 
digested DNA was transformed into X11-blue E. coli cells by heat shock, and DNA was 
purified using the miniprep procedure from 2.1. Sequencing was carried out using the 
G1uN3A 2 primer (Table 6). 
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Primer Sequence 
GIuN3A 2 5'-TCAATACCGCACGAAGCCAG-3' 
G703N_sense 5'-TCTGCTATGCCCTTCTGTTTAACAGAACAGCAGCCATCAAA-3' 
G703N_antisense 3'-AGACGATACGGGAAGACAAATTGTCTTGTCGTCGGTAGTTT-5' 
R704N_sense 5'-TCTGCTATGCCCTTCTGTTTGGCAATACAGCAGCCATCA-3' 
R704N_antisense 3'-AGACGATACGGGAAGACAAACCGTTATGTCGTCGGTAGT-5' 
R704D_sense 5'-CTATGCCCTTCTGTTTGGCGATACAGCAGCCATCAAACCCC-3' 
R704D_antisense 3'-GATACGGGAAGACAAACCGCTATGTCGTCGGTAGTTTGGGG-5' 
Table 6: Primers used for the production of GIuN3A mutations. GIuN3A_2 is the primer 
designed to anneal around 200 bp upstream from the mutation in the pore region. The 
remaining primers are the sense and antisense required to produce the mutations at position 
703 and 704. 
2.7 Oocyte Preparation 
Adult female Xenopus laevis were anaesthetised with MS-222 (Sigma) and a scalpel was 
used to make an incision on the ventral midline to expose the oocytes. These were 
removed and treated with 0.2 mg/ml collagenase in Ca2+ free gentamicin theophylline 
pyruvate (GTP, 96 mM NaC1,2 mM KC1,1mM MgC12,5 mM HEPES, 2.5 mM pyruvic 
acid, 0.5M theophylline, 5m1/1 gentamicin (50 mg/L), adjusted to pH7.5 with NaOH) to 
remove connective tissue and follicular cells. Oocytes were rinsed and stored in GTP (96 
mM NaCl, 2 mM KCI, 1.8 mM CaC12,1 mM MgCI2i 5 mM HEPES, 2.5 mM pyruvic acid, 
500 mM theophylline, 5 ml/1 gentamicin, adjusted to pH7.5 with NaOH) until required. 
Healthy oocytes were selected by eye and RNA encoding for the NMDA receptor 
subunits were injected using a nanolitre injector (World Precision Instruments). The 
RNA was injected at ratios of 1: 1 for G1uN1-la/2A (in the results section this is referred 
to as 1-la/2A) and 1: 1: 3 for G1uN1-1a/2A/3A (referred to in the results section as `3A') 
and GluN1-1a/2A/3B (referred to in the results section as `3BD. 50 nL was injected at a 
minimum concentration for each subunit of 50 ng/µL. Oocytes were incubated for two 
days at 18°C before assaying. 
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2.8 Electrophysiology 
Two electrode voltage clamp measurements were carried out using a voltage clamp 
amplifier (Gene Clamp 50, Axon) and recordings were sampled using an A/D converter 
(Digidata 1200) and recorded on an IBM compatible PC running WinEDR recording 
software (John Dempster, Strathclyde Electrophysiological Software) (Figure 23). 
Electrodes were produced using a P-97 Flaming Brown micropipette puller (Sutter 
Instruments Co) and had a resistance range of 0.5 to 3 MQ when filled with 3M KC1. 
Oocytes were placed in a bath and perfused with Mg2+ free Xenopus Ringer solution (96 
mM NaCl, 2 mM KC1,1.8 mM CaC12,10 mM HEPES adjusted to a pH of 7.5). 
Recordings were made at holding potentials of 
-100, -75 and -50 mV. Drugs were applied 
manually using a Valvelink 8 gravity perfusion system (Automatic Scientific Inc. ). 
Signal 
Generator Current 
Monitor 
n ý, 
Current 
Electrode 
Voltage 
Electrode 
Extraoellular 
Electrode 
Figure 23: TEVC recording setup for Xenopus oocytes. Shown is a cartoon representation 
of a TEVC recording setup. The voltage electrode and extracellular electrode are connected 
to a pre-amp and a signal generator which passes current to the oocytes to clamp the voltage 
at the desired voltage. 
Increasing concentrations of NMDA (0.01 µM to 1000 MM, Ascent Scientific) with 10 
µM glycine, and glycine (0.01 to 100 µM, Sigma) with 100 µM NMDA were applied to 
establish ECO values for the agonists at each receptor subtype. Mean-activation 
78 
measurements were made at each concentration of agonist as the percentage of 
maximum response. Agonist application also allowed saturating concentrations of agonist 
to be determined, and these were used when testing the open channel blockers. 
Increasing concentrations (between 0.01 µM and 100 µM) of the antagonists Mgt+, 
memantine (Sigma), PhTX-343, PhTX-12 (Both PhTX compounds gifts from Professor 
K Stromgaard, University of Copenhagen), methoctramine (gift from Dr Michela Rosini, 
University of Bologna) and MK-801 (Merck) were applied after a steady-state response to 
NMDA/glycine was reached. Mean-inhibition values were obtained from separate 
oocytes (at least three; typically six), across at least two different batches and were a 
percentage of the response to NMDA/glycine alone. 
EC50 values for 50% activation and ICS for 50% inhibition were calculated by fitting a 
four-parameter logistic equation (Hill equation) to concentration-response and 
concentration-inhibition plots respectively in Prism 5 (GraphPad Software Inc): 
1= 
Imax 
i+ 
[C] WH 
C; -. 
Where nH is the Hill coefficient, Imax is the predicted maximum current, [C] is the 
concentration of agonist or blocker, and XC50 is the concentration of agonist or blocker 
that produces a half-maximum inhibition or activation. 
To determine if the ICS values of the blockers were significantly different to each other 
they were compared pairwise using the extra sum-of-squares F-test to a null hypothesis 
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of ICS0 being the same for each pair (GraphPad Software Inc). Voltage-dependence was 
tested similarly, but as the F-test is omnibus and the results of individual pairwise 
comparisons were not necessary, the effect of voltage was determined by comparing the 
IC50 values for all three voltages to the null hypothesis of IC50 being the same at each 
voltage. The a level for statistical significance was set at 0.05. 
The Woodhull model was used to calculate the parameter 8 from the following equation 
(Woodhull, 1973, Ferrer-Montiel et al., 1998): 
zSV. mF I C50 (Vh) 
= 
1C5o (0 mV) x exp RT 
Where Z is the valence of the blocker (+2 for Mgt +1 for memantine, +3 for PhTX- 
343, +1 for PhTX-12, +4 for methoctramine and +1 for MK-801), Vh is the membrane 
potential (mV), R is the gas constant, T absolute temperature (K) and F is Faraday's 
constant (C/mol). 
I-V relationships were constructed by determining current in response to NMDA/glycine 
at a range of holding potentials. Oocytes were voltage-clamped between -100 and 0 mV 
in increments of 25 mV for the generation of I-V plots. Current was normalised to that at 
-75 mV. Linear regression was carried out in Prism 5 (GraphPad Software Inc) between - 
75 and 0 mV and the x intercept was considered the reversal potential. 
Peak/Plateau ratio measurements were made by dividing the peak level current with the 
plateau level current for each subunit at each voltage after NMDA/glycine application. 
These were analysed using the non-parametric Kruskal-Wallis test. Post-hoc analysis was 
carried out using Dunn's Multiple Comparison Test. Overall current levels produced after 
80 
NMDA/glycine application for the NMDA subunits were log transformed and 
compared by two-way AN OVA. Factors were `Current' and `voltage' and post-hoc 
analysis was carried out using the Bonferroni multiple comparison test. In order to test 
the claim of Ulbrich and Isacoff (2008) that two populations of receptor were produced 
in Xenopus oocytes when G1uN1/2 and 3 were injected, recordings were made with 
application of glycine and Zn2+ alone. 
The rise and decay of block were explored by taking steady-state current and applying 
IC50 concentrations of blocker until another steady state was achieved. The recovery 
phase was obtained by switching solutions back to NMDA/glycine until current returned 
to steady levels. Both the onset and decay phase of block were fitted well with a single 
exponential equation in WinWCP (John Dempster, Strathclyde Electrophysiological 
Software). These fits gave a time constant (T) for the rise and recovery of block which 
was repeated 4-8 times per blocker (separate oocytes over two batches) at 
-100, -75 and - 
50 mV at GluNl-la/2A, G1uN1-1a/2A/3A and GluN1-1a/2A/3B containing NMDA 
receptors. These were log transformed and compared using two-way ANOVA in Prism 5 
(GraphPad Software Inc). Factors were `Subunit' and `voltage' and post-hoc analysis was 
carried out using Bonferroni post tests. 
2.9 Multi Target Directed Ligands 
The study used a series of MTDLs are that are shown in Figure 24 (from Dr Michela 
Rosini, University of Bologna). The carbacrine compounds was tacrine, an 
acetylcholinesterase inhibitor, and the vasodilating (i blocken carvedilol (Lysko et al., 
1998, Rang et al., 2007). The differing group was designed with increasing chain size 
between the pharmacophores (Figure 24). Compounds group 1 and 2 were produced 
from donepezil, an acetylcholine esterase inhibitor, and carvedilol and are numbered 
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because they are unique entities described for the first time in this thesis (Francis et al., 
1999). Compounds la to le had increased chain length, while the compound 2 group had 
differing position for a methoxy group, and 2a and 2b had differing chain lengths (Figure 
24). Compounds 3,4 and 5 were based on dimebon with differing linker regions, while 
compounds 3a 
- 
3c had differing chain lengths (Figure 24). Again these compounds are 
numbered as this is the first time they have been described. Dimebon itself was also 
sourced from Dr Michela Rosini. Lipocrine was from the combination of lipoic acid, an 
antioxidant, and tacrine and has a number as it has been reported previously (Biewenga et 
al., 1997, Rosini et al., 2005). Compound 6 was derived from carvedilol and lipoic acid 
and takes a number as it is being first described in this thesis. 
Lipocrine, 1 and 2 were dissolved in a maximum of 1% DMSO. Activity was measured at 
V,, of 
-100, -80 and -50 mV, however, for 1 and 2 only -100 mV was tested due to limited 
availability. For the purposes of the current study 
-80 mV was chosen as the intermediate 
voltage to maintain parity with an already ongoing MTDL project (Rosini et al., 2008). 
The ICS0 values, voltage-dependence and Woodhull analysis were carried out as described 
above. 
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Figure 24: MTDL compounds tested at NMDA receptors. On the left is the originator 
molecules used to produce the MTDL compounds on the right. The values represented by n 
are the number of methylene groups between the positions indicated for clarity. 
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3 
Results 
3.1 Molecular Biology 
The plasmids containing rat G1uN1-1a and G1uN2A were labelled pRK7, but the plasmid 
maps were not available. The pRK7 plasmid (www. addgene. com) showed that it was 
under the control of a SP6 promoter sequence before the multiple cloning site. G1uN 1-1 a 
was sequenced using SP6 primer and the insert aligned with G1uN 1-1 a (U08261) (Figure 
25 and Figure 26). The alignment with GluN1-1b (U08263) showed that the Ni cassette 
was not present. The plasmid was also sequenced using the primer G1uN_1 which was 
designed to anneal around 200bp upstream from the C1 cassette (Figure 25). Sequence 
was aligned with GluN1-1a and G1uN1-2a (U08262) showing the C1 and C2 cassettes 
were present (Figure 27). Sequencing data from G1uN1_1 primer also showed the 
presence of a BamHI restriction site downstream of GluN1-la sequence which only 
appeared on the plasmid once (Figure 28). 
SP6 
ATG... (N1 
GIuN 1 
_1 
cl)-(C2 * 
Figure 25: Schematic representation exons that make up the splice variants of the 
GIuNI-1a receptor. White boxes represent exons of the sequence which are alternatively 
spliced, the N1 cassette (exon 5), C1 (exon 21) and C2 (exon 22). *represents the stop 
codon. Arrows denote primer sequencing regions and direction. 
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1 ICC 
1-la (11 ATGAGCACCATGCACCTGCTGACATTCGCCCTGCTTTTTTCCTGCTCCTTCGCCCGCGCCGCCTGCGACCCC. 4AGATCGTCAACATCGG000GGTGCTGA 
1-lb Cl) ATGAG(ACCATGCACCTGCTGACATTCGCCCTGCTTTTTTCCTGCTCCTTCGCCCGCGCCGCCTGCGACCCCAAGATCGTCAACATCGGCGCGGTSC1GA 
Sp6 (1) ATGAGCACCATGCACCTGCTGACATTCGCCCTGCTTTTTTCCTGCTCCTTCGCCCGCGCCGCCTGCGACCCCAAGATCGTCAACATCGGCGCGGTGCTGA 
1011 200 
1-la (10'-) GCACGCGCAAGCATGAACAGATGTTCCGCGAGGCAGTAAACCAGGCCAATAAGCGACACGGCTCTTGGAAGATACAGCTCAACGCCACTTCTGTCACCCA 
-lb (101) GCACGCGCAAGCATGAACAGATGTTCCGCGAGGCAGTAAACCAGGCCAATAAGCGACACGGCTCTTGGAAGATACAGCTCAACGCCACTTCTGTCACCCA 
sp6 ((01) GCACGCGCAAGCATGAACAGATGTTCCGCGAG, CAGTAAACCAGGCCAATAAGCGACACGGCTCTTGGAAGATACAGCTCAACGCCACTTCTGI'CACCCA 
201 300 
1-la (201) CAAGCCCAACGCCATACAGATGGCCCTGTCA3TGTGTGAGGACCTCATCTCTAGCCAGGTCTACGCTATCCTAGTTAGCCACCCGCCTACTCCCAACGAC 
. 
-lb (201) CAAGCCCAACGCCATACAGATGGCCCTGTCAGTGTGTGAGGACCTCATCTCTAGCCAGGTCTACGCTATCCTAGTTAGCCACCCGCCTACTCCCAACGAC 
ap6 (201) CAAGCCCAACGCCATACAGATGGCCCTGTCAGTGTGTGAGGACCTCATCTCTAGCCAGGTCTACGCTATCCTAGTTAGCCACCCGCCTACTCCCAACGAC 
301 4CC 
: 
-la (301) CACTTCACTCCCACCCCTGTCTCCTACACAGCTG0CTTCTACAGAATCCCTGTCCTGGGACTGACTACCCGAATGTCCATCTACTCTGACAAGAGTATCC 
, -lb (301) CACTTCACTCCCACCCCTGTCTCCTACACAGCTCGCTTCTACAGAATCCCTGTCCTGGGACTGACTACCCGAATGTCCATCTACTCTGACAAGAGTATCC 
sp6 (301) CACTTCACTCCCACCCCTGTCT'CCTACACAGCTGZ; CTTCTACAGAATCCCTGTCCTGGGACTGACTACCCGAATGTCCATCTACTCTGACAAGAGTATCC 
401 500 
:. 
-la (401) ACCTGAG'PTTCCTTCGCACGGTGCCGCCCTACTC. CACCAGTCCAGCGTCTGGTTTGAGATGATGCGAGTCTACAACTGGAACCACATCATCCTGCTGGT 
1-lb (401) ACCTGAGTTTCCTTCGCACGGTGCCGCCCTACTC-CACCAGTCCAGCGTCTGGTTTGAGATGATGCGAGTCTACAACTGGAACCACATCATCCTGCTGGT 
sp6 (401) ACCTGAGTTTCCTTCGCACGGTGCCGCCCTACTC7CACCAGTCCAGCGTCTGGTTTGAGATGATGCGAGTCTACAACTGGAACCACATCATCCTGCTGGT 
ý NI 
600 50'. 
i-la (501) CAGCGACGACCACGAGGGACGGGCAGCGCAGAAGZGCTTGGAGACGTTGCTGGAGGAACGGGAGTCCAAG------------------------------ 
1-lb (501) CAGCGACGACCACGAGGGACGGGCAGCGCAGAAG:: GCTTGGAGACGTTGCTGGAGGAACGGGAGT. CCAAGAGTAAAAAAAGGAACTATGAAAACCTCGAC 
sp6 (503) CAGCGACGACCACGAGGGACGGGCAGCGCAGAAGCGCTTGGAGACGTTGCTGGAGGAACGGGAGTCCAAG------------------------------ 
60. N1-i 70C 
1-la (571) 
--------------------------------- 
G-AGAGAAGGTGCTGCAGTTTGACCCAGGAACCAAGAATGTGACGGCTCTIGCTGATGGAGGC, 
--CGrG 
. 
-lb (601) CAACTGTCCTATGACAACAAGCGCGGACCCAAGGZAGAGAAGGTGCTGCAGTTTGACCCAGGAACCAAGAATGTGACGGCTCTGCTGATGGAGGCCCGGG 
sp6 (571) 
--------------------------------- 
GZAGAGAAGGTGCTGCAGTTTGACCCAGGAACCAAGAATGTGACGGCTCTG, TGA-GGAGGI, --',: GG 
701 600 
. 
-la (636) AACTGGAGGCCCGGGTCATCATCCTTTCTGCAAG: ýGAGGACGACGCTGCCACAGTGTACCGCGCAGCCGCAATGCTGAACATGACGGGCTCTGGGTACGT 
1-lb (701) AACTGGAGGCCCGGGTCATCATCCTTTCTGCAAGZGAGGACGACGCTGCCACAGTGTACCGCGCAGCCGCAATGCTGAACATGACGGGCTCTGGGTACGT 
Sp6 (638) AACTGGAGGCCCGGGTCATCATCCTTTCTGCAAG_GAGGACGACGCTGCCACAGTGTACCGCGCAGCCGCAATGCTGAACA^. GACGGGCTCT000TAC. G^. 
801 900 
1-la (738) GTGGCTGGTCGGGGAACGCGAGATCTCTGGGAAC3000TGCGCTACGCTCCTGATGGCATCATCGGACTTCAGCTCATCAATGGCAAGAATGAGTCAGCC 
1-lb (801) GTGGCTGGTCGGGGAACGCGAGATCTCTGGGAAC3000TGCGCTACGCTCCTGATGGCATCATCGGACTTCAGCTCATCAATGGCAAGAATGAGTCAGCC 
sp6 (738) GTGGCTGGTCGGGGAACGCGAGATCTCTGGGAAC3000TGCGCTACGCTCCTGATGGCATCATCGGACTTCAGCTCATCAATGGCAAGAATGAGTCAGCC 
901 921 
1-la (838) CACATCAGTGACGCCGTGGGC 
1-lb (901) CACATCAGTGACGCCGTGGGC 
sp6 (838) CACATCAGTGACGCCGTGGGC 
Figure 26: Sequence alignment for the proposed GIuN1-1a (SP6), GIuNI-1a and GIuNI- 
1b. Sequenced using SP6. Nucleotides are numbered from 1 starting at the A of the first ATG 
start codon in NRI-1 a. Shown is the N1 cassette which is only present in NRI-1b. 
2483 2582 
1-la (2483) TT^. TCCTCATTTTCAT^GAGATCGCCTACAAGCGACACAAGGATGCCCGTAGGAAGCAGATGCAGCTGGCTTTTGCAGCCGTGAACGTGTGGAGGAAGAA 
1-2a (2483) TT-TCCTCATTTTCATTGAGATCGCCTACAAGCGACACAAGGATGCCCGTAGGAAGCAGATGCAGCTGGCTTTTGCAGCCGTGAACGTGTGGAGGAAGAA 
G1uN: 
_1 
(1) TTTTCCTCATTTTCATTGAGA. TCGCCTACAAGCGACACAAGGATGCCCGTAGGAAGCAGATGCAGCTGGCTTTTGCAGCCGTGAACGTGTGGAGGAAGAA 
F-Cl 
2583 2682 
i-la (2583) CCTGCAGGATAGAAAGAGTGGTAGAGCAGAGCCCGACCCTAAAAAGAAAGCCACATTTAGGGCTATCACCTCCACCCTGGCCTCCAGCTTCAAGAGACGT 
"1-2a (2583) CCTGCAG--------------------------------------------------------------------------------------------- 
G1uN: 
_1 
(101) CCTGCAGGATAGAAAGAGTGGTAGAGCAGAGCCCGACCCTAAAAAGAAAGCCACATTTAGGGCTATCACCTCCACCCTGGCCTCCAGCTTCAAGAGACGT 
C1 ý-- C2 
2683 2782 
1-1a (2683) AGGTCCTCCAAAGACACGAGCACCGGGGGTGGACGCGGCGCTTTGCAAAACCAAAAAGACACAGTGCTGCCGCGACGCGCTATTGAGAGGGAGGAGGGCC 
: 
-2a (2590) ------------------AGCACCGGGGGTGGACGCGGCGCTTTGCAAAACCAAAAAGACACAGTGCTGCCGCGACGCGCTATTGAGAGGGAGGAGGGCC 
G1uN7_I (201) AGGTCCTCCAAAGACACGAGCACCGGGGGTGGAC_GCGGCGCTTTGCAAAACCAAAAAGACACAGTGCTGCCGCGACGCGCTATTGAGAGGGAGGAGGGCC 
2763 
C2 B mHI 2882 
1-1a (2783) AGCTGCAGCTGTGTTCCCGTCATAGGGAGAGCTG------------------------------------------------------------------ 
1-2a (2672) AGCTGCAGCTGTGTTCCCGTCATAGGGAGAGCTG------------------------------------------------------------------ 
G1uN1 1 (301) AGCTGCAGCTGTGTTCCCGTCATAGGGAGAGCTGATAGGATCCCCAATTCAATCGATGGCCGCCATGGCCCAACTTGTTTATTGCAGCTTATAATGGTTA 
2883 2982 
1-la (2818) 
---------------------------------------------------------------------------------------------------- 
1-2a (2706) 
---------------------------------------------------------------------------------------------------- 
GluNl 7 (401) CAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTC 
Figure 27: Sequence alignment for the proposed GIuNI-la (GluNI_1), GIuNI-la and 
GIuNI-2a. Proposed 1-1a sequenced using GIuN1_1 primer. Nucleotides are numbered from 
1 starting at the A of the first ATG start codon in 1-1 a. Shown are the C1 cassette which is 
not present in 1-2a, the C2 cassette and the BamHl restriction site. 
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Figure 28: Vector map for GIuN1-1a in pRK7. Shown are single cutter restriction enzyme 
sites. 
Further sequencing was carried out on the pRK7 G1uN2A plasmid. Sequencing data 
from the SP6 primer aligned with G1uN2A (D13211) which confirmed the presence of 
the insert in the plasmid (Figure 29). The plasmid was then sequenced using the primer 
GluN2_1 which was designed to anneal around 200bp upstream from the end of coding 
sequence. Sequence was aligned with G1uN2A confirming the presence of the insert, as 
well as the EcoRl restriction site downstream (Figure 30). The restriction map shows that 
EcoRI cut the plasmid once so it could be used for linearisation (Figure 31). 
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100 
2A (1) 
------------------------------- 
------------------_-_-------_--------------------------------------- 
sp6 (1) CAACTGCACCTCGGTTCTAAGCTTC': GCAGGTCGAC'PCTAGAAGAGAGGCTCCTGAGGTGCTGTGCCTGAGCATGGGGCTGGATGAGGTCTGAGAGTCGC 
01 200 
------- 2A (1) 
sp6 (101) GGCGGCAGCAATCAGCCCTGGAGATGACCAGGGGTGGCCACTGCTGAGAACTATGTGGAGAGAGGCTGCGAGCCCTGCTGCAGAGCCTCCGGCTGGGATA 
201 300 
----------------------------- 2A (1) 
sp6 (201) GCCGCCCCCCGTGGGGGTGATGCGGACAGCGCGGGACAGCCAGGGGAGCGCGCGGGGGCCGCAGCATGCGGGAACCCGCTAAACCTGGTGGCTGCTGAGG 
301 400 
2A (1) 
_______________________________________________________________________________ATGGGCAGATTGGGCTACTGG 
sp6 (301) CGGCCGAGATGCTCGTGCGCGCAGCACGCCCCATTGCATCCTCCACCTTCTCCGGCTACAGGGACCCTAAGTGGCGACCATGGGCAGATTGGGCTACTGG 
401 500 
2A (22) ACCTTGCTGGTATTGCCGGCCCTTCTGGTCTGGCGCGATCCGGCGCAGAACGCGGCGGCGGAGAAGGGTCCTCCAGCGCTGAACATTGCGGTGCTGCTGG 
sp6 (401) ACCTTGCTGGTATTGCCGGCCCTTCTGGTCTGGCGCGATCCGGCGCAGAACGCGGCGGCGGAGAAGGGTCCTCCAGCGCTGAACATTGCGGTGCTGCTGG 
501 600 
2A (: 22) GTCACAGCCACGACGTGACAGAACGCGAACTTCGAAATCTGTGGGGCCCAGAGCAGGCAACCGGCTTGCCCCTGGATGTGAACGTGGTGGCGTTATTGAT 
sp6 (501) GTCACAGCCACGACGTGACAGAACGCGAACTTCGAAATCTGTGGGGCCCAGAGCAGGCAACCGGCTTGCCCCTGGATGTGAACGTGGTGGCGTTATTGAT 
601 700 
2A (222) GAACCGCACTGACCCTAAGAGCCTCATCACGCATGTGTGCGACCTCATGTCCGGGGCGCGCATCCACGGCTTGGTGTTTGGAGATGACACGGACCAGGAG 
sp6 (601) GAACCGCACTGACCCTAAGAGCCTCATCACGCATGTGTGCGACCTCATGTCCGGGGCGCGCATCCACGGCTTGGTGTTTGGAGATGACACGGACCAGGAG 
701 800 
2A (322) GCTGTGGCCCAGATGCTGGATTTTATCTCCTCACAGACTTTTATCCCCATCTTGGGCATTCATGGGGGTGCATCTATGATCATGGCTGACAAGGATCCGA 
sp6 (701) GCTGTGGCCCAGATGCTGGATTTTATCTCCTCACAGACTTTTATCCCCATCTTGGGCATTCATGGGGGTGCATCTATGATCATGGCTGACAAGGATCCGA 
801 
2A (422) CATCC 
sp6 (801) CATCC 
Figure 29: Sequence alignment for the proposed GIuN2A (T7) plasmid and GIuN2A. 
GIuN2A sequenced using SP6. Nucleotides are numbered from 1 starting at the A of the ATG 
start codon in GIuN2A. 
4275 4374 
2A (4276) AGAGCA^GTTATGCCTTATGCTGCAAATAAGAATACCATGTACTCTACCCCCAGGGTTTTAAATTCCTGCAGCAATAGACGAGTGTACAAGAAAATGCCT 
G1uN2 1 (2) AGAG'-A'GTTATGCCTTATGCTGCAAATAAGAATACCATGTA:; CTA000CCAGGGTTTTAAATTCCTGCAGCAATAGACGAGTGTACAAGAAAATGCCT 
4375 4474 
2A (4376) AGTATCGAATCTGATGTTTAAGAT. CTTCC_______________________________________________________________________ 
G1uN2 1 (142) AG: A: CGAATCTGATGTTTAAGATCTTCCATCAGTATTTATCTATAAGGAAACATATAGAATGGCCAACATTATAGAGGGTAAATGTT'GGATGTCCGATA 
4475 4574 
2A ("4403) 
____________________________________________________________________________________________________ 
GI uN2 1 (202) GCACCC"'ACTAGGAGGAAGAGGG"ACAGGGAGGTACTTTTTGTTGGCTCTTTTGCACATGGCTCCATGCCATAATCTTCCACTCAAGGAATC. "TCTGAGA 
4575 4674 
2A ("4403) ---- ----------------------------------------------------------------------------------------------- 
G1uN2 1 (302) TATGTGCTGAGCACAGCATATACCAC7GTAGG-GAATCCTTAACCAAAAACAAATAAATACACATGGGCAAGTCTCCCAGACATGGCGACTGGGCACGGCG 
4675 4774 
2A ("4443) 
____________________________________________________________________________________________________ 
G1uN2 1 (442) GCAA^. 'AATGGTGCATCAGACGGCGATGGTGACATTGTGGTTGCCTATATTCCAAATTCCATGAAGATCAATCCACCATGTAACTTCCCCCATCAGAAATG 
4775 4874 
2A ("4403) 
------------------------------------------------'°---------------------------------____---___------ 
G1uN2 1 (502) CCTCACAGT'_TCTCTAATACAGAATAAGCAATATGGTATGCATGTAAGTCTGACGCAGACAATAAGACAGTTAAGAAT'GCATCTGCACTGTAGTAAGATT EcoRl 
4875 4974 
2A ("4403) 
____________________________________________________________________________________________________ 
G1uN2 1 (602) GACATGTGCAAGGATTAAGAAGTTTGGCTTGTAACAGTTCTCAGATTTCTTGTTATGCC^. TCCATGACAACCCTGGATCAGTCCCCCC. TCGT000GAATT 
4975 4985 
2A ("4403) 
----------- 
G1uN2 1 (702) CAATCGAT GC 
Figure 30: Sequence alignment for the proposed GIuN2A (GIuN2_1) plasmid and 
GIuN2A. Sequenced using GIuN2_1. Nucleotides are numbered from 1 starting at the A of the 
ATG start codon in GIuN2A. Also shown is the EcoRl site. 
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Figure 31: Vector map for GIuN2A in pRK7. Shown are single cutter restriction enzyme 
sites 
In order to confirm the G1uN3A was in pcDNA3.1 (+) it was sequenced using T7 primer 
and aligned with G1uN3A (U29873) (Figure 32). It was also sequenced using the primer 
G1uN3A_1 which was designed to anneal 200 bp upstream of the coding sequence 
(Figure 33). There was also a poly-(A) tail as well as a Nod restriction site downstream 
from the end of insert. Nod only appeared on the plasmid once as part of the multiple 
cloning site, and did not appear on G1uN3A (Figure 34). 
89 
1 100 
3A (1) 
------------------------------------------------------------ 
ATGAGGAGACIGAGTTTGTGGaGGCTGCTGAGCAGGGTCT 
T7 (1) GAGCTCGGATCCCCCGGGCTC-. CAGGAAT'TCGATCGCGCTTTCTCCCAGCGGGTCTCAGTAATGAGGAGACTGAGTTTGTGGTGGCTGCTGAGCAGGG^CT 
101 200 
3A (41) GTCTGCTGCTGCCGCCGCCCTGCGCACTGGTGCTGGCCGGGGTGCCCAGCTCCTCCTCGCACCCGCAACCCTGCCAGATCCTCAAGCGCATCGGACACGC 
T7 (101) GTCTGCTGCTGCCGCCGCCCTGCGCACTGGTGCTGGCCGGGGTGCCCAGCTCCTCCTCGCACCCGCAACCCTGCCAGATCCTCAAGCGCATCGGACACGC 
201 300 
3A (141) GGTGAGGGTGGGCGCGGTGCACTrGCAACCCTGGACCACGGCCCCACGCGCAGCCAGTCGCGCTCAGGAAGGCGGCAGGGCGGGTGCCCAGAGGGATGAT 
T7 (201) GGTGAGGGTGGGCGCGGTGCACTTGCAACCCTGGACCACGGCCCCACGCGCAGCCAGTCGCGCTCAGGAAGGCGGCAGGGCGGGTGCCCAGAGGGA^GAT 
301 400 
3A (241) CCAGAGTCCGGGACGTGGCGGCCACCGGCGCCCTCGCAAGGC3CACGCTGGTTGGGGAGCGCCCTGCATGGCCGG. GTCCA000GGCTCCCGAAAGCTCG 
T7 (301) CCAGAGTCCGGGACGTGGCGGCCACCGGCGCCC^. CGCAAGGCGCACGCTGGTTGGGGAGCGCCCTGCATGGCCGGGGTCCACCCGGCTCCCGAAAGC? CG 
401 500 
3A (341) GGGAGGGCGCGGGGGCCGAGACCCPG7G000GCGGGATGCCCTACTGT: CGCTGTGGAAAACTTGAACCGTGTGGAAGGGCTCCTACCCTACAACCTGTC 
T7 (401) GGGAGGGCGCGGGGGCCGAGACCCTGTGGCCGCGGGATGCCCTACTGTTCGCTGTGGAAAACTTGAACCGTGTGGAAGGGCTCCTACCCTACAACCTGTC 
501 600 
3A (441) TTTGGAAGTAGTGATGGC--ATTGAG. CG; GCCTGGGCGATCTGCCGCTTATGCCCTTCTCTTCCCCAAGCTCACCGTGGAGCAGTGACCCTTTCTCCTTT 
T7 (501) TTTGGAAGTAGTGATGGCCATTGAGGCGGGCCTGGGCGATCTGCCGCTTATGCCCTTCTCTTCCCCAAGCTCACCGTGGAGCAGTGACCCTTTCTCCTT°. 
601 628 
3A (541) CTGCAGAGCGTGTGCCACACCGTAGTGG 
T7 (601) CTGCAGAGCGTGTGCCACACCGTAGTGG 
Figure 32: Sequence alignment for GIuN3A sequenced by T7 aligned with GIuN3A. 
Nucleotides are numbered from 1 starting at the A of the ATG start codon in GIuN3A. 
3187,3286 
3A (3188) GGG. SAAGCAGACTCC(: TCAATG-AAC`. CGGAGCTCCGTGATTCAGGAACTCTCTGAGTTGGAGAAGCAGATCCAAGTGATCCCCAGGAGCTGCAGTTGG 
G1uN3A-I (2) GGGAAAGCAGACTCCCTCAA-GTAACTCGGAGCTCCGTGATTCAGG. TiACTCTCTGAGTTGGAGAAGCAGATCCAAGTGA^. 000CCACGAGCTGCAGTTGG 
3287 3386 
3A (3288) CTGTAAGCAGGAAoACAüA(3C-GGAGGAG. ATCA. sAGACAAATCGGACTT'GTGAAT'CC'CAG-------------------------------------- 
Gl']N3A_1 (102) C. 'GT 5Gi; AGGAAC; A"A(iAG("iGC; AC; GA(=, A7'CAAAAC; ACAAAT000A(: 1'T(iI'C; AFTC; CTAGGCTGTG1'C'1'C(; 000'C: A^: 'TCAGC(C( 1'c; (. 'PACTCT 
3387 3486 
3A ("3348) 
_____________________________________________ 
G1uN3A 1 (202) GAAGCCCTTGAGACACTTTGTAAAGCCCT^. TTATATTCCTTGACAAAGGTGTGGGGTCTGGCAATGAAGTGTGCTGTTCTCT3CCTATCGACCTCGAGGG 
348-7 3586 
3A ("3348) 
---------------------------------------------------------------------------------------------------- 
01uN3A_1 (302) GGAGCTTGATCTGG-TACCAC°. AAACCAGCCTCAAGAACACCCGAATGGAGTCTCTAAGCTACATAATACCAACTTACACTTTACAAAATGTTGTCCCCC 
3587 3666 
3A ("3348) 
-----------------------------------------------_____. 
-----------°_ 
GiuN3A_1 (402) AAAATGTAGCCAT. TCGTATCGCTCCTAATAAAAAGAAAGTTTCTTCACATTCT CCCCCCCCCCCCC 
NO 
3687 3721 
3A ("3348( 
----------------------------------- 
G1uN3A 1 (502) CCCCTGCAGGATCCAGCACAGTGGCGGCCGCTCGA 
Figure 33: Sequence alignment for GIuN3A plasmid and 3A. Sequenced using GIuN3A_1 
and also shown is Noti restriction site. 
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Figure 34: Vector map for GIuN3A in pcDNA3.1(+). Shown are single cutter restriction 
enzyme sites. 
GluN3B in pcDNA3.1(+) was sequenced using T7 primer and aligned with G1uN3B 
(AF440691), confirming its presence (Figure 35). However, a consensus difference at 
position 556 (A/G) was found (Figure 35). A BLAST search returned G1uN3B 
(AF440691) and no SNP was found. It was also sequenced using the primer G1uN3B_1 
which was designed to anneal 200bp upstream of the coding sequence where it aligned 
with GluN3B (Figure 36). A poly-(A) tail and Xbal restriction site were also found. Xbal 
only appeared on the plasmid once as part of the multiple cloning site, and did not 
appear on G1uN3B (Figure 37). 
91 
1 100 
G1uN3B (1) 
------------------------------------ 
ATGGAGASTC, -G-GGAC. GCTGTGC, CTCAGCC, TGGCCCTGGCGCTGGCGGTGGGCTCCCGAGTCG 
T7 (2) A'TCCACTAGTM'CAGT, T; GT3GAA? TCý; CCGCCGCCAT, GAGAGTGTGCGGACG^, TGTGGC'. CAGCGTGG000TGGCGCTGGCGGTGGGGT CCCGAGTGG 
101 200 
GI uN3B (66) TGCGCGGTCACC TCAG"CCTGC-G, GTTCC. CACGCGCGCT, CG CC9'CCGTG: GCCTGGCGGCGCTCCTGCCCCGGGCGCCCGCCGCCCGCGCCCGCGT 
TI (1 C2) TGCG^GGTCACC: TCAGCCCTGCCGGGTTCCCA^GCGC; CTGGGGCCTCCGTGCGCCTGGCGGCGCTCCTGCCCCGGGCGCCCGCCGCCCGCGCCCGCGT 
201 fJ0 
G1uN3B (166) CCTAG^.: GCCCTGGCCACCCCT3CGCC3CGGC7GCCGCACAACCTGAGTCTGGAACTGGTGGCCGTCGCGTCCCCGACCCGGGACCCCGCGTCGCTAGCT 
17 (202) CCTA3 TGCCC GGCCACCCCTGCGCC3CGGC-GCCGCACAACCTGAGTCTGGAAC7GGTGGCCGTCGCGT000CGACCCGGGACCCCGCG'TCGC; 'AGCT 
301 400 
G1uN3B (266) CGAGGTCTGTGC CAGG7 TC77, CCAC:: 000T, GCGTGGT GGCCTCTATAGCCTTTCCCGAGGCGCGGCCCGAGCTGCGGCTACTGCAGTTCCTGGCAGCCG 
T7 (302) CGAGGTCTG7000AGG4T'C: GGCACCGC:: TGGCGTGGTGGCCTCTATAGCC_TTCCCGAGGCGCGGCCCGAGC'TGCGGCTACTGCAGTTCCTGGCAGCCG 
401 500 
G1uN3B (366) CCACAGAGA7000AGTGGTGAG: GTCC;, CGGAG, GAGGTGCGCACGGCCCTCSGAGCCCCGACTCCG': TCCATCTGCAGCTGGACTGGGCTAGTCCCCT 
T7 (4C2) CCACAGAGACCCCAGTG, TGAG: 'GTCCT, CGGAGGGAGGTGCGCACGGCCCTCGGAGCCCCGACTCCGTTCCATCTGCAGCTGGACTGGGCTAGCCCCCT 
501 600 
G7 uN 3B (466( r. rAGA: 'CATACT: GATt-. f rGi 'f Afc 7CACATf im3; (; A 3ACATTCC"'CTAr-A(7TCT0Cr. rT(7TI'Cff, GA000TGGCAGCCTGGTG 
T7 (5C2) GGAGA,.. CATACT3GATGTGC^GGTGT-. C^. TýýTACGG-.. ACATGCCTGGGAGGACATTGCTCTAGTACTCTGCCGTGTCCGGGACCCTG, CGGCCTGGTG 
601 700 
G1uN3B (566) ACACTCTGGACTAACCATGCTAG^CA; C, 7TCCAAAGTT', GTGC': GGACCTGAGCCGGCTGGACAGCAGGAAGACAGCCTTCGGGCTGGACTGGCCCTGT 
T7 (602) ACACTCTGGACTAACCATGCTAGCCAGGCTCCAAAGTTT. GTGCTGGACCTGAGCCGGCTGGACAGCAGGAATGACAGCCTTCGGGCTGGACTGGCCCTGT 
701 800 
G1uN36 (666) TGGGGGCGCTGGAAGGA-, GGGGAAG^.. ^CAGTGC^_TGCAGCAGTCITCCTAGGCTGCAGCACTGCCCGTGCACATGAGGT'CCTAGAGGCTGCACCACCGGG 
T7 (702) TGGGGGCGCTGGAAGGAGGGGGAACCCCAGTGCCTG^. AGCAGTCCTCCTAGGCTGCAGCACTGCCCGTGCACATGAGGTCCTAGAGGCTGCACCACCGGG 
8C1 823 
G1uN3B (766) TCOCC_AGT'GGTTGC`GGGCACAC 
Ti (6C2) TCCCCAGTGGTTGCT3G CACAC 
Figure 35: Sequence alignment for GIuN3B sequence by T7 and aligned with GIuN3B. 
Nucleotides are numbered from I starting at the A of the ATG start codon in GluN3B. 
2856 2955 
3B (2257) AGCGGAGCTGCi3GGAGCTGGAGCTGCGCAT'PGAGGCTGCACGGGAGCGGCTGCGCAGTGCGCTGTTGCGGCGCGGGGAGCTGCGGGCCCTGCTTGGGGAT 
GO uN3B 1 (2) AGCGGAGCTGCGGGAGCTGGAGCTGCGCATTGAGGCI'GCACGGGAGCGGCTC, CGCAG'rGCGCTGTTGCGC, CGCGGGGAGCTGCGGGCCCTGC'77GGGGAT 
2956 3055 
3B (2957) GGCACCCGGCTCAGGCCACTGCGCCTGT7'GCATGCGGCGCCTGCTGAGAGCTGA------------------------"'------------------- 
G1uN30_1 (102) GGCACCCGGCTCAGGCCACTGCGCCTGTTGCATGCGGCGCCTGCTGAGAGCTGAGGAACCACAAGGCCG-, ACTGTCCACGA'AGTT TATTCTATATACAA 
Xbd 
3056 3155 
3B )"3009) 
---------------------------------------------------------------------------------------------------- 
G1uN3B 1 (202) ACACGAC1'CTIiTACAC'CGCAATTAAATACiCG'I'GGAACGTGAAAAAAAACTC'AGAGGGCCCGI'TTAAAC. CGCPGATCAGCCT CGACTGTGCCT'CC'lAG'1' 
3156 3255 
38 (. 3009) 
---------------------------------------------------------------------------------------------------- 
G1uN3B 1 (302) TGCCAGCCATCTGTTGTTTGCCCCTCCCCC, GTGCCTTCCTTGACCC. TGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAAT'. " GCATCGC 
516 3355 
3B ("3009) 
____________________________________________________________________________________________________ 
G1uN38 1 (402) ATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGT 
3356 3438 
3B ("3009) 
----------------------------------------------------------------------------------- 
G1uN30 1 (502) GGGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCGCCCTGTAGCGGCGCATTAAGCG 
Figure 36: Sequence alignment for proposed GIuN3B sequenced by GIuN1_1 and 
aligned with GIuN3B. Nucleotides are numbered from 1 starting at the A of the ATG start 
codon in GIuN3B. Also shown is the Xbal restriction site.. 
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Figure 37: Vector map for GIuN3B in pcDNA3.1(+). Shown are single cutter restriction 
enzyme sites. 
The G1uN3AG703N mutation was confirmed using primer G1uN3A_2, designed to anneal 
around 200 bp upstream from the N-site. The mutations G2185A and G2186A changed 
the codon from GGC (glycine) to AAC (asparagine) at amino acid position 703 (Figure 
38). The G1uN3AR704N mutation produced sequence that showed that G2189A and 
A2190T changed the codon from AGA (arginine) to AAT (asparagine) at amino acid 
position 704 (Figure 39). The mutation for G1uN3AR704Dwas sequenced and it was found 
that mutations A2188G, G2189A and A2190T changed the codon from AGA (arginine) 
to GAT (aspartate) at amino acid position 704 (Figure 40). 
93 
2000 2099 
3A (2000) GAGCCTTCATGTGGCCACTCCACTGGA^_. CATGTGGCTGGGAAT0TTCGTGGCTCTCCATATCACTGCCATTTTTCTCACTC'GTATGAATGGAAGAGCCC 
G1uN3A 2 (1) GAGCCTTCATGTGGCCACTCCACTGGACCATGTGGCTGGGAATTTTCGTGGCTCTCCATATCACTGCCATTTTTCTCACTC: 'GTATGAATGGAAGA000C 
2100 2199 
3A (2100) CTTTGGTATGACCCCTTJIGGGGAGGAACAGAAACAAFtGTCTTCTCCTTCTCC'CAGCTTTGAAT GTCTGCTA: GCCCTTCTGTTTGGCAGAACAGCAGCC 
G1uN3A 2 (101) CTTTGGTA^GACCCCTAAGGC{AGGAACAGAAACAAAGTCTT^. '"CCTTCTCCTCAGCTTTGAATGTCTGCTATGCCCTTCTGTTTAACAGAACAGCAGCC 
2200 2299 
3A (2200) A'I'CAAACCCCCAAAA'1'3"^GG. 4CTGGAAGGTTT:: °GATGAA'I'C'"'1'TGGGCCA'PTTTCI'GTATG'fT'. "TGCCTTTCT ACAI'A(-. ACAGCGAAC'PTGGCTGC: TG 
G1uN3A 2 (201) ATCAAACC-CCCAAAAT311TGGACTGGAAGGTTTCTGATGAATCTTTGGGCCATTTTCTGTATGTTTTGCCTTTCTACATACACAGCGAACTTGGCTGCTG 
2300 2399 
3A (2300) TCATGGTAGGT GAGAAGATCTATGAAGAGCTTTCTGGAATTCATGACCCTAAGCTTCATCATCCTTCTCAAGGCTTCCGCT'-TGGAACTG'^CCGGGAAAG 
G1UN3A 2 (301) TCATGGTAGCTGAGAAGATC'TATGAAGAGCTTTCTGGAATTCA. GACCCTAAGCTTCATCATCCTTCTCAAGGCTTCCGCT : 'TGGAACTGT000GGAAAG 
2400 2499 
3A (2400) CAGTGCT3AAGACTATG'TGCGCCAGAGCTTCCCAGAGATGCATGAGTACATGAGAAGGTACAACGTGCCAGCCACCCCTGA? GGAGTGCAGTATCTGAAG 
G1uN3A 2 (401) CAGTGCT3AAG. ACTATGTGCGCCAGAGC^. TCCCAGAGATGCATGAGTACATGAGAAGGTACAACGTGCCAGCCACCCCTGATGGAGTGCAGTATCTGAAG 
2500 2599 
3A (250C) AATGATCCAGAGAAACTAGACGCCTTCATCAI'GGACAAAGCCC: 'TCTGGATTATGAAGTGTCAATAGATGCTGACTGCAAGCTTCTGACCGTAGGAAAGC 
G1'N3A 2 (501) AATGATC^_AGAGAAACTAGACGCCTTCATCATGGACAAAGCCCTTCTGGATTATGAAGTGTCAAAGATGCTGACTGCAAGCTTCTGACCGTAGGAAAGC 
2600 2699 
3A (2600) CATTTGCCATCGAAGGATATý; GCATTGGTCTCCCTCCAAACTCTCCATTGACCTCTAATATATCTGAGCTCATCAGTCAGTACAAGTCTCACGGC: T': TAT 
G1uN3A 2 (601) CATT^-GCCATCGAAGGATA'f, GCATTGGTCTCCCTCCAAACTCTC7:: ATTGACCTCTAATATATCTGAGCTCATCAGTCAGTACAAGTCTCACGGGTT'"A1' 
2700 2785 
3A (2700) GGA1'G'IGCTCCA': 'GACAAGTC3CTA(CAAGG"'GGTTCCCTGCGGAAAGAGAAGCTTTGCCGTCACCGAGACTTTGCAAATGGGCATCA 
G1 uN3A 2 (701) GGATGTGCTCCATGACAAGT3GTACAAGGTGGTT000I'GCGGAAAGAGAAGCTTTGCCGTCACTGAGACTTTGCAAATGGGCATCA 
Figure 38: Sequence alignment for GluN3AG703N with 30' using primer GluN3A 2. 
Consensus differences are highlighted in yellow. 
1986 2085 
3A (1986) AGCAGCTCCAATTGGAGCCTTCATGTGGCCACTCCACTGGACCATGTGGCTGGGAATTTTCGTGGCTCTCCATATCACTGCCAT: 'TTTCTCACTCTGTAT 
G1uN3A 2 (+) AGCAGCTCCAATTGGAGCCTTCATGTvGCCACTCCACTGGACCATGTGGCTGGGAATTTTCGTGGCTCTCCATATCACTGCCATTTTTCTCACTCTGTAT 
2086 2185 
3A (2086) GAATGGAAGAGCCCCTTTOGTATGACCCCTAAGGGGAGGAACAGAAACAAAGTCTTCTCCTTCTCCTCAGCTTTGAATGTCTGCTATGCCCTTCTGTTTG 
G1uN3A 2 CO'. ) GAATGOAAGAGC. CCTTTGGTA^GACCCCTAAGGGGAGGAACAGAAACAAAGTCTTCTCCTTCTCCTCAGCTTTGAATGTCTGC'ATGCCCTTCTGTTTG 
2186 2285 
3A (2186) GCAGAACAGCAG-CATCAAACCCCCAAAATGCTGGACTGGAAGGTTTCTGATGAATCTTTGGGCCATTTTCTGTATGTTTTGCCT: 'TCTACATACACAGC 
GOON3A 2 (201) GCAATACAGCAGCCATCAAACCCCCAAAATGCTGGACTGGAAGGTTTCTGATGAATCTTTGGGCCATTTTCTGTATGTTTTGCC: TTCTACATACACAGC 
2286 2385 
3A (2286) GAACTTGGCTCCTCTCATGGTAGGTGAGAAGATC1'AT1AAGAGCT. TTCTGGAATTCATGACCCTAAGCTTCATCATCCTTCTCAAGGCTTCCGCTTTGGA 
G1cN3A 2 (301) GAACTTGGCTGCTGTCATGGTAGGTGAGAAGATCTATGAAGAGCTTTCTGGAATTCATGACCCTAAGCTTCATCATCCTTCTCAAGGCTTCCGCTTTGGA 
2.386 2485 
3A (2386) ACTGTCCGGGAAAGCAGTGCTGAAGACTATGTGCGCCAGAGCTTCCCAGAGATGCATGAGTACATGAGAAGGTACAAC3TGCCAGCCACCCCTGATGGAG 
GO N3A 2 (401) ACTGTCCGGGAAAGCAGTGCTGAAGACTATGTGCGCCAGAGCTTCCCAGAGATGCATGAGTACATGAGAAGGTACAACGTGCCAGCCACCCCTGATGGAG 
2486 2585 
3A (2486) TGCAGTATCTGAAGAATGATCCAGAGAAACTAGACGCCTTCATCATGGACAAAGCCCTTCTGGATTATGAAGTGTCAATAGATGCTGACTGCAAGCTTCT 
G1uN3A 2 (501) TGCAGTATCTGAAGAATGATCCAGAGAAACTAGACGCCTTCAT. CATGGACAAAGCCCTTCTGGATTATGAAGTGTCAATAGATGCTCACTGCAAGCTTCT 
2586 2665 
3A (2586) GACCGTAGGAAAGCCATTTGCCATCGAAGGATATGGCATTGGTCTCCCTCCAAACTCTCCATTGACCTCTAATATATCTG 
G1uN3A 2 (60: ) GACCGTAGGAAAGCCATTTGCCATCGAAGGATATGGCATTGGTCTCCCTCCAAACTCTCCATTGACCTCTAATATATCTG 
Figure 39: Sequence alignment for GluN3AR7"" with 3A'" using primer GluN3A 2. 
Consensus differences are highlighted in yellow. 
94 
1959 2058 
3A (1959) GGGGATC"'TAG'. GAGGACTCGAGACACAGCAGCTCCAA, TGIAGCCTTCATGTGGCCACTCCACTGGACCATGTGGCTGGGAAT-'T"CGIGGCTCTC('A'I, 
G1uN3A 2 (: ) GGGGATCI': AG: GAGGACTCGAGACACAGCAGCTCCAA-. -, vGAGCCTTCATGTGGCCAC'. 'CCAC": GGACCATGTGGCTGGGAATT^TCGTGGCTCTCCAT 
2019 2158 
3A (2059) ATCACTGCCATTT. TT. CTCACTC^. GTA'_*_; AATGGAAGAGCCCCTT'TGGTATGACCCCTAAGGGGAGGAACAGAAACAAAGTCTTCTCCTTCTCCTCAGCTT 
G1uN3A 2 (101) ATCACTGCCATTTS'TCTCACTCTGTATGAATGGAAGAGCCCCTTTGGTATGACCCCTAAGGGGAGGAACAGAAACAAAGTCTTC^. CCTTCTCCTCAGCTT 
2159 2258 
3A (2159) TGAATGTCTGC7ATGCCCTTCTGTTTGGCAGAACAGCAGCCATCAAACCCCCAAAATGCTGGACTGGAAGGTTTCTGATGAAY'CT. TG000CAT'TTTCTG 
G1uN3A 2 (20') TGAATGTC'GCTATGCCCTTCTGTTTGGCGATACAGCAGCCATCAAACCCCCAAAATGCTGGACTGGAAGGTTTCTGATGAATCTTTGGGCCATTTTCTG 
2259 2358 
3A (2259) TATGTTTTGCCTTTCTACATACACAGCGAACTTGGCTGCTGTCATGGTAGGTGAGAAGATCTATGAAGAGCTTTCTGGAATTCA': GA000TAAGCTTCAT 
G1uN3A 2 (30: ) TATGTTT. GC'C: TTCTACATACACAGCGAACTTGGC'PSCTG'. "CAT. GGTAGGTGAGAAGATCTATGAAGAGCTTTCTGGAA'. TCATTA000TAAGCTTCAT 
23(9 2458 
3A (2359) CATCCT^CTCAAGGCTTCCGCT. '7GGAAC^GTCCGGGAAAGCAGTGCTGAAGACTATGTGCGCCAGAGCTTCCCAGAGATGCATGAGTACATGAGAAGGT 
G1uN3A 2 (40: ) CATCCT? CT. CAAGGCTTCCGCTTTGGAACTGTCCGGGAAAGCAGTGCTGAAGACTATGTGCGCCAGAGCTTCCCAGAGATGCATGAGTACATGAGAAGGT 
2459 2558 
3A (2459) ACAACGTGCCAGCCACCCCTGA^_GGAGTGCAGTATCTGAAGAATGATCCAGAGAAACTAGACGCCTTCATCATGGACAAAGCCCTTCT'GGATTATGAAGT 
G1uN3A 2 (501) ACAACGTGCCAGCCACCCCTGATGGAGTGCAGTATCTGAAGAATGATCCAGAGAAACTAGACGCCTTCATCATGGACAAAGCCCTTCTGGATTATGAAGT 
2559 2658 
3A (2559) GTCAATAGATGCTGACTGCAAGCTTCTGACCGTAGGAAAGCCATTTGCCATCGAAGGATATGGCATTGGTCTCCCTCCAAACTCTCCATTGACCTCTAAT 
G1uN3A 2 (60? ) GTCAATAGATGCTGACTGCAAGCTTCTGACCGTAGGAAAGCCATTTGCCATCGAAGGATATGGCATTGGTCTCCCTCCAAACTCTCCATTGACCTCTAAT 
2659 2691 
3A (2659) ATATCTGAGCTCATCAGTCAGTACAAGTCTCAC 
G1uN3A 2 (101) ATATCTGAGCTCATCACTCAGTACAAGTCTCAC 
Figure 40: Sequence alignment for GluN3AR704O with 3A'"4 using primer GIuN3A 2. 
Consensus differences are highlighted in yellow. 
3.2 cRNA Synthesis 
In order to confirm if the restriction sites identified by bioinformatic analysis for 
linearisation of the plasmid cut only once, agarose gel electrophoresis was carried out. 
The subunits GluN1-1a, G1uN2A, G1uN3A and G1uN3B were cut with the appropriate 
enzymes and all produced single bands (Figure 41). The RNA was then visualised and the 
bands that were produced were of the correct size (Figure 41). 
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Figure 41: Agarose gel electrophoresis of NMDA receptor subunits. (A) GIuN1 and 
GIuN2 DNA single digest. Lanes show ladder, GluN1-1a cut with BamHl, GluN1-1a uncut 
plasmid, GIuN2A cut with EcoRl and GIuN2A uncut plasmid. (B) GIuN3A and GIuN3B DNA 
single digest. Lanes show 1kbplus ladder, GIuN3A uncut, GIuN3A cut with Noll, GIuN3B uncut 
and GIuN3B cut with Xbal. (C) GIuN1 and GIuN2 RNA. Lanes showing 1 kb plus DNA ladder 
and cRNA from GIuN1-1a, 2A, +ve and 
-ve controls. (D) GIuN3A and GIuN3B RNA. Lanes 
showing 1kb plus DNA ladder and cRNA from 1-1a, 2A, +ve and 
-ve controls. 
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3.3 Agonist 
Concentration-response data for NMDA, using 10 µM glycine as a co-agonist, were used 
to estimate EC50at 1-1a/2A, 3A and 3B receptors (Figure 42, Figure 43, Table 7). The 
EC, O for NMDA was not significantly different at all subunit combinations tested 
(between 5 and 10 µM). The EC50 for glycine was determined using 100 µM NMDA 
(Figure 43, Table 7). The presence of 3A and 3B produced EC50 values for glycine that 
were not significantly different to each other, but were now significantly lower than 1- 
la/2A. At 10 pM glycine and 100 µM NMDA the maximum response was elicited, while 
at concentrations above this efficacy was reduced. Therefore, 10 µM glycine and 100 µM 
NMDA were considered maximal and were used to elicit responses for the remainder of 
the study. 
0.001 0.01 1 10 
100 1000 
NMDA (NM) 
(+10 pM Glycine) 
500 nA 
20s 
Figure 42: TEVC current recording of increasing concentrations of NMDA currents 
mediated by 1-1a/2A containing NMDA receptors at -50 mV. Shown are responses to 
increasing concentrations of NMDA in the presence of 10 pM Glycine. 
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Agonist EC50 
Subunit (95% CI M 
NMDA Glycine 
1-1 a/2A 8.46 1.27 4.90 to 14.60 0.67 to 2.39 
10.58 0.37 
3A 6.65 to 16.82 0.24 to 0.58 
*P=0.3118 *P<0.001 
5.66 0.44 
2.34 to 13.72 0.19 to 0.99 
3B 
*P=0.458 *P<0.001 
tP=0.225 tP=0.654 
Table 7: EC50(95% Cl) values for NMDA and glycine at 1-1a/2A, 3A and 3B containing 
NMDA receptors. * denotes statistical significance against 1-1a/2A and t denotes 
significance against 3A. 
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Figure 43: Concentration response relationship for NMDA and glycine in 1-1a/2A, 3A 
and 3B containing NMDA receptors at 
-50 mV. % control response (mean ± S. E. M, n=3-8) 
values were plotted and fitted with the Hill equation (A, C to give estimates of EC50 (B, D). 
NMDA EC50 was calculated using 10 pM glycine, while the glycine EC50 was calculated using 
100 pM NMDA. Bars show EC5o (95% Cl) NM. Groups that do not share a letter are 
statistically significant. 
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3.4 Wild-type 
3.4.1 IN Relationship 
I/V relationships were produced from voltage steps between 
-125 and -0 mV (Figure 44). 
These were then used to produce the mean at each voltage and were fitted with a linear 
equation to give the reversal potential (Figure 45). For 1-la/2A in 2 mM Ca'+VR = 12.15 
(95% CI 
-19.37 to 43.68) mV and was reduced with 3A containing receptors toVR =- 
2.646 (95% Cl 
-16.89 to 11.60) mV. 
NMDA/Glycine 
200 nA 
25 s 
-0 mV 
- 
-25 mV 
- 
-50 mV 
- -75 mV 
- 
-100 mV 
- -125 mV 
Figure 44: TEVC current recording of NMDA/glycine currents mediated by 1-1a/2A 
containing NMDA receptors at 0 to 
-125 mV. Recordings were made from one individual 
oocyte. 
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Figure 45: IN relationship 1-1a/2A and 3A receptors. Discrete voltage steps between 
-100 
and 0 mV normalised to current at 
-75 mV (mean ± S. E. M., n=4-8). 
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3.4.2 Steady-State Current 
The steady state current for each oocytes response was established for each oocyte 
(Figure 46). In order to determine if the presence of the G1uN3 subunits had any effect 
on inward current, two-way ANOVA was carried out (Figure 47). Post-hoc analysis 
using the Bonferroni test for multiple comparisons revealed that there was a significant 
reduction in current for 3A (P<0.001) and 3B (P<0.001) compared with 1-la/2A, and no 
difference between the G1uN3 subunits at all voltages tested. 
1-1a/2A 
NMDA/Glycine 
Plateau/ 
200 nA Peak Steady State Current 
10s 
Figure 46: Location on recording trace where peak and plateau measurements were 
taken. Response from Xenopus oocytes expressing 1-1a/2A NMDA receptors in response to 
NMDA/glycine. Steady state current is highlighted and is the level at which current was 
compared between subunits. The peak current level was used to calculate the peak/plateau 
ratio for section 3.4.3. 
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Figure 47: Effect of subunit and voltage on steady-state current recorded for 1-1a/2A, 
3A and 3B NMDA receptors. Bars represent mean (95% Cl, n=40-85) log current (nA). Two- 
way ANOVA subunit (P<0.001), voltage (P=0.198) subunit x voltage interaction (P=0.353). 
Within a voltage, bars that do not share a letter are significantly different (Bonferroni P<0.05). 
3.4.3 Peak/Plateau Ratio 
The ratio of peak current to steady state response was measured for 1-1a/2A, 3A and 3B 
containing receptors at 
-100, -75 and -50 mV (Figure 48). Numbers tending toward one 
indicate no difference between the peak and plateau levels. At 
-100 mV the Kruskal- 
Wallis test showed a significant effect of subunit on ratio (P<0.001). Post hoc testing 
using Dunn's Multiple Comparison Test found that the ratio at 3A and 3B were not 
significantly different to each other, but there was a significant reduction in the ratio for 
3A and 3B (both P<0.001) compared with 1-la/2A at 
-100 mV. At -75 mV there was a 
significant effect of subunit (P<0.001) and post-hoc testing found again that 3A and 3B 
(both P<0.001) significantly reduced the ratio compared with 1-1a/2A. However, it was 
found that at this voltage 3A was significantly lower than 3B (P<0.01). At -50 mV the 
same pattern was found as 
-100 mV. 
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Figure 48: Effect of subunit on Peak/Plateau ratio. Bars show mean ratio (95% Cl, n=40- 
85). Kruskal-Wallis test, subunit (P<0.001). Within a voltage, bars that do not share a letter 
are significantly different. PostHoc Dunn's Multiple Comparison Test (P<0.05). 
3.4.4 Glycine Activation 
It was found that 1 mM glycine, and 1 mM glycine with 1 mM Zn`+, did not activate 3A 
containing receptors. When NMDA/glycine was applied the receptors showed inward 
current as expected (Figure 49). 
Glycine (1 mM) 
Glycine (1 mM) Zn2 (1 mM) 
ýwm 
10 nA 
Figure 49: TEVC current recording of attempted glycine activation of currents mediated 
by 3A containing NMDA receptors at 
-50 mV. Recordings were made from the same 
oocyte. 
102 
-100 -75 -50 
NMDA (0.1 mM) 
Glycine (0.01 mM) 
3.4.5 NMDA Receptor Antagonism 
Block by increasing concentrations of Mg2+ of NMDA/glycine responses for 1-la/2A, 
3A and 3B containing receptors were used to calculate the IC50 (Figure 50, Table 8). At all 
voltages, block by Mgg+ at 1-la/2A had the lowest ICSOwhich was significantly lower than 
3A and 3B. 3A had an intermediate ICO for Mg2+ which was significantly lower than 3B. 
These data gave a subunit order of IC50 for Mg" at all voltages of as 1-1a/2A<3A<3B. 
IC50 (95% Cl) pM 
Voltage (mV) 1a/2A 3A 3B 
1.74 5.83 15.74 
1.48 to 20.44 4.99 to 6.81 12.09 to 20.50 
-100 
*P<0.001 *P<0.001 
tp<0.001 
4.23 22.35 40.07 
3.48 to 5.13 19.00 to 26.29 30.14 to 53.28 
-75 
*P<0.001 *P<0.001 
tp<0.001 
16.03 25.77 71.59 
12.77 to 20.12 1.92 to 3.46 55.71 to 92.01 
-50 
*P<0.001 *P<0.001 
P<0.001 
Table 8: IC50 values for Mg2+ block of NMDA/glyclne responses at 1-1a/2A, 3A and 3B 
containing NMDA receptors. * denotes statistical significance against 1-1a/2A and t 
denotes significance against 3A. 
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Figure 50: Mgt+block of NMDA/glycine responses in 1-1a/2A, 3A and 3B containing 
NMDA receptors. (A) TEVC current recordings of Mg2+ block of NMDA/glycine responses at 
- 
100 mV. (B, D, F) % control response (mean ± S. E. M, n=6-7) values were plotted and fitted 
with the Hill equation to give estimates of IC50 (C, 
-100 mV; E, -75 mV; G, -50 mV). Bars show 
IC50 (95% Cl) NM. Groups that do not share a letter are significantly different. 
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The ICS for memantine was then calculated (Figure 51, Table 9). At -100 and -75 mV 1- 
1a/2A had the lowest IC50 (0.80 and 2.48 . tM respectively) which was significantly lower 
than 3A and 3B. Memantine block of 3A had an intermediate IC50 which was significantly 
lower than 3B. The subunit order of IC50 for memantine at -100 and -75 mV was 1- 
la/2A<3A<3B. At 
-50 mV 1-1a/2A had the lowest ICSO, which was significantly lower 
than 3A and 3B, but at this voltage 3A was not significantly different to that of 3B. The 
subunit order of IC50 at 
-50 mV was 1a/2A<3Az3B. 
IC50(95% CO NM 
Voltage (mV) 1a/2A 1a/2A/3A Ia/2A/3B 
0.80 2.55 17.77 
0.64 to 0.99 1.75 to 3.74 8.49 to 37.20 
-100 
'P<0.001 "P<0.001 
P<0.001 
2.48 7.54 17.54 
2.04 to 3.02 6.27 to 9.07 11.42 to 26.94 
-75 
"P<0.001 "P<0.001 
P<0.001 
3.94 15.89 18.23 
3.46 to 4.49 12.13 to 20.82 12.51 to 26.56 
-50 
*P<0.001 *P<0.001 
P<0.548 
Table 9: lC$O values for memantine block of NMDAlglycine responses at 1-1a/2A, 3A and 
3B containing NMDA receptors. * denotes statistical significance against 1-1a/2A and t 
denotes significance against 3A. 
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Figure 51: Memantine block of NMDA/glycine responses in 1-1a/2A, 3A and 3B 
containing NMDA receptors. (A) TEVC current recording of memantine block of 
NMDA/glycine responses at 
-100 mV. (B, D, F) % control response (mean ± S. E. M, n=6-9) 
values were plotted and fitted with the Hill equation to give estimates of IC50 (C, 
-100 mV; E, - 75 mV; G, 
-50 mV. Bars show IC50 (95% Cl) NM. Groups that do not share a letter are 
significantly different. 
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The IC50 for PhTX-343 was then established for all subunit combinations (Figure 52, 
Table 10). At 
-100 mV 1-la/2A had the lowest IC50which was significantly lower than 
3A and 3B, but both the G1uN3 containing receptors were not significantly different to 
each other. The subunit order of IC50 was 1 a/2A<3Az3B. At 
-75 mV no significant 
differences were found between all receptor subtype combinations tested. At 
-50 mV the 
IC50 at 3B significantly increased relative to both 1-1a/2A and 3A, while no significant 
difference between 1-la/2A and 3A was found. The subunit order of IC50 was 
1a/2A=3A<3B at 
-50 mV. 
ICo (95% Cl) NM 
Voltage (mV) 1a/2A 3A 3B 
0.30 1.40 0.93 
0.21 to 0.44 0.83 to 2.37 0.63 to 1.36 
-100 
*P<0.001 *P=0.001 
tP=0.205 
2.95 4.64 5.74 
1.57to5.54 3.10to6.94 3.84to8.59 
-75 
'P=0.213 *P=0.065 
P=0.467 
17.22 17.28 62.80 
9.19 to 32.27 8.72 to 34.25 40.11 to 98.31 
-50 
*P=0.994 'P=0.001 
P=0.003 
Table 10: ICsO values for PhTX-343 block of NMDAlglycine responses at 1-1a/2A, 3A and 
3B containing NMDA receptors. * denotes statistical significance against 1-1a/2A and t 
denotes significance against 3A. 
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Figure 52: PhTX-343 block of NMDA/glycine responses in 1-1a/2A, 3A and 3B 
containing NMDA receptors. (A) TEVC current recording of PhTX-343 block of 
NMDA/glycine responses at 
-100 mV. (B, D, F) % control response (mean ± S. E. M, n=6-1 1) 
values were plotted and fitted with the Hill equation to give estimates of IC50 (C, 
-100 mV; E, - 
75 mV; G, 
-50 mV). Bars show IC50 (95% Cl) NM. Groups that do not share a letter are 
significantly different. 
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The ICS0 for methoctramine was calculated for at all subunit combinations (Figure 53, 
Table 11). At 
-100 mV, methoctramine had the lowest IC50 at 1-la/2A which was 
significantly lower than at 3A and 3B, but the IC50 for methoctramine at both G1uN3 
containing receptors were not significantly different. This gave a subunit order of ICs0 , as 
1a/2A<3A; z3B. At 
-75 mV 1-la/2A and 3A were not significantly different to each 
other, but the IC50 for methoctramine at 3B increased so it was now significantly higher 
than 1-1a/2A and 3A. The subunit order of methoctramine IC50 was 1a/2A; z3A<3B at 
- 
75 mV. At 
-50 mV there were no significant differences between all the subunits 
combinations tested. 
IC50 (95% CO NM 
Voltage (mV) 1a/2A 3A 3B 
1.42 2.78 3.07 
0.98 to 2.05 2.33 to 3.32 2.33 to 4.05 
-100 
*P=0.003 'P=0.001 
tP=0.574 
1.94 2.63 4.81 
1.25 to 3.01 2.04 to 3.40 3.43 to 6.74 
-75 
*P=0.252 *P=0.002 
P-0.006 
5.36 5.29 4.69 
3.83 to 7.50 3.68 to 7.61 4.09 to 5.36 
-50 
*P=0.959 'P=0.537 
P=0.472 
Table 11: IC50values for methoctramine block of NMDAlglycine responses at 1-1aI2A, 
3A and 3B containing NMDA receptors. * denotes statistical significance against 1-1a/2A 
and t denotes significance against 3A. 
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Figure 53: Methoctramine block of NMDA/glycine responses in 1-1a/2A, 3A and 3B 
containing NMDA receptors. (A) TEVC current recording of methoctramine block of 
NMDA/glycine responses at 
-100 mV. (B, D, F) % control response (mean ± S. E. M, n=5-8) 
values were plotted and fitted with the Hill equation to give estimates of IC50 (C, 
-100 mV; E, - 
75 mV; G, 
-50 mV). Bars show IC50 (95% Cl) NM. Groups that do not share a letter are 
significantly different. 
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IC5. values for MK-801 inhibition were calculated (Figure 54, Table 12). At 
-100 mV 1- 
1a/2A had the lowest IC50which was significantly lower than 3A and 3B, but 3A and 3B 
were not significantly different. This gave a subunit order of MK-801 IC50 as 
1a/2A<3Az3B. At 
-75 mV 1-1a/2A had an IC50 for MK-801 that was not significantly 
different to 3A, but the IC50 at 3B was increased so that it was significantly higher than 
both 1-la/2A and 3A. At 
-75 the rank order of methoctramine IC50 was Ia/2A=3A<3B. 
At 
-50 mV the same pattern was found as at 75 mV. 
IC50 (95% CI) pM 
Voltage (mV) la12A 3A 3B 
0.193 0.46 0.68 
0.12 to 0.31 0.40 to 0.54 0.34 to 1.39 
-100 
*P<0.001 *P=0.003 
tP=0.212 
0.21 0.31 2.19 
0.13 to 0.34 0.21 to 0.45 0.97 to 4.96 
-75 
*P=0.204 *P<0.001 
P<0.001 
0.50 0.49 3.56 
0.29 to 0.85 0.37 to 0.64 1.98 to 6.38 
-50 
*P=0.94 *P<0.001 
P<0.001 
Table 12: IC50 values for MK-801 block of NMDAIglycine responses at 1-1a/2A, 3A and 
3B containing NMDA receptors. * denotes statistical significance against 1-1a/2A and t 
denotes significance against 3A. 
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Figure 54: MK-801 block of NMDA/glycine responses in 1-1a/2A, 3A and 3B containing 
NMDA receptors. (A) TEVC current recordings of MK-801 block of NMDA/glycine responses 
at 
-100 mV. (B, D, F) % control response (mean ± S. E. M, n=5-7) values were plotted and 
fitted with the Hill equation to give estimates of IC50 (C, 
-100 mV; E, -75 mV; G, -50 mV). Bars 
show IC50 (95% Cl) NM. Groups that do not share a letter are significantly different. 
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Concentration-inhibition data was used to produce ICS0 , values for PhTX-12 inhibition 
(Figure 55, Table 13). At 
-100 mV 3A had the lowest IC50 which was significantly lower 
than both 1-1a/2A and 3B. The IC50 for 1-la/2A was not significantly different to 3B. 
This gave a subunit order of IC50 as 3A<1a/2Az3B. At 
-75 mV the pattern remained; 
however, at 
- 
50 mV the IC50values for PhTX-12 were now not significantly different to 
each other for any subunit combination. 
IC50 (95% CO NM 
Voltage (mV) 1a/2A 3A 3B 
164.90 77.47 157.00 
127.30 to 213.50 45.99 to 130.50 122.80 to 200.60 
-100 
'P=0.014 *P=0.779 
P=0.023 
293.60 122.30 402.30 
209.00 to 412.40 75.57 to 200.50 191.00 to 847.30 
-75 
'P=0.031 *P=0.390 
P=0.033 
734.50 433.90 476.00 
348.20 to 155.00 144.90 to 129.90 134.40 to 168.60 
-50 
*P=0.466 *P=0.912 
tP=0.602 
Table 13: IC50values for PhTX-12 block of NMDA/glyclne responses at 1-1a/2A, 3A and 
3B containing NMDA receptors. * denotes statistical significance against 1-1a/2A and t 
denotes significance against 3A. 
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Figure 55: PhTX-12 block of NMDAIglycine responses in 1-1a/2A, 3A and 3B containing 
NMDA receptors. (A) TEVC current recordings of PhTX-12 block of NMDA/glycine responses 
at 
-100 mV. (B, D, F) % control response (mean ± S. E. M, n=6) values were plotted and fitted 
with the Hill equation to give estimates of IC50 (C, 
-100 mV; E, -75 mV; G, -50 mV). Bars show 
IC50 (95% Cl) pM (note altered y-axis scale). Groups that do not share a letter are significantly 
different. 
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3.4.6 Voltage Dependence 
Concentration-inhibition values were fitted with the Hill equation for Mgt+, memantine, 
PhTX-343 methoctramine, MK-801 and PhTX-12 at the range of voltages tested for 1- 
1a/2A NMDA receptors (Figure 56). There was a significant (P<0.001), effect of voltage 
on the IC50 all the blockers. 
Voltage was then determined for 3A receptors (Figure 57). There was a significant effect 
of voltage on ICS0 for Mg 2+ (P<0.001), memantine (P<0.001), PhTX-343 (P<0.001), 
methoctramine (P=0.001) and MK-801 (P=0.046). At 3A block by PhTX-12 was not 
voltage-dependent (P=0.174). Voltage-dependence was also tested at 3B containing 
receptors (Figure 58). There was a significant effect of voltage on 'C50 for Mg2+ 
(p<0.001), PhTX-343 (P<0.001), methoctramine (P=0.025) and MK-801 (P=0.002). At 
3B block by memantine (P=0.987) and PhTX-12 (P=0.629) were not voltage-dependent. 
The 8 value from the Woodhull equation was calculated for 1a/2A, 3A and 3B 
containing NMDA receptors (Figure 59, Table 14). Mg2+ showed a decrease in 8 for 3A 
and 3B compared with 1-la/2A. Memantine showed an increase in 8 for 3A compared 
with 1-1a/2A, whereas 3B showed a large decrease. For PhTX-343 it was found that 
there was a decrease in 8 for 3A, but an increase with 3B compared with 1-la/2A. 
Methoctramine showed a decrease with 3A compared with 1-1a/2A, and there was a 
further decrease with 3B. MK-801 showed a large decrease with 3A, but an increase with 
3B compared with 1-la/2A. PhTX-12 showed no change between 3A and 1-la/2A, but 
a decrease with 3B. 
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Figure 56: Concentration inhibition relationship showing block of NMDA-glycine- 
evoked responses mediated by 1-1a/2A NMDA receptors at 
-100, -75 and -50 mV. % 
control response (mean ± S. E. M) values were plotted and fitted with the Hill equation for (A) 
Mgt+, (B) memantine, (C) PhTX-343, (D) methoctramine, (E) MK-801 and (F) PhTX-12. 
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Figure 57: Concentration inhibition relationship showing voltage-dependence of block 
of NMDA/glycine-evoked responses mediated by 3A containing NMDA receptors at - 
100, 
-75 and -50 mV. % control response (mean ± S. E. M) values were plotted and fitted with 
the Hill equation for (A) Mgt+, (B) memantine, (C) PhTX-343, (D) methoctramine, (E) MK-801 
and (F) PhTX-12. 
117 
-8 -6 -4 -2 
Lo9IM92+1 (M) 
-8 -6 -4 -2 
Log[PhTX343] (M) 
-8 -6 -4 -2 
Log[Methoctramine] (M) 
A 
0 0 
a 
m 
ö 
c 
0 
U 
e 
C 
c 0 
m 
m 
ö 
c 0 
U 
\o 0 
E 
m 
a 
m 
ö 
c 
0 t) 
B 
100 
N 
p 75 
a U) 
so 
0 
25 
D 
100 
W 
p 75 
a 0 
50 
0 
C 0 U 
e 
F 
100 
p 75 
m 
50 0 
c 
ýj 25 
)0 mV 
5 mV 
mV 
8 
-6 -4 -2 
Log[Memantine] (M) 
Figure 58: Concentration inhibition relationship showing voltage-dependence of block 
of NMDA/glycine-evoked responses mediated by 3B containing NMDA receptors at - 
100, 
-75 and -50 mV. % control response (mean ± S. E. M) values were plotted and fitted with 
the Hill equation for (A) Mgt+, (B) memantine, (C) PhTX-343, (D) methoctramine, (E) MK-801 
and (F) PhTX-12. 
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a 
(95% Cl) 
Compound la/2A 3A 3B 
0.650 0.250 0.345 
Mg 2+ 
-0.065 to 1.365 -1.889 to 2.389 -0.282 to 0.972 
0.652 0.839 0.0133 
Memantine 
-1.691 to 2.995 -0.294 to 1.971 -0.180 to 0.206 
PhTX-343 0.610 0.454 0.812 0.335 to 0.885 0.262 to 0.646 0.521 to 1.103 
0.213 0.104 0.046 
Methoctramine 
-0.436 to 0.861 -0.566 to 0.775 -0.414 to 0.506 
0.246 0.034 0.672 
MK-801 
-2.165 to 3.400 -2.973 to 3.040 -1.686 to 3.029 
PhTX-12 0.854 0.855 0.434 
-0.460 to 2.167 0.530 to 1.181 
-2.451 to 3.319 
Table 14: Calculated ö values from the Woodhull equation for 1-1a/2A, 3A and 3B 
NMDA receptors. 
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Figure 59: Voltage dependence of IC50 for memantine block of NMDA/glycine responses 
from 1-1a/2A, 3A and 3B containing receptors fitted with the Woodhull equation. IC50 
(95% Cl) pM for (A) Mgz+, (B) memantine, (C) PhTX-343, (D) methoctramine, (E) MK-801 and 
(F) PhTX-12 (note altered y-axis). 
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3.4.7 Rank Order of ICIQ 
Concentration-inhibition curves for each blocker were used to calculate rank order of 
IC50 values (Figure 60). Statistical significance, and the direction of change, is represented 
by the < and z separates compounds that are not significantly different to each other. At 
-100 mV for 1-1a/2A this gave a rank order of ICsoof MK-801 = PhTX343 < 
memantine < methoctramine z Mg < PhTX-1 2. At 
-75 mV the order was MK- 
801<methoctraminezmemantinez PhTX-343= Mgt+<PhTX-12. At 
-50 mV the rank 
order IC50 was MK-801 <memantine zýmethoctramine= PhTX-343 Mgt+=PhTX-12. 
Rank of ICs0 was then established for the blockers at 3A containing receptors (Figure 61). 
At 
-100 mV rank was MK-801 < PhTX-343 z methoctramine memantine < Mg2+< 
PhTX-12. At 
-75 mV it was MK-801 < methoctramine < PhTX-343 < memantine < 
Mgt+< PhTX-12. Finally, at 
-50 mV was MK-801 < methoctramine < memantine 
PhTX-343 z Mg" < PhTX-12. Rank was again established for 3B containing receptors 
(Figure 62). The order was MK-801 z PhTX-343 < methoctramine < Mg2+= memantine 
< PhTX-12 at 
-100 mV. At -75 mV it was MK-801 < PhTX-343 = methoctramine < 
memantine < Mg2+ < PhTX-12. Lastly, at 
-50 mV the rank order was MK-801 < 
methoctramine < memantine < PhTX-343 = Mgt+< PhTX-12. A full list of statistical 
comparisons is given in the appendix. 
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Figure 60: Concentration-inhibition relationships for rank order of block of 
NMDA/Glycine-evoked responses mediated by 1-la/2A NMDA receptors at 
-100, -75 and 
-50 mV. (A, C, E) % control response (mean ± S. E. M) values were plotted and fitted with the 
Hill equation to give estimates of IC50 (B, 
-100 mV; D, -75 mV; F, -50 mV). Bars show IC50 (95% Cl) pM Groups that do not share a letter are significantly different. 
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Figure 61: Concentration-inhibition relationships for rank order of block of 
NMDA/Glycine-evoked responses mediated by 3A NMDA receptors at 
-100, -75 and -50 
mV. (A, B, C) % control response (mean ± S. E. M) values were plotted and fitted with the Hill 
equation to give estimates of IC50 (B, 
-100 mV; D, -75 mV; F, -50 mV). Bars show IC50 (95% 
Cl) pM Groups that do not share a letter are significantly different 
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Figure 62: Concentration-inhibition relationships for rank order of block of 
NMDAIGlycine-evoked responses mediated by 3B NMDA receptors at 
-100, -75 and -50 
mV. (A, C, E) % control response (mean ± S. E. M) values were plotted and fitted with the Hill 
equation to give estimates of IC50 (C, 
-100 mV; E, -75 mV; G, -50 mV). Bars show IC50 (95% 
Cl) pM Groups that do not share a letter are significantly different 
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3.4.8 On Rate of Block 
The average time constant T describing an exponential equation to the onset phase 
application of the IC; O concentration of antagonist was measured at -100, -75 and -50 mV 
(Figure 63 and Figure 64). It was analysed using two-way ANOVA and Bonferroni post- 
hoc testing. At 
-75 mV Mg2+ at 3A containing receptor had a significantly faster T than 1- 
1 la/2A (P<0.01). Memantine had aT that was not significantly different between subunits 
at any voltage. For PhTX-343, post-hoc testing revealed that T was significantly faster at 
3A than 1-1a/2A at 
-75 (P<0.05) and -50 mV (P<0.001). It also revealed that 3B was 
significantly faster than 1-1a/2A at 
-100 (P<0.001), -75 (P<0.05) and -50 mV (P<0.05). 
Methoctramine had ai that was significantly faster for 3A than 1-1a/2A at 
-75 (P<0.01) 
and 
-50 mV (P<0.05). MK-801 had aT that was significantly faster for 3A than 1-1a/2A 
at 
-100 (P<0.001), -75 (P<0.001) and -50 mV (P<0.001), and 3B was significantly faster 
than 1-1a/2A at 
-75 (P<0.01) and -50 mV (P<0.01). Post-hoc testing also showed that 
3B had aT that was significantly slower than 3A at 
-100 (P<0.001) and -75 (P<0.001) 
mV. 
1-la/2A 
200 nA 
25 : 
Figure 63: TEVC current recording of Mgt+block of NMDA/glycine currents mediated by 
1-1a/2A NMDA receptors at 
-100 mV. The onset and decay of block are shown by the 
exponential fit highlighted in red. 
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Figure 64: Time constant of a single exponential fit to the development phase of block 
of NMDAlglycine response at 
-100, -75 and -50 mV. (A) TEVC current recording of Mg2+ 
block of NMDA/glycine currents mediated by 1-1a/2A containing NMDA receptors at 
-100 mV. 
Log T (95% Cl, n=5-7). Two-way ANOVA with Bonferroni post-hoc test. Within a voltage, bars 
that do not share a letter are significantly different (Bonferroni P<0.05). (A) Mgt+, subunit 
(F(2,41)=7.935 P=0.002), voltage (F(2,41)=0.456 P=0.637) subunit x voltage interaction 
(F(4,41)=1.338 P=0.272) (B) memantine, (F(2,44)=3.762 P=0.031), voltage (F(2,44)=0.399 
P=0.674) subunit voltage x interaction (F(4,44)=0.596 P=0.668) (C) PhTX-343, subunit 
(F(2,40)=20.74 P<0.001), voltage (F(2,40)=1.429 P=0.252), subunit x voltage interaction 
(F(4,40)=2.853 P=0.036) (D) methoctramine, subunit (F(2,46)=11.82 P<0.001), voltage 
(F(2,46)=1.265 P=0.865) and subunit x voltage interaction (F(4,46)=0.3177 P=0.292). and (E) 
MK-801, subunit (F(2,43)=52.78 P<0.001), voltage (F(2,43)=18.17 P<0.001) and subunit x 
voltage interaction (F(4,43)=6.890 P<0.001). 
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3.4.9 Off Rate of Block 
The average time constant t describing an exponential equation fitted to the recovery 
phase of block was measured and analysed by two-way ANOVA (Figure 65). For Mg2+ 
block, Bonferroni multiple comparison tests revealed that at 
-100 mV, 1-1a/2A had ar 
that was significantly slower than that of 3A (P<0.001) and 3B (P<0.05), and that at 
-50 
mV the r for 3B was significantly slower than 3A (P<0.05). Post-hoc testing for 
memantine revealed that T was significantly slower for 3A than 1-1a/2A at 
-100 (P<0.05), 
-75 (P<0.001) and -50 (P<0.001) mV. It also found that for 3A T was significantly slower 
than that of 3B at 
-75 (P<0.05) and -50 (P<0.01) mV. 
Block by PhTX-343 showed that 3A had ar that was significantly faster than 1-1a/2A at 
-100 (P<0.05), -75 (P<0.001) and -50 mV (P<0.001). 3B also had az that was 
significantly faster than 1-1a/2A at 
-100 (P<0.01), -75 (P<0.001) and -50 mV (P<0.01). It 
was also found that at 
-50 mV T for 3A was significantly faster than 3B (P<0.01). 
Methoctramine showed no significant differences between subunits at any voltage. MK- 
801 post-hoc testing revealed that 2 for 3A was significantly faster than 1-la/2A at 
-100 
(P<0.001), 
-75 (P<0.001) and -50 (P<0.001) mV and that 3A was significantly faster than 
3B at 
-100 (P<0.001) and -75 (P<0.001) mV. 
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Figure 65: Time constant of a single exponential fit to the recovery phase of block of 
NMDA/glycine response at 
-100, -75 and -50 mV. Two-way ANOVA with Bonferroni post- 
hoc test. Within a voltage, bars that do not share a letter are significantly different (Bonferroni 
P<0.05). Shown are Logt (95% Cl) (n=6-7) for (A) Mgt+, subunit (F(2,43)=7.118 P=0.002), 
voltage (F(2,43)=1.331 P=0.275) and subunit x voltage interaction (F(4,43)=3.952 P=0.008) 
(B) memantine, subunit (F(2,44)=25.64 P<0.001), voltage (F(2,44)=0.826 P=0.444) and 
subunit x voltage interaction (F(4,44)=0.938 P=0.451) (C) PhTX-343, subunit (F(2,41)=44.83 
P<0.001), voltage (F(2,41)=0.4453 P=0.645) and subunit x voltage interaction (F(4,41)=3.769 
P=0.011) (D) methoctramine, subunit F(2,44)=3.544 P=0.037), voltage (F(2,44)=1.261 
P=0.299) and subunit x voltage interaction (F(4,44)=1.114 P=0.362) (E) MK-801, subunit 
(F(2,38)=74.37 P<0.001), voltage (F(2,38)=0.6476 P=0.529) and subunit x voltage interaction 
(F(4,38)=6.376 P=0,011). 
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3.5 Mutations 
3.5.1 Steady State Current 
In order to determine if the presence of the GIuN3 subunit had any effect on inward 
current, two-way ANOVA was carried out. Post-hoc analysis using the Bonferroni test 
for multiple comparisons revealed that there was significantly less inward current for 3A 
compared with G703N (P<0.001), R704N (P<0.001), and R704D (P<0.001) at all 
voltages. It was also found that R704N had significantly less current than R703N 
(P<0.001) at all voltages. 
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3A R704D 
Figure 66: Effect of mutation and voltage on steady-state current recorded from 
Xenopus oocytes. Bars represent mean (95% Cl, n=39-64). Two-way ANOVA subunit 
(P<0.001), voltage (P=0.124) and subunit x voltage interaction (P=0.995). Bars that do not 
share a letter within a voltage are significantly different. 
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3.5.2 NMDA Receptor Antagonism 
The IC50 for Mg2+ at 3AG703N, 3AR704N and 3AR704D was calculated and compared to 1- 
la/2A and 3A wild-type (Figure 67, Table 15). At 
-100 and -75 mV 3AG703N resulted in an 
intermediate IC50 for Mg2+ that was significantly lower than that for 3A wild-type, but still 
significantly higher than that of 1-1 a/2A. At 
-50 mV the pattern changed and the IC50 for 
3AG703N increased relative to the other subunits and was now significantly higher than 
both wild-type 3A and 1-1a/2A. At 
-100 mV the 3AR704N mutation also produced an 
intermediate IC50 for Mg2+ that was significantly lower than that for wild-type and 
significantly higher than that of 1-la/2A. At 
-75 mV the IC50was again significantly lower 
(P=0.0072) than 3A wild-type, but was now reduced to a level that was not significantly 
different to 1-1a/2A. At 
-50 mV 3AG704N had an IC50 for Mg2+ that was not significantly 
different to wild-type 3A or 1-1a/2A. With the 3AR704D mutation at 
-100 mV there was no 
effect on the IC50 for Mg2+ as it was not significantly different than that for wild-type 3A. 
At 
-75 mV the ICs0 , for Mgg+ was now intermediate and was significantly lower than 3A 
wild-type and significantly higher than 1-1a/2A. At 
-50 mV Mg 2+ was found to have an 
IC50 that was increased relative to 3A and was now significantly higher than both wild- 
type 3A and 1-la/2A. 
The IC50 for Mg" at the mutated 3A subunits was also compared at each voltage. 3AG703N 
and 3AR7041N had IC., values for Mg2+ that were not significantly different to each other 
(P=0.5786). 3AR704D had the highest IC50 which was significantly higher than both 3AG703N 
(P<0.001) and 3AR704N (P<0.003). At 
-75 mV again 3AG703N and 3AR704N had IC,, values 
for Mg2+ that were not significantly different to each other (P<0.995). Again, 3AR704D had 
the highest IC50 that was significantly higher than 3AG7O3h (P<0.001), but was not 
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significantly different to 3AR704N (P=0.083). At 
-50 mV there were no significant 
differences between the mutated subunits. 
IC50 (95% Cl) NM 
Voltage (mV) 3AG703N 3AR70, " 3AR70, D 
3.17 2.77 5.92 
2.53 to 3.98 1.71 to 4.48 4.89 to 7.18 
-100 
*P<0.001 *P=O. 050 *P<0.001 
tp<0.00 P=0.002 tP=0.891 
7.58 7.56 14.53 
5.56 to 10.33 3.35 to 17.00 12.56 to 16.81 
-75 
*P=0.003 *P=0.138 *P<0.001 
P<0.001 P=0.007 P<0.001 
48.83 27.01 46.38 
38.02 to 62.70 13.47 to 54.15 37.24 to 57.77 
-50 
*P<0.001 *P=0.138 *P<0.001 
P<0.001 P=0.898 P O. 016 
Table 15: IC50 values for Mg2+ at 3AG703N, 3Aß703N and 3AR70, D containing receptors. * 
denotes statistical significance against 1-1a/2A and t denotes significance against 3A. 
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Figure 67: Concentration-inhibition relationship for Mgt` block of NMDAIglycine-evoked 
currents mediated by 1-1 a/2A and 3A together with the mutations G70314 
, 
3AR704N and 
3AR704D NMDA receptors at 
-100, -75 and -50 mV. % control response (mean ± S. E. M, n=5- 
8) were plotted and fitted with the Hill equation (A, B, C, 
-100 mV; E, F, G, -75 mV; I, J, K -50 
mV) to estimate IC50 (D 
-100 mV, H -75 mV and L -50 mV). Bars show IC50 (95% Cl) pM and 
those do not share a letter are significantly different. 
The IC50 for memantine block of 3AG703N, 3AR704N and 3AR704D NMDA receptors were 
calculated and compared with 1-1 a/2A and 3A (Figure 68, Table 20). The 3Ac7o3N 
mutation resulted in an intermediate IC510 for memantine that was significantly lower than 
that for 3A wild-type but was still significantly higher than that of 1-1 a/2A at 
-100, -75 
and 
-50 mV. At -100 and -75 mV the 3A`ß'04`` mutation resulted in an IC; 0 for memantine 
that was significantly lower than that for 3A wild-type but was reduced to a level that was 
not significantly different to that of 1-1 a/2A. At 
-50 mV the IC50 for 3AR704N was now 
intermediate, as it was found to be significantly lower than wild-type and significantly 
higher than 1-1 a/2A. 
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At 
-100 mV the ICS0 for memantine at 3AR704D had no effect as it was not significantly 
different to wild-type 3A, whilst continuing to be significantly higher that 1-1 a/2A. At 
- 
75 mV the IC50 for memantine was reduced as it was now not significantly different to 1- 
1 a/2A and was significantly lower than 3A. At 
-50 mV the pattern remained as the 
mutation resulted in an intermediate IC50. 
When comparing memantine block of the mutated subunits, 3AR704D had the highest IC50 
which was significantly higher than 3AG703N (P=0.021) but not 3AR7O4N (P=0.061) at 
-100 
mV. There was no significant difference between 3AG703N and 3AR704N (P=0.982). At 
-75 
mV 3AG703N had the highest ICs0 of the mutations, and was significantly higher than 
3AR704N (P<0.001) and 3AR7O4D (P<0.001) while 3AR704N and 3AR704D had IC50values that 
were not significantly different to each other (P=0.951). At 
-50 mV 3AR704D had the 
lowest IC50 which was significantly lower than 3AG703N (P<0.001) and 3AR704N (P<0.001). 
There was no significant difference between 3AG703N and 3AR704N at 
-50 mV (P=0.124). 
ICSO (95% Cl) NM 
Voltage (mV) 3AG703N 3AR7"" 3AR70+D 
1.18 1.190 2.11 
0.90 to 1.55 0.77 to 1.83 1.40 to 3.20 
-100 
*P<0.023 *P=0.081 *P<0.001 
P-0.001 tp-0.009 P=0.499 
5.39 2.68 2.644 
4.72 to 6.14 1.90 to 3.77 2.019 to 3.460 
-75 
*P<0.001 *P=0.689 *P=0.708 
tp-0.006 P<0.001 P<0.001 
5.53 7.01 3.25 
4.81 to 6.36 5.23 to 9.39 2.51 to 4.20 
-50 
*P<0.001 *P<0.001 *P=0.154 
P<0.001 P<0.001 tp<0.001 
Table 16: IC50 values for memantine at 3AG703N, 3AG703N and 3AR704D containing receptors. 
* denotes statistical significance against 1-1a/2A and t denotes significance against 3A. 
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Figure 68: Concentration-inhibition relationship for memantine block of NMDA/c lycine- 
evoked currents mediated by 1-1a/2A and 3A together with the mutations 3AG70 
3AR704N and 3AR7O4D NMDA receptors at 
-100, -75 and -50 mV. % control response (mean t 
S. E. M, n=6-8) values were plotted and fitted with the Hill equation. (A, B, C 
-100 mV; E, F, G- 
75 mV; I, J, K 
-50 mV) to estimate IC50 (D -100 mV, H -75 mV and L -50 mV). Bars show IC50 (95% Cl) NM. Groups that do not share a letter are significantly different. 
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The IC50 for Ph TX-343 block of NMDA/glycine responses were calculated at 3Ac7osr 
3A R704N and 3AR704D containing NMDA receptors (Figure 69, Table 17). At 
-100 mV all 
the mutations resulted in an intermediate IC50 that was significantly lower than that for 
wild-type but still significantly higher than that of 1-la/2A. At 
-75 and -50 mV the 
mutations had no effect. 
The IC50 values for PhTX-343 at the mutated subunits were also compared at each 
voltage. At 
-100 mV these were not significantly different to each other. At -75 mV the 
IC50 for 3AG703N was significantly higher than 3AR7O4N (P=0.047) and 3AR7O4D (P=0.031). 
3AR704N and 3AR704D were not significantly different to each other (P=0.782). At 
-50 mV 
3AR'04N had an ICs0 
, 
for PhTX-343 that remained significantly higher than 3AG'o3N 
(P=0.006) and 3AR704D (P<0.001), while 3AG703N and 3AR704D again were not significantly 
different to each other (P=0.059). 
IC50 (95% CO MM 
Voltage (mV) 3AG703N 3AR70+" 3AR7M 
0.49 0.51 0.51 
0.62 to 0.39 0.36 to 0.71 0.41 to 0.64 
-100 
"P=0.032 'P=0.046 "P=0.017 
tP=0.002 tPU0.00 P<0.001 
5.40 3.12 3.30 
3.61 to 8.08 2.15 to 4.52 2.65 to 4.11 
-75 
'P=0.0988 'P=0.876 *P=0.718 
tP=0.62 P=0.204 P=0.213 
22.04 29.67 17.41 
18.73 to 25.94 25.91 to 33.97 14.46 to 20.97 
-50 
*P=0.400 *P=0.065 *P=0.970 
P=0.468 P=0.111 P=0.982 
Table 17: IC50 values for PhTX-343 at 3AG703N, 3AGTO3N and 3AR70`D containing receptors. 
denotes statistical significance against 1-1a/2A and t denotes significance against 3A. 
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Figure 69: Concentration-inhibition relationship for PhTX-343 block of NMDA/glycine- 
evoked currents mediated by 1-1a/2A and 3Atogether with the mutations 3Ac703r,, 
3AR704N and 3AR704D NMDA receptors at 
-100, -75 and -50 mV. % control response (mean t 
S. E. M, n=6-11) values were plotted and fitted with the Hill equation (A, B, C 
-100 mV; E, F, G 
-75 mV; I, J, K -50 mV) to estimate IC50 (D -100 mV, H -75 mV and L -50 mV). Bars show IC50 
(95% Cl) NM and those that do not share a letter are significantly different (P<0.05) 
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Block by increasing concentrations of methoctramine to NMDA/glycine responses were 
used to estimate its IC, only at 3A1703` and 3AR704N (Figure 70, Table 18). At 
-100 mV the 
3AG703N mutation resulted in an IC50 for methoctramine that was significantly lower than 
that for 3A wild-type, toward a level that was not significantly different to 1-1 a/2A. At 
- 
75 mV the IC50 for 3AG703N was not significantly different to that of the wild-type or 1- 
1a/2A. At 
-50 mV the IC50 for methoctramine was reduced relative the other subunit 
combinations, 3AG703N it was found to have an ICs0 , that was significantly lower than both 
wild-type and 1-1 a/2A. 
For 3AG704N at 
-100 mV the mutation resulted in an ICS that was not significantly 
different to wild-type or 1-la/2A. When the voltage was increased to 
-75 and 50 mV the 
3AR7041 mutation did not have any effect. The IC_, values for the mutations were also 
compared with each other at each voltage tested. At 
-100 and -75 mV they were not 
significantly different to each other. At 
-50 mV 3AG703' had an IC5. that was significantly 
lower than 3AR704' (P=0.002). 
IC5o (95% Cl) NM 
Voltage (mV) 3AG703N 3AR704N 
1.85 1.83 
1.29to2.64 1.18to2.84 
-100 
*P=0.297 *P=0.379 
P=0.039 tP=0.056 
2.50 3.28 
2.08 to 3.01 1.96 to 5.49 
-75 
*P=0.316 *P=0.139 
P=0.735 tP=0.416 
2.80 6.08 
2.02 to 3.89 4.24 to 8.71 
-50 
"P 0.009 *P=0.608 
P=0.015 tP=0.591 
Table 18: IC50values for methoctramine at 3AG703N, 3Aß703N containing receptors. 
denotes statistical significance against 1-1a/2A and t denotes significance against 3A. 
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Figure 70: Concentration-inhibition relationship for methoctramine block of 
NMDA/glycine-evoked currents mediated by 1-1a/2A and 3Atogether with the mutations 
3AG703N, 3AR704N and 3AR7040 NMDA receptors at 
-100, -75 and -50 mV. % control response (mean ± S. E. M, n=5-8) values were plotted and fitted with the Hill equation (A, B, 
-100 mV; D, 
E, F 
-75 mV; G, H -50 mV) to estimate IC50 (C -100 mV, F -75 mV and I -50 mV). Bars show 
IC50 (95% Cl) NM. Groups that do not share a letter are significantly different. 
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The effect of the mutations on the IC,, for MK-801 was explored (Figure 71, Table 19). 
At 
-100 mV both the 3AG7O3` and 3AR7O4N mutations resulted in a reduction in IC50 that 
was significantly lower than that for 3A wild-type to a level that was not significantly 
different to that of 1-la/2A. At 
-75 and - 50 mV 3AG703N had no effect. At -75 mV the 
3AR704N mutation also had no effect; however, at 
-50 mV it was found that the ICS was 
reduced and was now was significantly lower than 3A wild-type, but was also not 
significantly different to 1-la/2A. The IC50 values for MK-801 block at the mutated 
subunits were not significantly different to each other at each voltage tested. 
ICS (95% CI) pM 
Voltage (mV) 3AG703N 3AR70, " 
0.24 0.209 
0.17 to 0.34 0.143 to 0.306 
-100 
'P=0.453 *P=0.788 
P<0.001 P<0.001 
0.39 0.21 
0.26 to 0.66 0.13 to 0.33 
-75 
*P=0.084 *P=0.204 
P=0.467 tP=0.187 
0.39 0.21 
0.26to0.66 0.14to0.33 
-50 
'P=0.29 *P=0.051 
tp= tp=0.008 
Table 19: IC50 values for MK-801 at 3AG703N, 3AG703N containing receptors. * denotes 
statistical significance against 1-1a/2A and t denotes significance against 3A. 
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Figure 71: Concentration-inhibition relationship for MK-801 block of NMDA/glýrcine- 
evoked currents mediated by 1-1a/2A and 3Atogether with the mutations 3Ac 03N 
3AR704N and 3AR704D NMDA receptors at 
-100, -75 and -50 mV. % control response (mean t S. E. M, n=5-7) values were plotted and fitted with the Hill equation (A, B, D, E, F, G, H) to 
estimate IC50 (C 
-100 mV, F -75 mV and I -50 mV). Bars show IC50 (95% CI) NM. Groups that do not share a letter are significantly different. 
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3.5.3 Voltage-Dependence 
The voltage dependence of the blockers at 3AG703N MDA receptors at 
-100, -75 and -50 
mV was determined (Figure 72). There was a significant effect of voltage on IC50 for 
Mgt+(P<0.001), memantine (P<0.001), PhTX-343 (P<0.001) and MK-801 (P<0.001). It 
was found that block by methoctramine (P<O. 112) was not voltage-dependent. 
Voltage-dependence was then established at 3AR704N receptors (Figure 73). There was a 
significant effect of voltage on IC50 for Mg2+ (P<0.001), memantine (P<0.001), PhTX-343 
(P<0.001) and methoctramine (P<0.006). Although block by MK-801 was not voltage- 
dependent (P=0.357). For 3AG704D receptors voltage-dependence was determined only for 
those tested: Mgt+, memantine and PhTX-343 (Figure 74). There was a significant effect 
of voltage on ICS0 
, 
for Mg2+ (P<0.001) and PhTX-343 (P<0.001). With this mutation the 
IC50 for memantine was not voltage-dependent (P=0.184). 
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Figure 72: Concentration inhibition relationship showing voltage-dependence of block 
of NMDA-glycine-evoked responses mediated by 3AG703 NMDA receptors at 
-100, -75 
and 
-50 mV. % control response (mean ± S. E. M) values were plotted and fitted with the Hill 
equation for (A) Mgz+, (B) memantine, (C) PhTX-343, (D) methoctramine and (E) MK-801. 
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Figure 73: Concentration inhibition relationship showing voltage-dependence of block 
of NMDA-glycine-evoked responses mediated by 3AR7O4 NMDA receptors at 
-100, -75 
and 
-50 mV. % control response (mean ± S. E. M) values were plotted and fitted with the Hill 
equation for (A) Mgt+, (B) memantine, (C) PhTX-343, (D) methoctramine and (E) MK-801. 
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Figure 74: Concentration inhibition relationship showing voltage-dependence of block 
of NMDA-glycine-evoked responses mediated by 3AR704 NMDA receptors at 
-100, -75 
and 
-50 mV. % control response (mean ± S. E. M) values were plotted and fitted with the Hill 
equation for (A) Mgz+, (B) memantine, (C) PhTX-343, (D) methoctramine and (E) MK-801. 
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The 8 value was determined from the Woodhull equation for 3AG703', 3AR704N and 3AR704D 
for Mgt+, memantine and PhTX-343. At 3AG703N and 3AR704N it was also carried out for 
methoctramine and MK-801 (Figure 75). The 8 parameters from are shown in Table 20. 
For Mg2+ the 3AG703N resulted in a8 that was higher than level of 1-1a/2A. 3AR704N and 
3AR704D restored 8 to levels toward that found with 1-1 a/2A. For memantine 3AG703N and 
3AR'°4D reduced 8 beyond the level of 1-la/2A. 3AR704N had a8 that was higher than both 
3A and 1-1a/2A. The 8 for PhTX-343 at 3AR7o4N and 3AR704D restored it to levels toward 
that found with 1-la/2A, but for 3AR7' it was highly reduced. For methoctramine there 
was no change for 3AR704N, but a reduction was found with 3AG703N. For MK-801 3AG7O3N 
and 3AR704N had an intermediate 8 between that of 1-la/2A and 3A. 
a 
(95% Cl) 
Compound 1-la/2A 3A G703N R704N R704D 
Mg 2+ 0.650 0.250 0.914 0.632 0.571 
-0.065 to 1.365 -1.889 to 2.389 -0.536 to 2.364 0.213 to 1.051 0.136 to 1.006 
Memantine 0.652 0.839 0.467 0.952 0.218 
-1.691 to 2.995 -0.294 to 1.971 -4.795 to 5.729 0.433 to 1.470 0.144 to 0.293 
PhTX-343 0.610 0.454 0.183 0.765 0.571 0.335 to 0.885 0.262 to 0.646 
-2.149 to 2.515 0.528 to 1.002 0.433 to 0.709 
Methoctramine 0.213 0.104 0.0501 0.155 
- 
-0.436 to 0.861 -0.566 to 0.775 -0.129 to 0.223 0.122 to 0.189 
MK-801 0.246 0.034 0.132 0.176 
- 
-2.165 to 3.400 -2.973 to 3.040 -2.313 to 2.577 -0.909 to 1.261 
Table 20: ö values from the Woodhull equation for 3Aß7O3N, 3AR704N and 3AR7O4D NMDA 
receptors. 
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Figure 75: Voltage dependence of IC50 for memantine block of 1-1a/2A, 3A and 3B 
NMDAR-mediated responses fitted with the Woodhull equation. IC50 (95% CI) pM for (A) 
Mgt+, (B) memantine, (C) PhTX-343, (D) methoctramine and (E) MK-801. 
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3.5.4 Rank Order of IC 
Concentration-inhibition data was used to determine IC5. values for the blockers at the 
3AG703N mutation (Figure 76). At 
-100 mV there was a rank order of IC50 of MK- 
801 <PhTX-343<memantine <methoctramine< Mgt+. At 
-75 mV the order was of MK- 
801<methoctramine <memantinezPhTX-3432 Mgt+. At 
-50 mV it was MK- 
801 <memantine< methoctramine< PhTX-343<Mg2+. Rank was then determined for 
3A R704N containing NMDA receptors (Figure 77). The rank order of IC50 at 
-100 mV was 
MK-801 <PhTX-343<memantinezmethoctraminez Mg2'. At 
-75 it was MK- 
801<memantine'zPhTX-343zmethoctraminez Mgt+. At 
-50 there was an order of MK- 
801<methoctraminezmemantine< Mgt+zPhTX-343. 
Inhibition by increasing concentrations of blocker were used estimate IC50 at 3AR7O4D 
receptors (Figure 78). At 
-100 mV there was a rank order of ICS0 as PhTX-343 
<memantine< Mgt+. At 
-75 mV the rank was memantine=PhTX-343<Mg2+. At -50 mV 
there was a rank order of IC_, of memantine<PhTX-343<Mg2+. A full list of statistical 
comparisons is given in the appendix. 
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Figure 76: Concentration-inhibition relationships for rank order of block of 
NMDAIGlycine-evoked responses mediated by 3AG703N MDA receptors at 
-100, -75 and 
-50 mV. (A, C, E) % control response (mean ± S. E. M) values were plotted and fitted with the 
Hill equation to give estimates of IC50 (B, 
-100 mV; D, -75 mV; F, -50 mV). Bars show IC50 (95% Cl) pM Groups that do not share a letter are significantly different. 
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Figure 77: Concentration-inhibition relationships for rank order of block of 
NMDAIGlycine-evoked responses mediated by 3AR704N MDA receptors at 
-100, -75 and 
-50 mV. (A, C, E) % control response (mean ± S. E. M) values were plotted and fitted with the 
Hill equation to give estimates of IC50 (B, 
-100 mV; D, -75 mV; F, -50 mV). Bars show IC50 (95% Cl) NM. Groups that do not share a letter are significantly different. 
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Figure 78: Concentration-inhibition relationships for rank order of block of 
NMDA/Glycine-evoked responses mediated by 3AR704D NMDA receptors at 
-100, -75 and 
-50 mV. (A, C, E) % control response (mean ± S. E. M) values were plotted and fitted with the 
Hill equation to give estimates of IC50 (B, 
-100 mV; D, -75 mV; F, -50 mV). Bars show IC50 (95% Cl) NM. Groups that do not share a letter are significantly different. 
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3.5.5 On-Rate of Block 
The average time constant i describing an exponential equation fitted to the onset phase 
of block for 3A wild-type and the mutations were an analysed using two-way ANOVA 
(Figure 79). For the onset of Mg", memantine and PhTX-343 block no significant 
differences were found. For methoctramine, Bonferroni post-hoc tests revealed that the 
3AG703N mutation had aT that was significantly slower than 3A wild-type at 
-100 
(P<0.001), 
-75 (P<0.001) and -50 mV (P<0.01). It was also found that 3AR704N had at 
that was significantly slower than 3A at 
-100 (P<0.05), -75 (P<0.01) and -50 mV 
(P<0.01). For MK-801, post-hoc analysis revealed that 3AR703N had T that was 
significantly slower than 3A at 
-75 (P<0.01) and -50 mV (P<0.01). It was also found that 
3AR704' had ar that was significantly slower than 3A at 
-100 (P<0.001) and -75 (P<0.001) 
mV, and that 3AR704N had at that was significantly slower than 3AR703N at 
-100 (P<0.01) 
and 
-50 (P<0.001) mV. 
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Figure 79: Time constant of a single exponential fit to the development phase of block 
of NMDAI I cine responses from 3AG703N R704N R704D gy, 3A and 3A NMDA receptors at 
-100, - 
75 and 
-50 mV. Bars show Log i (95% Cl, n=5-6) Two-way ANOVA with Bonferroni post-hoc 
test (P<0.05). Within a voltage, groups that do not share a letter are significantly different. (A) 
Mgz+, subunit (F(3,51)=0.956 P=0.421), voltage (F(2,51)=0.286 P=0.752) subunit x voltage 
interaction (F(6,51)=0.522 P=0.789) (B) memantine, subunit (F(3,60)=2.210 P=0.096), 
voltage (F(2,60)=0.1428 P=0.867) and no subunit x voltage interaction (F(6,60)=0.5255 
P=0.787). (C) PhTX-343, subunit (F(3,50)=1.235 P=0.307), voltage (F(2,50)=0.4097 P=0.666) 
and subunit x voltage interaction (F(6,50)=1.620 P=0.161) (E) methoctramine, subunit 
(F(2,41)=27.91 P<0.001), voltage (F(2,41)=0.02649 P=0.974) and subunit x voltage 
interaction (F(4,41)=0.228 P=0.921) and (F) MK-801, subunit (F(2,45)=35.00 P<0.001), 
voltage (F(2,45)=0.5779 P=0.565) and subunit x voltage interaction (F(4,45)=7.006 P<0.001). 
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3.5.6 Off-Rate of block 
The average time constant i describing an exponential equation fit to the recovery phase 
of block was obtained at 3A and compared with the 3A mutations using two-way 
ANOVA (Figure 80). For Mgt+block Bonferroni post-hoc testing revealed that 3AG703N 
had aT that was significantly slower than 3A wild type at 
-100 (P<0.01) and -50 mV 
(P<0.05). It was also found that T for 3AR704N was significantly slower than 3A at 
-50 mV 
(P<0.05). 3AR704D had ai that was significantly slower than 3A at 
-100 mV (P<0.05). At - 
100 mV it was also found that 3AR704N had az for Mg2+ that was significantly faster than 
3AG703N (P<0.05) and 3AR7O4D (p<0.01). 
For memantine block post-hoc testing revealed that 3AG703' had a2 that was significantly 
faster than 3A at 
-75 (P<0.05) and -50 mV (P<0.05). 3AR7O4N had aT that was significantly 
faster than 3A at 
-75 (P<0.01) and -50 mV (P<0.01). It was also found that 3AR704D had a 
T that was significantly faster than 3A at 
-75 (P<0.01) and -50 mV (P<0.05). For PhTX- 
343 no significant differences were found. For methoctramine it was shown that 3AG703N 
had aT that was significantly slower than 3A at 
-100 (P<0.001), -75 (P<0.05) and -50 mV 
(p<0.05). It was also found that 3AR704N had ar that was significantly faster than 3AG703N 
at 
-100 mV (P<0.01). For MK-801 post-hoc analysis revealed that 3AR704N had ar that 
was significantly slower than 3A at 
-100 (P<0.001) -75 (P<0.001) and -50 mV (P<0.05). 
It was also found that 3AG703N had az that was significantly faster than 3AR704N at 
-100 
mV (P<0.01). 
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Figure 80: Time constant of a single exponential fit to the recovery phase of block of 
NMDAlglycine responses from 3AG703N, 3AR704" and 3AR704D NMDA receptors at 
-100, -75 
and 
-50 mV. Log T (95% Cl, n=5-6). Two-way ANOVA with Bonferroni post-hoc test. Within a 
voltage bars that do not share a letter are significantly different (A) Mgt+, subunit 
(F(3,52)=9.925 P<0.001), voltage (F(2,52)=0.4118 P=0.665) and subunit x voltage interaction 
(F(6,52)=2.114 P=0.064). (B) memantine, subunit (F(3,61)=7.791 P<0.001), voltage 
(F(2,61)=0.336 P=0.716) and no subunit x voltage interaction (F(6,61)=0.950 P=0.470) (C) 
PhTX-343, subunit (F(3,49)=2.423 P=0.077), voltage (F(2,49)=0.057) and voltage x subunit 
interaction (F(6,49)=1.331 P=0.262) (D) methoctramine, subunit (F(2,40)=18.53 P<0.001), 
voltage (F(2,40)=2.344 P=0.109) and subunit x voltage interaction (F(4,40)=1.474 P=0.228) 
(E) MK-801, subunit (F(2,39)=31.91 P<0.001), voltage (F(2,39)=0.002 P=0.998) and no 
voltage x subunit interaction (F(4,39)=1.146 P=0.349). 
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3.6 MTDL Drug Design for Alzheimer's Disease 
The compounds were successfully produced by the collaborators at the University of 
Bologna and are shown again in (Figure 81). 
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Figure 81: MTDL compounds used in the study. Carbacrine was derived from carvedilol 
and tacrine, and the series was based on the number of methylenes at position highlighted 
with the arrow. Compounds I and 2 were based on donepezil and carvedilol, and the series 
was based on increasing number of methyienes at position shown by the arrow. Lipocrine was 
based on lipoic acid and tacrine. Group 3 were based on dimebon and had increased 
methylene groups at the position marked with the arrow. Compounds 4 and 5 were based on 
dimebon with differing linker regions. Compound 6 was based on carvedilol and lipoic acid. 
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3.6.1 Memantine 
Concentration-inhibition data for memantine was plotted and fitted with the Hill 
equation in order to estimate IC50 (Figure 82). The range of voltages required for this 
chapter was different to that in chapter 3, where 
-80mV was used as the intermediate 
voltage (Figure 82). 
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Figure 82: Memantine block of NMDA/glycine-evoked currents mediated by 1-1a/2A 
receptors at 
-100, -80 and -50 mV. (A) Concentration-inhibition relationships for memantine 
block. % control response (mean ± S. E. M., n=6) values were plotted and fitted with the Hill 
equation (A) to give estimates of IC50 (B). 
3.6.2 Carbacrine Series 
Concentration-inhibition curves were produced for the carbacrine compounds at G1uN 1- 
la/2A receptors to establish a rank of potency amongst each other and with memantine 
(Figure 83). These were then used to calculate IC50 values for the blockers tested (Figure 
83). The rank order of IC,, at 
-100 mV was carbacrine(3)zmemantine>carbacrine 
(6)zcarbacrine(5) Z-carbacrine(4) comparison. At 
-80 mV it was memantinez 
carbacnne(3)<carbacrine(6)zcarbacrine(4)zcarbacnne(5). At 
-50 mV, the rank order of 
161 
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IC50 was carbacrine(3)zmemantine<carbacrine(6)z carbacrine(4)zcarbacrine(5). See 
appendix for a full statistical comparison. 
Block by increasing concentrations of the carbacrine compounds of NMDA/glycine 
responses at 
-100, -80 and -50 mV were plotted and fitted with the Hill equation to 
determine voltage-dependence (Figure 84). There was a significant effect of voltage on 
IC50 for carbacrine(3) (P<0.001) and carbacrine(5) (P=0.034). Block was not voltage 
dependent for carbacrine(4) (P=0.686) and carbacrine(6) (P=0.613). 
ICW (95% CI) NM 
MTDL 
-100 mV -80 mV -50 mV 
Carbacrine(3) 0.74 1.14 3.35 0.43 to 1.28 0.74 to 1.76 2.15 to 5.24 
Carbacrine(4) 30.25 23.07 32.23 18.93 to 48.31 13.04 to 40.83 15.55 to 66.80 
Carbacrine(5) 18.24 53.41 107.00 8.095 to 41.11 25.78 to 110.70 20.18 to 567.70 
Carbacrine(6) 12.99 14.22 20.08 6.19 to 27.26 6.84 to 29.56 10.87 to 37.11 
Table 21: IC50 values for carbacrine compounds 
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Figure 83: Concentration-inhibition relationships for rank order of carbacrine block of 
NMDA/glycine-evoked currents mediated by 1-1a/2A NMDA receptors at 
-100, -80 and - 
50 mV. % control response (mean ± S. E. M., n=5-12) values were plotted and fitted with the 
Hill equation (A, C, E) to give estimates of IC50 (B, D, F). Bars show ICso (95% Cl) and those 
that do not share a letter are significantly different. 
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Figure 84: Concentration-inhibition relationship showing voltage dependence of 
carbacrine block of NMDA/glycine-evoked currents mediated by 1-la/2A NMDA 
receptors at 
-100, -80 and -50 mV. % control response (mean ± S. E. M) values were plotted 
and fitted with the Hill equation (A) carbacrine(3), (B) carbacrine(4), (C) carbacrine(5) and (D) 
carbacrine(6). 
3.6.3 Donepezil Derived Compounds I and 2 
2b, 2a and ld were found to weak blockers of NMDA receptor responses (Figure 85). 2b 
was shown to only inhibit the control response to a level of 87.5% ± 3.5 (mean ± S. E. M) 
with 100 µM. 2a also showed little activity, with only 66.8% ± 9.4 control response 
remaining with 100 µM. id was not soluble at 100 µM, but inhibited control responses to 
87.30 ± 3.26 % at 10 µM. 
The remaining compounds had increased potency at the NMDA receptor. 
Concentration-inhibition curves were produced at 
-100 mV (Figure 86). The rank order 
IL 
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of IC50 was memantine<1b<1ez1az1c at 
-100 mV, and the full list of statistical 
comparisons are shown in the appendix. 
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Figure 85: Concentration-inhibition relationship for 1 and 2 block of NMDAlglycine- 
evoked currents mediated by 1-1a/2A receptors. % control response (mean ± S. E. M, n=6- 
7). Curves were constructed for 1d, 2a and 2d. Shown are connecting lines for clarity. 
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Figure 86: Compound I and 2 block of NMDA/glycine-evoked currents mediated by 1- 
1a/2A receptors at 
-100 mV. (A) Concentration-inhibition relationships for I and 2 block. % 
control response (mean ± S. E. M., n=6) values were plotted and fitted with the Hill equation (A) 
to give estimates of IC50 (B, D). Bars show IC50 (95% Cl) and those that do not share a letter 
are significantly different. (C) TEVC current recording of 1c block of NMDA/glycine evoked 
currents mediated by 1-1a/2A NMDA receptors at -100 mV. 
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3.6.4 Dimebon Derived Compounds 
Block by increasing concentrations of 3,4,5 and dimebon of NMDA/glycine responses 
were plotted and fitted with the Hill equation to estimate IC50 (Figure 88, Table 22). The 
rank order of IC5)was memanrine<4z5z3cz3bz3azdimebon. At 
-80 mV this was 
memantine<4<dimebonz3cz5z3b<3a. At 
-50 mV there was a rank order of 1C;,, of 
memantine<4<3bz3c<3az5<dimebon. For statistical comparisons see appendix. 
The voltage-dependence of dimebon derived series was explored by comparing IC, ) 
values at a range of voltages (Figure 89). Block by all the compounds were found to be 
voltage-dependent, showing a significant effect of voltage on IC50 for dimebon 
(P<0.001), 3a (P<0.001), 3b (P<0.001), 3c (P<0.001), 4 (P<0.001) and 5 (P<0.001). 
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Figure 87: TEVC current recording of dimebon and 3 and 4 block of NMDA/glycine 
evoked currents mediated by 1-1a/2A NMDA receptors. (A) Dimebon, (B) 4, (C) 5 at 
-100 
mV. (D) 3b at 
-100 (black) and -50 mV (red). 
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IC50 (95% Cl) NM 
MTDL 
-100 mV -80 mV -50 mV 
13.85 11.98 149.10 Dimebon 7.66 to 25.05 5.82 to 24.65 84.05 to 265.6 
12.58 29.14 51.11 3a 9.00 to 17.60 21.14 to 40.18 37.96 to 68.82 
3b 10.95 17.94 27.53 
8.22 to 14.57 14.19 to 22.68 20.76 to 36.52 
3c 9.66 14.76 35.20 
7.77 to 12.01 11.22 to 19.41 28.99 to 42.74 
4 9.66 14.76 35.20 
7.77 to 12.01 11.22 to 19.41 28.99 to 42.74 
5 8.72 15.22 57.33 
4.72 to 16.13 9.05 to 25.60 34.20 to 96.11 
Table 22: IC50 values for Dimebon, 3,4 and 5. Shown is IC50 (95% CO calculated from the 
Hill equation. 
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Figure 88: Concentration-inhibition relationships for rank order of 3,4 and dimebon 
block of NMDA/glycine-evoked currents mediated by 1-1a/2A NMDA receptors at 
-100, - 
80 and 
-50 mV. % control response (mean ± S. E. M., n=5-6) values were plotted and fitted 
with the Hill equation (A, C, E) to give estimates of IC50 (B, D, F). Bars show IC50 (95% Cl) 
and those that do not share a letter are significantly different. 
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Figure 89: Concentration-inhibition relationship showing voltage-dependence of 
dimebon and RG block of NMDA/glycine-evoked currents mediated by 1-1a/2A NMDA 
receptors at 
-100, -80 and -50 mV. % control response (mean ± S. E. M) values were plotted 
and fitted with the Hill equation for (A) dimebon, (B) 3a, (C) 3b, (D) 3c, (E) 4 and (F) S. 
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3.6.5 Lipocrine 
Block by increasing concentrations of lipocrine to NMDA/glycine responses were 
plotted and fitted with the Hill equation to estimate IC51) (Figure 90). The IC51) for 
lipocrine was compared with that of memantine at each voltage. Lipocrine had a 
significantly lower IC5,, than memantine at 
-100 mV (P<0.001), -80 mV (P<0.001) and - 
50 mV (P<0.001). Block was found to be voltage-dependent, showing a significant effect 
of voltage on IC54 (P<0.001). 
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Figure 90: Lipocrine block of NMDA/glycine-evoked currents mediated by 1-la/2A 
receptors. (A) Concentration-inhibition relationships for lipocrine block. % control response 
(mean ± S. E. M., n=5) values were plotted and fitted with the Hill equation (A) to give 
estimates of IC50 (B, D). Bars show IC50 (95% Cl) and those that do not share a letter are 
significantly different. Note altered Y-axis scale (C) TEVC current recording of lipocrine block 
of NMDA/glycine evoked currents mediated by 1-1a/2A NMDA receptors at 
-100 mV. 
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3.6.6 Carvedilol and Lipoic Acid derived Compound 6 
Compound 6 was found to be a weak inhibitor of NMDA/glycine current, with 100 µM 
inhibiting the control response to 56.44 ± 11.12 (mean ± S. E. M) % control response at 
- 
100 mV (Figure 91). Showing some voltage-dependence, inhibition at 
-80 mV was to 
63.52 ± 9.19 % and at 
-50 mV was reduced to 84.69 ± 6.52 % of the control response 
with 100 µM. 
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Figure 91: MM3 block of NMDA/glycine-evoked currents mediated by 1-1a/2A receptors. 
(A) TEVC current recording of MM3 block of NMDA/glycine evoked currents mediated by 1- 
1a/2A NMDA receptors at 
-100 mV. (B) Concentration-inhibition relationship for MM3 block of 
NMDA/glycine-evoked currents mediated by 1-1 a/2A receptors at 
-100, -80 and -50 mV. % 
control response (mean ± S. E. M, n=6-7). 
3.6.7 Woodhull Model 
The Woodhull equation was used to determine 8 for the MTDL compounds (Figure 92, 
Table 23). The carbacrine compounds alternated between 0.2 and around 10-fold less. 
The 3a-d and 4 had similar 8 values around 0.1, with 5 being slightly increased to around 
0.2. Lipocrine had the highest 6 of all the compounds tested around 0.6. 
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Figure 92: Voltage-dependence of IC50 for MTDL block of 1-1a/2A NMDAR-mediated 
responses fitted with the Woodhull equation. IC50 (95% CI) pM for (A) carbacrine series 
(B) RG series, (C) dimebon and (D) lipocrine. 
MTDL 
Carbacrine(3) Carbacrine(4) Carbacrine(5) Carbacrine(6) Lipocrine 
a 
0.283 0.020 0.243 0.080 0.0.554 
(95% CI) -0.054 to -0.661 to -0.439 to -0.108 to to 0 .765 0.621 0.701 0.925 0.268 
MTDL 
3a 3b 3c 4 5 
0.150 0.108 0.175 0.124 0.267 
267 to 
-0 -0 093 to 0.034 to 0.315 -0.034 to -0.012 to (95% CI) . 0.568 . 0.309 0.282 0.545 
Table 23: 5 values for the MTDL compounds. ö (95% Cl). 
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4 
Discussion 
To simplify discussion of the pore region of the NMDA receptor all amino acids are 
referred to by their relationship to the N-site amino acid, which is under this 
nomenclature is position 0, or the N-site. Position 1 is the N+1 site and position +5 
would be C-terminal to the N-site. Furthermore, the receptor combinations will now be 
written out in full during the discussion, e. g. G1uN1-1a/2A/3A and individual subunits 
will be referred to with the prefix G1uN, e. g. G1uN3A. 
4.1 Molecular Biolo 
There was a single consensus difference in the G1uN3B subunit when it was sequenced 
with T7. However, A BLAST search revealed no SNP at this position and so may have 
been a reading error. There was also a single consensus difference for GluN3AR704D 
mutation that was not in the same region as the mutation. But as this did not appear on 
any other G1uN3A sequence, this is likely a further reading error. 
4.2 AAgonist 
For both agonists, the concentrations used in the study were at maximal efficacy. 
Therefore, these were considered saturating for glycine and NMDA at all combinations 
of receptor, which is required when investigating the activity of open channel blockers 
(Li, 1999). There was a decrease in efficacy with concentrations above these levels which 
has been previously reported for glycine, but not NMDA in Xenopus oocytes (Mirshahi 
and Woodward, 1995, de Carvalho et al., 1996). 
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It was shown that the EC,, values for NMDA were not significantly different for all the 
subunit combinations tested suggesting that the number of G1uN2 subunits did not 
change. The glycine EC50was found to be significantly reduced for G1uN1-1a/2A/3A 
and G1uN1-la/2A/3B compared with G1uN1-1a/2A which was consistent with the 
subunit being present in the receptor assembly, as glycine has been shown to bind to the 
G1uN3A subunit with a 650-fold lower Kd than G1uN1 (Yao and Mayer, 2006). However, 
a previous study found that that the EC., for glutamate and glycine was not significantly 
different between wild-type and transgenic mice overexpressing G1uN3A (Tong et al., 
2007). GluN2A/3A has been shown to form dimers, but only a heteromeric complex 
containing G1uN1 were able to exit from the ER (Perez-Otano et al., 2001). If there was 
a G1uN2A/3A dimer in the heteromeric receptor complex then there would possibly 
have to be an additional GluN1-1a/2A or GluN1-la/3 dimer, and the former outcome 
may be more likely as the ECO for NMDA was shown in the current study to be 
unchanged. Such an interpretation is required because GluN3 lacking NMDA receptors 
have two GluN2 subunits (Sobolevsky et al., 2009). 
4.3 NMDA Receptor Antagonism 
4.3.1 Mg2± 
At all voltages tested Mgt+showed an increase in ICS for between G1uN1-1a/2A/3A 
('-5-fold) and G1uNI-1a/2A/3B (-10-fold) compared with the IC-, for GluN1-1a/2A, 
and G1uN1-la/2A/3B was significantly higher than G1uN1-1a/2A/3A. The N-site of 
G1uN1 and G1uN2 and the N+1 site of GluN2 have been shown to form the Mg2+ 
binding sites of the NMDA receptor (Wollmuth et al., 1998a, Wollmuth et al., 1998b). 
The G1uN3 subunits have aG then the positively charged R at these positions and it may 
be that the loss of the polar partial negative charge of N, as well as the addition of the 
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positive R, reduced Mg2+ affinity. The amino group of MK-801 may also interact with the 
N-site, as well as the amino group of memantine accounting the increased IC-, values 
found (Tikhonov et al., 2002, Chen and Upton, 2005). 
The binding site for Mg2+ for G1uN3 containing receptors may have been lost. The 
orientation of the threonines in the M3 SYTANLAAF motif in G1uN1/3A receptors has 
been shown to form a narrow constriction restricting entry to the pore (Wads et al., 
2006). Entry to the N-site may be impaired and due to the constriction it may form a new 
binding site for open channel blockers that has a lower affinity (Figure 93). Woodhull 
analysis supported such a conclusion for Mg2+ as it suggested that depth of block 
occurred at 0.6 similar to previous reports of the N-site, which was decreased with the 
presence of G1uN3A and G1uN3B (Zhu and Auerbach, 2001). Current flow, and the 
relative speeds of the ions through the channel, have been shown to affect Mg2+ affinity 
(Yang et al., 2009). It may therefore be that the threonine ring reduced ion flux through 
the channel leading to reduced affinity for Mg2+ at the N-site of the G1uN1-la and 
G1uN2A subunits, rather than through modified interactions with specific binding sites. 
A further constricted region has been found at the tip of M3 at P +45 of G1uN1, but 
with the GIuN3A and G1uN3B subunits the cyclic side chains are lost, possibly 
expanding the pore (Sobolevsky et al., 2009). Furthermore, the bulky W residue at 
-8 has 
been shown to influence Mg2+ block, but mutations here only resulted in a loss of activity 
if there was a loss of the aromatic ring, indicating there may be a cation-fl interaction 
(Williams et al., 1998). The Aromatic ring structure may contribute to the high energy 
barrier and further constrain the pore. 
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Figure 93: Model of open channel block of NMDA receptors. One subunit has been 
omitted for clarity. Shown on the left is 1-1a/2A and on the right a GluN3 containing receptor. 
Position of block shown by the red disc. 
The N mutations at position 703 and 704 of GluN3A partially restored 1C;,, for Mg" 
toward levels seen with 1-1a/2A at 
-100 and -75 mV. By restoring the deep binding site, 
while retaining the threonine ring, it may have led to a situation where block was 
mediated by the mixed properties of both sites (Chen and Lipton, 2005). Or it may have 
been that restoring binding at the N-site, without restoring flux (as the ring is unaffected), 
led to a situation where only a proportion of block could be restored (Yang et al., 2009). 
Full restoration of block could require double N mutation at N and N+1 as it has been 
shown that the G1uN2 subunit requires both asparagines to provide its binding site 
(Wollmuth et al., 1998a). The GluNl-1a/2A/G1uN3AR704N mutation seemed to show that 
there was a return to the N-site, as 6 was restored to 0.6; however, G1uN1-la/2A/ 
G1uN3AG703N resulted in a8 value that was greater than 1-1 a/2A so this interpretation 
may be unlikely. 
The Woodhull model was originally developed to measure depth of block by H+ through 
the Na' channel, but it has been more recently thought to represent voltage-dependence 
or electrical interactions, rather than an actual position in space (Woodhull, 1973, Chen 
2A 
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and Lipton, 2005). The electrical field of the NMDA receptor has also been shown to be 
concentrated around the N-site and is weaker in the outer region, meaning depth cannot 
be accurately described by the model (Antonov et al., 1998). Furthermore, at voltages 
greater than 
-60 mV intracellular and extracellular monovalent permeant ions bind to the 
channel and influence the kinetics of open channel blockers (Chen and Lipton, 1997, 
Antonov et al., 1998). Therefore, it is more likely that the increased 6 for G1uN1- 
1a/2A/3A G703N represents increased electrical interactions with the receptor. At 
-50 mV 
the G1uN1-1a/2A/3AG703N mutation resulted in an IC50 value for Mg2+ that was now 
significantly higher than G1uN1-1a/2A/3A wild-type. As the Woodhull analysis found 
the GluN1-1a/2A/3AG703N mutation had the most electrical interactions, then it would 
mean that block was more influenced by the increase in voltage, leading to the higher 
IC50 compared to the other mutants and that was what was found. 
The G1uN1-1a/2A/3AR704D mutation had no effect on Mg" block at 
-100 mV which may 
mean that changing the charge to negative at this position had no effect. However, as the 
voltage was increased to-75 mV the IC50 for Mg2+ was intermediate, and at 
-50 mV it was 
increased relative to G1uN1-la/2A/3A similar to G1uN1-1a/2A/3AG703N. Therefore, at 
increased voltages these mutations may have had equivalent effects on Mg2+ block, 
possibly mainly due to removal of the positive charge, rather than the addition of the 
negative charge. 
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N-site changes do not however explain why there was a further significant increase in 
ICS for G1uN1-la/2A/3B compared with G1uNI-la/2A/3A. Both subunits have the 
same GR at the N and N+1 site, as well as the Tin the SYTANLAAF motif (Figure 94), 
although it is not known if G1uN1/3B receptors have the same constriction. However, 
the section from the N-site to the M3 region contains residues that are different for the 
G1uN3A and GluN3B subunits, and these may influence block. For the G1uN3B subunit 
there is a possible gain of a polar side chain at +4(A-S), +5(I-S), +44(1-T) but these 
would be expected to lower the ICO and are therefore unlikely to be involved, although 
some of these substitutions could lead to increased phosphorylation by serine/threonine 
kinase. It is more likely to be the loss of the polar side chain at +27(C-V) for G1uN3B 
compared with G1uN3A could explain the changes in IC50 found (Figure 94). G1uN3B 
also has an additional proline at +11(W-P) within the M3 alpha helix which may 
introduce kinks or a flexibility that affects gating (Cordes et al., 2002). The difficulty in 
determining if these M3 residue differences are involved is that mutations have been 
shown to lead to constitutively open channels (Chang and Kuo, 2008). 
Mg 2+ binding may be influenced by monovalent ions binding in a putative permeation 
pathway. It is thought that there are two extracellular sites where monovalent ions can 
bind, and if this has occurred, then it could slow entry to, or trap Mg2+ at the N-site (Zhu 
and Auerbach, 2001). The binding of these ions altered the rate constants for Mg2+ and 
hence affinity. The exact residues involved are unknown, although it has been reported as 
being 0.25 through the electric field which is the same S as what was found for Mg2+ 
block at G1uN1-1a/2A/3A containing receptors (Zhu and Auerbach, 2001). It may be 
that the amino acid differences in the M3 alter the permeation pathway leading to 
increases in IC5. for G1uN1-la/2A/3A and GluN1-la/2A/3B. 
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A constricted pore region is not supported by rates that were measured for block. The 
on-rate of Mg2+ was shown to be significantly faster at G1uN1-1a/2A/3A than G1uN1- 
1 a/2A at 
-75 mV, but in general the GluN3 subunits and the G1uN3A mutations had no 
effect. Changes in the Mg" off-rate were also not uniform across the voltages. G1uN 1- 
1a/2A was significantly slower at 
-100 mV while G1uN1-la/2A/3B had a significantly 
slower off-rate at 
-50 mV, compared to the remaining subunit combinations. The on- 
rates and off-rates for the blockers do not form a clear pattern across voltage, across 
subunits and across the blockers tested. The IC., concentration was used to determine 
the rates. So the different concentrations may have been altering the rates, rather than the 
subunits or changes in voltage, although off-rate is not concentration-dependent. The 
variance of T was also large between oocytes and would mean that the ANOVA could 
not detect the differences. Power analysis should have been carried out to determine the 
number of repeats required to show the differences sufficiently. Furthermore, the 
variability could also be due to differences in perfusion when the solutions were changed 
although it was kept at a minimum. 
These data have shown that the effect of the G1uN3 subunits on Mg 2+ sensitivity was 
smaller than expected from the N-site changes alone, and that the G1uN3B impaired 
block more than G1uN3A. What was found is less substantial than claims in review 
papers that the receptor becomes completely resistant with GluN3 present (Petrenko et 
al., 2003, Paoletti and Neyton, 2006). In fact, evidence was weak, and seemed to be based 
only on the bioinformatic analysis of the N-site site rather than from experimental data. 
One study did however show that the IC50 for Mg2+ in hippocampal neurones from 
transgenic mice overexpressing G1uN3A was around 14-fold higher than wild type, 
although the voltage was not stated (Tong et al., 2007). The changes in IC50 were small 
similar to what was found in the present study, and the difference with the current 
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recombinant study may be due to the differing G1uN2 subunits present in neurones 
(Kuner and Schoepfer, 1996). 
Sensitivity to Mg2+ is dependent on the G1uN2 subunit that is expressed. G1uN2A and 
GIuN2B are the most sensitive, and G1uN2C and G1uN2D containing receptors are the 
least (Kuner and Schoepfer, 1996). It is currently unknown if the different GIuN2 
subunits alter the Mg2+ sensitivity of GluN3 containing receptors. It may be that if the 
binding site is moved to the threonine ring then the differing GIuN2 subunits may lose 
their ability to influence block, and no difference may be found. But as the G1uN2 
subunits have the same residues at the N and N+1 site they must not mediate differences 
in Mg2+ block by changes in the selectivity filter. Chimeras of the transmembrane 
domains, the linkers to the ligand binding domains, linkers to the N-terminal domain and 
the N-terminal domain itself have all been shown to be involved in various aspects of 
channel gating and Mg2+ sensitivity (Wrighton et al., 2007, Yuan et al., 2009). These 
regions could similarly be transferred incorporating the G1uN3 subunits to determine if 
they play a role, although it must be noted that transferring the M2 region of G1uN3A to 
G1uN1-la did not produce functional channels (Villmann et al., 1999). 
4.3.2 Memantine 
Memantine showed a similar pattern to Mg2+ as there was a significant increase in IC50 for 
GluN1-1a/2A/3A and G1uN1-1a/2A/3B compared with GluN1-la/2A, and G1uN1- 
1a/2A/3B was significantly higher than GluN1-1a/2A/3A. The amine head group is 
thought to bind to the N-site of G1uN1-1a (Chen and Upton, 2005). If G1uN1-1a was 
replaced by a G1uN3 subunit then it would account for the increase in IC50 found with 
G1uN1-1a/2A/3A and G1uN1-1a/2A/3B, as well as the partial recovery with the 
G1uN1-1a/2A/3A N mutations. But from the EC50 data it seems less likely that a G1uN2 
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subunit was replaced. The number electrostatic interactions within the pore would be 
reduced as GluN2 has been shown to mediate these (Chen and Lipton, 2005). However, 
the Woodhull model has shown that suggest that the presence of G1uN3A subunit had a 
higher S than GluN1-la/2A alone. Further positions that have previously been shown to 
be involved in memantine block are altered with the GluN3 subunits (Figure 94). 
Changes at +29 (A-S) led to the loss of hydrophobic side chain and the loss of the 
aromatic residue at 
-8 (W-N) and the may have led to the increased IC50 values found, but 
are the same for the G1uN3A and G1uN3B subunits (Kashiwagi et al., 2002). 
The Woodhull model showed that the GluN1-1a/2A/3AR704N mutated receptor had an 
increased S even beyond the level of G1uN1-la/2A/3A, while a complete change of 
charge with GluN1-la/2A/3AR704D caused a dramatic reduction in 8 below the level of 
G1uNl-1a/2A receptors. Memantine interaction with GluN2 subunit is thought to 
involve the externally pointing carbonyl oxygen of position 704 (Chen and Upton, 2005). 
Therefore, G1uN3A wild-type which has a full positive charge (R) and GluN3A170D 
which has a full negative at this position may be interfering with binding, as the 
G1uN3AR704N mutation was shown to have the highest 8. Interpreting the 8 values is also 
further complicated as it has been proposed that two memantine molecules bind in the 
channel, and that would produce an average S of around 0.45 which is the value found 
for GluN3AG704N (Sobolevsky and Koshelev, 1998, Kashiwagi et al., 2002). 
The on-rate for memantine seemed unaffected by at G1uN1-la/2A/3A and G1uN1- 
1a/2A/3B as no significant differences were found at any voltage, or with the G1uN3A 
mutations. However, with G1uN1-la/2A/3A the off-rate had aT that was generally 
significantly slower than G1uN1-1a/2A and G1uN1-1a/2A/3B. All the G1uN3A 
mutations restored the speed of t, but an effect was only found at 
-75 and -50 mV. The 
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slower off-rate of GluN1-1a/2A/3A may be related to the number of electrical 
interactions between G1uN1-la/2A/3A and memantine, as it had an increased S 
compared with G1uN1-la/2A. By this reasoning GluN1-1a/2A/3AR704N should have had 
the slowest rate, but it was not found. 
Block by memantine at G1uN1-1a/2A/3B containing receptors was not voltage- 
dependent and a large decrease in 6 was found. It may be that amino acid differences, or 
constrictions in the pore, caused the compound to bind at the superficial site, which has 
been indirectly estimated to have an IC50 of 79.1 µM at 
-66 mV (Kotermanski et al., 
2009). The current study found that memantine had an IC5. at G1uN1-1a/2A/3B of 
17.54 µM at 
-75 mV, and may be a better measure. The superficial site ICS was calculated 
using a double-pulse protocol hoping that the second pulse left the superficial site free, 
and may not have been sufficiently accurate. At 
-50 mV the ICS for memantine was not 
significantly different between GluN1-la/2A/3A and G1uN1-1a/2A/3B indicating that 
binding at G1uN1-la/2A/3A may have shifted to the superficial site, which has been 
shown to occur at voltages more positive than 
-60 mV (Antonov et al., 1998). Block at 
the GluN1-1a/2A/3AR704D mutation was also shown to not be voltage-dependent and it 
also had a8 that was lower than GluN1-la/2A. However, it may not represent binding at 
the superficial site as the ICO for memantine was not similar to that of GluN 1- 
la/2A/3B, and remained potent. The superficial site is located at position +35 and could 
be mutated in order to determine if block at G1uN1-1a/2A/3B or GluN1-1a/2A/3AR704D 
was impaired. 
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4.3.3 M K-801 
Compared to the other compounds tested MK-801 was the most potent at all receptor 
subunit combinations at all voltages. When comparing the IC50 of the various subunits at 
-100 mV MK-801 showed a significant increase in IC50 with G1uN1-la/2A/3A and 
G1uN1-1a/2A/3B (around 3-fold), but no significant difference was found between the 
G1uN3 subunits. However, the effect of G1uN1-1a/2A/3A was dependent on voltage as 
when it was increased no difference was found, while G1uN1-1a/2A/3B continued to 
have an increased ICso. MK-801 is thought to bind with high affinity to the N-site in such 
a way that agonist can dissociate and the channel can close while it is still bound in the 
pore, and the restoration of activity found with the GluN3A N mutations support the 
claim that binding occurs in this region (Kashiwagi et al., 2002). It has also been shown 
that there are many further residues that influence MK-801 binding across the channel 
(Figure 94). It is unlikely that the compound can bind to MI, M3 and the N-site 
simultaneously, unless more than one molecule can block the receptor. The wide range of 
residues may represent a pathway into the N-site. 
The aromatic groups of MK-801 are more likely to make hydrophobic interactions that 
possibly encourage entry into the pore similar manner to the DRPEER motif that attracts 
Cat+. Changes could due to increased aromatic residues such at W (+8), F (+26) and Y 
(+45) for G1uN3A and F (+45) for G1uN3B. However, few residues that have been 
directly implicated in MK-801 block are different between the GluN3 subunits (Figure 
94) (Kashiwagi et al., 2002). It may be that the voltage-dependent differences in IC50 for 
MK-801 are representative of structural changes within the M3 region restricting access 
to the N-site, such as the threonine ring. It could also be due to an altered M3 region as 
the P at position +11 may have introduced kinks or flexibility into the a-helix (Cordes et 
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al., 2002). Such a change may explain the Woodhull analysis which showed that GluN 1- 
1a/2A/3B containing receptors had the most electrostatic interactions with MK-801, 
even though G1uN1-1a/2A/3A had the most additional aromatic groups. If the G1uN1- 
1a/2A/3B N-site mutation showed no effect then that would support the conclusion 
that the structure of M3 was impairing access. 
The presence of G1uN3A in a G1uN1-1a/2A/3A receptor assembly led to a faster on- 
rate for MK-801 while the mutations GluN1-1a/2A/3Ac'o3N and GluN1-1a/2A/3AR704N 
were shown to slow the rate back down. The off-rate showed a similar pattern, with 
G1uN1-1a/2A/3A generally being significantly faster than the other subunit 
combinations, while the G1uN1-1a/2A/3AR704N mutation slowed the rate. Woodhull 
analysis has shown that G1uN1-1a/2A/3A had the lowest S for MK-801 block and the 
faster rate may represent easier access, even though the G1uN3A has more additional 
aromatic residues in the pore compared to G1uN3B. 
4.3.4 PhTX 
PhTX-343 had an ICS0 
, 
that was not significantly different to MK-801 at G1uN1-la/2A or 
G1uN1-1a/2A/3B at 
-100 mV, meaning that at low voltages it can be considered a 
particularly potent compound. GluN 1 
-1 a/2A/3A and G1uN1-1a/2A/3B were both 
shown to significantly increase IC50 for PhTX-343 by the same magnitude (-10-fold), but 
only at 
-100 mV. The subunit differences may be related to the ability for the terminal 
amine group to reach a deep site at 
-100 mV which was impaired by the presence of the 
G1uN3 subunits or by increased voltage. For polyamines to have maximum potency at 
AMPA receptors they require two amine groups; whereas for block of the NMDA 
receptor they require three (Mellor et al., 2003, Nelson et al., 2009). The additional charge 
is thought to bind to the N-site of NMDA receptors which is not implicated in some 
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models of AMPA receptor binding, which show two amines binding to G at +2 while the 
head group binds in the M3 vestibule (Andersen et al., 2006). At NMDA receptors the 
head group of the anthraquinone toxins has been shown to bind in M3 region, with the 
tail binding to the negatively charged E at position +5 of GluNl, located beyond the 
selectivity filter (Figure 94) Qin et al., 2007). At G1uN3A +5 is I and at G1uN3B it is S, so 
at 
-100 mV the binding may be impaired, leading to the increased IC50 values that were 
found. As the voltage was increased then it may not have been possible for the terminal 
amine to reach the site at any receptor combination, as no differences were found for 
PhTX-343 block at any subunit combinations. 
PhTX-343 was the most voltage-dependent of the compounds tested supporting the 
conclusion that deeper binding site was only accessible as the voltage was made more 
negative. The Woodhull model found a reduction in 8 with G1uN1-1 a/2A/3A compared 
with G1uN1-1a/2A indicating that there may have been reduced interactions possibly 
related to position +5. The G1uN1-1a/2A/3AR704N mutation also had an increased 8 and 
may represent an additional binding site for the compound when the positive charge was 
removed and replaced with N. The increased S may also represent deeper binding as the 
R residue was removed. G1uN1-la/2A/3B had the highest 8 of all the subunit 
combinations tested which may be a result of further binding of the head group within 
the M3 region similar to the anthraquinone toxins and MK-801 (Kashiwagi et al., 2007). 
However, the Woodhull model may again have limitations as it is unable to describe 
multiple complex binding properties in a non-uniform electrical field, properties that are 
characteristic of the polyamines. 
For PhTX-343 the presence of the G1uN3A and G1uN3B subunits generally led to a 
faster on-rate and off-rate at all voltages. The amine groups of PhTX-343 may bind to 
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less residues on G1uN3A and G1uN3B leading to faster kinetics. There could be the loss 
of interaction at deep position +5 which may have led to an increased off-rate, but is not 
supported by the continued increased rates as the voltage was increased. It could be that 
the interaction with the N-site was lost; however, it was shown that the G1uN3A 
mutations did not restore the binding kinetics, which would have been expected. 
For the anthraquinone toxins the mutation at the N-site of G1uN1 to G reduced the 
potency of AQ343 and AQ444 (Kashiwagi et al., 2002). At the same site on G1uN2B the 
G mutation increased the potency of AQ343 (Kashiwagi et al., 2007). Therefore, the G at 
the N-site of the G1uN3 subunits could have been expected to not interfere with PhTX- 
343 binding. But this was not found as all the mutations partially restored block at 
-100 
mV. One explanation is that the positively charged R at position 703 could have been 
blocking the terminal amine group from reaching the deep binding site. Therefore, the N 
and D mutations at position 704 removed the barrier increasing potency, but only 
partially as the N-site was not also restored. 
The selectivity filter has been shown to be important for the activity of polyamine toxins. 
An R at the Q/R site on the G1uA2 subunit of the AMPA receptor results in receptors 
that are not blocked by polyamines (Isaac et al., 2007). However, the same was not 
found with the R at the N+1 site of the G1uN3 subunits, as the loss of activity by PhTX- 
343 was less dramatic. It may be that the residue is not exposed in the pore, or the charge 
is not located at a critical position. Mutating the G to R at the N-site of the G1uN3 
subunits may result in NMDA receptors that are not blocked by polyamines, but if so it 
may mean that no PhTX will have the same discriminative effect that is found with 
AMPA receptors (Andersen et al., 2006). 
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The presence of G1uN3A showed a different pattern with PhTX-12 than the other 
blockers. A significant decrease in ICS compared to 1-1 a/2A at 
-100 mV and -75 mV was 
found, with no difference between G1uNI-la/2A and G1uN1-la/2A/3B containing 
receptors. PhTX-343 requires three charges to optimally block the NMDA receptor; 
therefore, the loss of two charges with PhTX-12 impaired potency consistent with 
previous reports (Mellor et al., 2003). However, at G1uN3A there is aG at the N-site so 
the loss of charge with PhTX-12 means that it was not interacting at this site even at 
G1uN1-1 a/2A receptors therefore amino acid changes did not impair block. The G may 
expand the channel and allow deeper binding, letting terminal amine group interact with 
G+2 similar to AMPA receptor (Andersen et al., 2006). Such an interaction could be 
further explored using PhTX-74 or PhTX-84 which could possibly have increased 
potency compared with PhTX-12 due to the increased charge at the end of the tail group. 
PhTX compounds with two amines on the tail group may also stop it from folding back 
on itself, which may be what occurs with PhTX-12 (Tikhonov et al., 2004). Therefore, 
these compounds may retain a shape that is accommodated better in the pore region than 
PhTX-12, increasing potency. 
The ICS for PhTX-12 also shows again that the R at +1 does not have the same effect as 
the Q/R switch in G1uA2. But the data shows that changes in the pore led to increased 
potency of PhTX-12 at G1uN1-1a/2A/3A containing receptors. But as the G1uN3A and 
G1uN3B subunits are similar in this region it does not explain why there was no similar 
decrease in IC,, for G1uN3B. The Woodhull analysis found that G1uN1-la/2A and 
G1uN1-1a/2A/3A receptors had the same S value while there was a reduction for 
G1uN1-1 a/2A/3B. Potency and S may not be not tightly correlated, and changes to the 
on-rate and off rates may have helped explain this, but only limited quantities were 
available. 
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PhTX-12 was the least potent of all the blockers tested and its activity may just be 
unspecific in nature. Block was not voltage-dependent at G1uN 1-1 a/2A/3A and G1uN 1- 
la/2A/3B containing NMDA receptors, although the results may be due to the poor fits 
of the Hill equation masking statistical significance when the IC50 values were compared. 
Lack of voltage-dependence can indicate that open channel block is not occurring; 
however, it is not the case that all open channel blockers are voltage-dependent. 
Picrotoxin blocks GABA receptors in a manner that cannot be voltage-dependent as it 
does not have a charge (Bali and Akabas, 2007). It has also been shown that block of 
NMDA receptors by bicuculline is not voltage-dependent, even though it is thought to 
bind in the pore (Li, 1999). Block of muscle nAChR by PhTX-12 was shown to not be 
voltage-dependent and may be due to the chain/head group structure becoming radically 
distorted (Mellor et al., 2003). It has been shown that if the tail section of the PhTX-12 
molecule folds back on itself it would have a diameter around 10-141 which would be 
larger than the pore, therefore block may be occurring in extracellular regions of the 
NMDA receptor (Tikhonov et al., 2004). The current study found that the IC50 for 
PhTX-12 was 293 µM at 
-75 mV whereas NMDA responses to whole rat brain RNA 
have been previously shown to have an IC_, of 7 µM at 
-80 mV (Mellor et al., 2003). The 
latter expressed the whole range of G1uN1 splice variants, G1uN2 and G1uN3 subunits so 
the reduced potency found in the current study may be due to inhibition at the Ni 
cassette or due to a differing activity at regions of the G1uN2 subunit, possibly the NTD 
similar to spermine. 
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4.3.5 Methoctramine 
The study also reports for the first time the ability of methoctramine to inhibit 
recombinant NMDA receptors, and was shown to be a potent compound with an IC,,, in 
the µM range. Similar to MK-801, there was a significant increase in the IC50 with 
G1uN1-1a/2A/3A and G1uN1-1a/2A/3B containing receptors at 
-100 mV, but when the 
voltage was increased the difference with G1uN1-1a/2A/3A was lost while GluN1- 
1a/2A/3B continued to impair block. However, unlike MK-801 the presence of the 
GIuN3B subunit had no effect at 
-50 mV. Results from the Woodhull model suggest that 
methoctramine had a low S for all subunit combinations tested, particularly GluN 1- 
1 a/2A/3B. Such a finding is surprising for a compound with the largest number of amine 
groups tested (4), and may mean that it does not interact with the same residues that the 
extended polyamine PhTX-343 tail does. 
Methoctramine is large compound with two aromatic groups at either end of a chain that 
may orientate itself in aV shape (Rosini et al., 2002). It may be that the aromatic rings 
interact with the same residues that interact with MK-801 in the M3 region, as it has a 
similar pattern of activity. The amines in the linker region could then interact with the 
selectivity filter as the G1uN3A N mutations were shown to partially restore block at 
-100 
mV. Methoctramine has been shown to be less potent than PhTX-343 at 
-100 mV, so the 
increase in amines did not lead to increased potency. However, as the voltage was 
increased methoctramine retained potency as the deep site E at position +5 implicated in 
PhTX-343 block may not be involved. 
The on-rate for methoctramine was significantly faster for G1uN1-la/2A/3A but only at 
-75 and -50 mV and was unaltered by the GluN1-1a/2A/3A mutations. The presence of 
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G1uN1-1a/2A/3A and G1uN1-1a/2A/3B significantly slowed the off-rates, but were not 
restored by the G1uN3A mutations. In fact, the G1uN1-1a/2A/3AG703' mutation further 
slowed the off-rate. They generally had the same 8 so must be unrelated to electrical 
interactions. The changes in rate may again represent binding of the aromatic resides in 
methoctramine to aromatic residues in the pore. 
4.4 Channel Properties 
The I/V relationship showed that G1uN1-1a/2A had a reversal potential of +12.15 mV 
which was reduced to 
-2.646 mV for GluN1-1a/2A/3A, indicating reduced Ca2+ current, 
similar to previous reports (Sasaki et al., 2002). Both receptor types also showed negative 
slope conductance at voltages less than 
-100 mV that is unrelated to Mg2+ block, similar 
to previous reports (Soloviev et al., 1996). GluN1 /3A glycine activated receptors have 
been shown to be have the same negative slope at voltages lower than 
-50 mV, and it is 
thought that it is due to inhibition by Ca 2+ (Madry et al., 2010). The negative slope region 
may have been pushed to more negative voltages in the current study by the presence of 
the GluN2 subunit. 
The current study also found that there was a significant reduction in steady state current 
through the NMDA receptor after activation by NMDA/glycine when the G1uN3A and 
G1uN3B subunits were present. Flux may have been reduced due to the threonine ring 
and as the current measured for G1uN1-la/2A/3A and G1uN1-1a/2A/3B was not 
significantly different to each other indicating that the ring was present in G1uN1- 
1a/2A/3B as well as G1uN1-1a/2A/3A. Reduced current could also be due to the 
DRPEER motif which is not present on the GluNZA, G1uN3A or G1uN3B and is 
important for mediating Ca 2+ permeability (Watanabe et al., 2002). If a G1uN3 subunit 
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replaced a GluN 1-1 a subunit then it would lead to reduced Ca 2+ current through the 
channel. 
NMDA receptors are known to be susceptible to Ca" dependent 
desensitisation/inactivation over the region of 10 to 50 s (Medina et al., 1995). In 
Xenopus oocytes, the initial peak transient component of the NMDA response was 
previously shown to be reduced in GluN1 /GluN3B glycine activated channels indicating 
reduced Ca2+ entry through the receptor (Chatterton et al., 2002). The current study has 
shown that there was a significant decrease in the peak to plateau ratio, indicating 
reduced Ca 2+ permeability through G1uN1-la/2A/3A and GluNl-la/2A/3B containing 
channels, by suffering less from Ca 2+ induced desensitisation. 
4.5 Glycine Gated NMDA Receptors 
It was previously thought that G1uN1 expressed alone in Xenopus oocytes produced 
functional glycine activated channels; however, this has been shown to be due to the 
presence of an endogenous XenGluN2 subunits (Schmidt and Hollmann, 2008). The 
same study also showed that there was a full set of homologous G1uN2 mRNA in 
oocytes, while GluN2B protein was also found. It has also been shown that low 
concentrations of Zn 2+ potentiate, rather than inhibit, responses for XenGluN 1- 
1 /XenG1uN2B receptors, and the same effect was also thought to occur with the 
apparent homomeric G1uN1 current (Traynelis et al., 1998, Schmidt and Hollmann, 
2008). 
Any study which relies on the absence of a subunit which has a homologous protein 
present in the expression system may be being misinterpreted. Early attempts to express 
glycine gated receptors failed, but if such an assembly was robust then these should have 
192 
consistently produced receptors since it was first attempted (Ciabarra et al., 1995, Sucher 
et al., 1995, Smothers and Woodward, 2009). During the course of the study they could 
not be obtained. But as XenG1uN2B levels have been shown to be highly variable it 
would explain the difficulties found when they were originally expressed (Smothers and 
Woodward, 2009). Interpreting the nature of these receptors would be further 
complicated when considering the opposite effect Zn2+ can have on these channels. 
When considering XenGluN2B it would change the claims of Madry et al., 2008 and 
Madry et al., 2010 where glycine activated receptors with Zn 2+ potentiation were found. 
In fact, NTD deletions of G1uN1 and G1uN3A did not alter the potentiation, possibly 
indicating a different subunit was involved (Madry et al., 2008). 
Homomeric G1uN1 currents and GluN1/3 receptors were never found with HEK-293 
cells possibly ruling out the existence of an endogenous G1uN2 subunit in this system 
(Nishi et al., 2001, Perez-Otano et al., 2001). But these cells require both G1uN3A and 
G1uN3B to produce functional glycine activated receptors, and may represent a folding 
requirement where G1uN3B is allowed to take the position taken by the endogenous 
XenG1uN2B subunit. If G1uN3B was acting as a G1uN2 then it may explain why it is 
thought that GluN1 /3A/3B glycine gated receptors are preferentially formed in Xenopus 
oocytes (Ulbrich and Isacoff, 2008). 
When the XenG1uN2B is present it may mean that gating is altered so it can be activated 
by glycine alone. In glycine gated receptors it has been shown that glycine binding to the 
G1uN1 subunit causes fast desensitisation rather than activation, and that glycine binding 
to G1uN3 alone will open the channel (Awobuluyi et al., 2007, Madry et al., 2007). Now 
that the XenG1uN2B subunit has been cloned these gating properties can be tested. 
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Glycine has been previously shown to activate oocytes injected with G1uN1-1a/2A and 
again may represent the influence of XenG1uN2B (Meguro et al., 1992). 
G1uN1-3b/G1uN3B receptors expressed in Xenopus oocytes have also been shown to be 
activated by glutamate alone (Cavara et al., 2009). They state that batch-batch differences 
in XenG1uN2B expression could influence results, and that such recordings had to be 
manually eliminated. The same study showed that G1uN1-4a/2A/3A produced channels 
in HEK-293 cells that were opened by glutamate or glycine alone (Smothers and 
Woodward, 2009). However, it was previously shown that glutamate or NMDA alone did 
not activate G1uN1-la/2A/3A, but in that study they did not state which G1uN1 splice 
variant was used (Chatterton et al., 2002). Although it is known that NMDA receptors 
require both agonists for the pore to open, it has been shown in single channel studies 
that AMPA receptors show subunit specific opening depending on agonist occupancy 
(Rosenmund et al., 1998). The G1uN3 and Xen2B subunit may allow altered gating to 
occur where only either agonist is required for channel opening, rather than both. 
Altered gating may be dependent on which position the subunits take in the receptor. 
Those in the proximal position (A, C) have an extended M3 region that would be 
constricted at P +45, and they move less than those in the distal position (B, D) (Figure 
95) (Sobolevsky et a1., 2009). The proximal subunits were shown to be G1uN1 and 
therefore have a lesser role in gating. The G1uN3 subunits may lead to the loss of the 
proline at +45 which could widen the channel at the gate, allowing it to open under 
different circumstances. 
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Proximal 
istal 
Figure 95: AMPA receptor composition showing stoichometry of subunits. A/C are termed 
proximal, and B/D are termed the distal, to the overall two-fold axis of symmetry. 
The current study has shown that glycine alone did not lead to channel opening. Rat 
G1uN2A does not have the same properties as XenGluN2B and it therefore may have 
retained the original gating properties. The fact that glycine alone did not open the 
channel also questions the conclusions of Ulbrich and Isacoff (2008) which suggested 
that two separate populations of receptor would be formed, G1uNI/2 and G1uNI/3. If 
this was occurring then glycine alone or with Zn 2+ would have activated the glycine 
activated component, but it was not found. In the Ulbrich and Isacoff study only G1uN2 
(green) and G1uN3 (red) subunits were tagged. The receptors that contained the 
endogenous subunit could be interpreted as being G1uN1 /3, as only the GluN3 would 
have been detected. The authors also freely admitted that that they found receptors with 
both red and green spots. They used a Monte Carlo method to confirm it was possible 
with their interpretation, rather than admit their conclusions may have some 
shortcomings. They also did not determine if functional channels were produced. Even if 
their interpretation was correct then it does not explain why some studies have shown 
that channels could be activated by glutamate alone, as the G1uN1-la/2A component 
would still need both agonists for activation (Cavara et al., 2009, Smothers and 
Woodward, 2009). 
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If the glycine activated receptors are not just a phenomenon resulting from the 
combination of exogenous and endogenous subunits in ways that have not evolved in 
nature, the lack of convincing evidence in vivo is problematic. It would be expected that 
transgenic animals overexpressing G1uN3 subunits would lead to an abundance of glycine 
activated currents, but currents mediated by glycine alone were not found (Tong et al., 
2007). Excitatory glycine currents in the presence of strychnine were however found in 
cerebrocortical neurones (Chatterton et al., 2002). These were inhibited by D-serine 
rather than potentiated which would have been expected with GluN 1-1 a/2A, but the 
experiment has never been repeated. Therefore, the remaining evidence in vivo is patches 
that have two different conductance levels with no direct transitions, although no 
superimpositions were found (Perez-Otano et al., 2001, Sasaki et al., 2002). Furthermore, 
these studies did not check if glycine activated the lower conductance alone. If glycine 
activated receptors were abundant in the nervous system then it would be expected to 
have been found, waiting for the glycine gated receptors to be identified. Then there is 
the lack of subsequent convincing evidence even when researchers were actively looking 
for the receptors, tending to support the conclusion that they are merely a quirk of the 
expression systems used (Das et al., 1998, Chatterton et al., 2002, Sasaki et at, 2002, 
Tong et al., 2007). 
As the G1uN3 subunits are known to be rapidly incorporated into endogenous NMDA 
receptors, as well as to undergo rapid endocytosis throughout development, it may be 
that the two conductance states merely represent such a process (Perez-Otano et al., 
2001, Tong et al., 2007). If expression is not uniform throughout the membrane, and 
GluN3 was being incorporated and removed dynamically, then the system would by 
produce a G1uN1-1a/2A channel and another containing G1uN3. By increasing the ratio 
196 
of G1uN3 it has been shown that the larger G1uN1-1a/2a conductance is reduced and 
may represent a larger proportion of G1uN3 being incorporated into NMDA receptors 
(Das et al., 1998). However, biphasic dose response curves were not found and the 
inhibition curves tended toward zero in the current study. Therefore it is suggested that 
uniform expression of GluN1/2/3 was obtained. 
4.6 Resolving GIuN3 Receptor Assemblies 
To solve the glycine gated story their gating properties could be explored by expressing a 
range of rat GluN1 and G1uN3 together with XenG1uN2B. Furthermore, inhibition by 
ifenprodil is retained with the XenGluN2B subunit but, as stated they are potentiated by 
Zn 2+ (Schmidt and Hollmann, 2009). The combination of these modulators provides a 
pharmacological tool for establishing the presence of XenG1uN2B in glycine activated 
receptor studies, which would be confirmed if they were inhibited by ifenprodil and 
2+ potentiated by Zn. 
Glycine activated receptors are known to be difficult to express and were not found 
during the course of the work reported in this thesis (Sucher et al., 1995, Ciabarra et al., 
1995). A possible way to gain more robust expression would be to mutate the ligand 
binding domain of G1uN1, which causes fast desensitisation, so it cannot bind glycine or 
block the binding site pharmacologically using MDL-29951, L689560 or 5,7-DCKA (Yao 
and Mayer, 2006, Awobuluyi et al., 2007, Madry et al., 2007). If consistent expression of a 
glycine gated component occurred then an siRNA could be injected to block 
XenG1uN2B expression. If there were then no fucntional channels then it would show 
that the endogenous XenG1uN2B subunit was required to produce them. 
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An additional way to determine the stoichometry of G1uN3 containing receptors is to 
exploit the positioning of residues found with the AMPA crystal (Sobolevsky et al., 2009). 
It was found that position P at +45 (part of the DRPEER motif) on the G1uN 1-1 a 
subunits in the proximal position were positioned close together. When they were 
mutated to a cysteine they cross-linked and this effect was detected by western blotting. 
The G1uN3 subunit is thought to replace the GluN1 subunit in a G1uN1 /2 dimer (Perez- 
Otano et al., 2001). By producing the C mutants at P +45 on G1uN1 which is I at the 
same position on GluN3A their proximity could be determined. If these mutations 
resulted in crosslinking then it would show that there were G1uN1 and G1uN3 subunits 
in the proximal position. 
4.7 Alzheimer's Disease and Multi-target Ligands 
4.7.1 Carbacrine Series 
It was found that of the carbacrine compounds, carbacrine(3) was the most potent with 
an IC50 around 0.74 µM at 
-100 mV. Due to its potency it was promisingly shown to have 
an ICS that was not significantly different to memantine at all the voltages tested. The 
potency of carbacrine(3) must be unrelated to charge as all members of the group had the 
same number of amines. Increasing the chain length was shown to impair block, 
therefore alkyl chains of three or less may have been required for potency. It may be that 
those with alkyl chains of less than three carbons would have an increased potency, but 
no smaller compounds were produced. For other classes of NMDA receptor antagonist 
chain length has been shown to produce non-systematic effects on potency. For none, 
one and two carbons between the phenylcyclohexyl and the terminal amino group of a 
range of compounds tested, the smallest (IEM-1921) and largest chains (IEM-2044) were 
shown to be 10-fold more potent than the compound with the intermediate length (IEM- 
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2014) (Bolshakov et al., 2005). Chain length has been shown to alter block by competitive 
antagonists of the G1uN2 binding site. With a heptyl chain ((R)-CPP) it was found that 
there was a 50-fold difference in affinity across the G1uN2 subunits, whereas those 
compounds which had pentyl chain showed a 5-fold difference (Feng et al., 2005). 
Therefore, carbacrine(3) with its propyl linker may have a potency that was already 
optimal, and no improvements can be made by reducing its size. 
It was found that block by carbacrine(3) and carbacrine(5) was voltage-dependent 
suggesting that they may be open channel blockers, possibly at the N-site typical of most 
compounds of this type. However, Woodhull analysis resulted in aS value of 0.2 which 
does not support block at the N-site if 8 is taken as a measure of distance, so it may 
represent limited electrostatic interactions with the receptor (Zhu and Auerbach, 2001). It 
may be that these compounds were blocking in an area similar to the superficial 
memantine site; however, the 8 value was greater than that for G1uN3B containing 
receptors from the first chapter. Block at the superficial site could be tested with the 
GluN1N676D mutation which has been shown to allow block at different sites with 200. tM 
and 2 mM memantine (Chen and Lipton, 2005). Carbacrine(3) and carbacrine(5) were 
shown to be voltage-dependent, it is not a property of the superficial site limiting the 
interpretation (Kotermanski et al., 2009). 
On the contrary, block by carbacrine(4) and carbacrine(6) was not voltage-dependent and 
Woodhull analysis showed these to have a low 8 similar to that found with G1uN3B 
containing receptors. These are more likely to indicate block at the superficial memantine 
site as they were not voltage-dependent. However, the changes in the 6 values indicated 
by the Woodhull model may also be explained by less electrical interactions between the 
compounds and the receptor. Carbacrine is a large molecule that has two 
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pharmacophores that can both interact with the pore and may have interactions that were 
impaired with chain lengths of four and six. 
The carbacrine compounds were numbered according to their alkyl chain length, but it 
was shown that extending of the chain from propyl to pentyl gave voltage-dependent 
properties that may indicate binding at the N-site. Although it is a competitive antagonist, 
a similar alternating chain effect has been shown with AP5, where increasing the alkyl 
chain by one carbon reduced potency, but was restored with a subsequent additional 
group (Evans et al., 1982). Determining where these compounds block would depend on 
their promise as MTDL drugs, and due to the low activity of carbacrine(4), carbacrine(5) 
and carbacrine(6) at the NMDA receptor it would only be worthwhile to determine these 
properties for carbacrine(3). 
The carbacrine compounds were combinations of the pharmacophores derived from the 
f3-blocker carvedilol and the AChEI tacrine. However, carvedilol has been shown to be 
competitive for MK-801 binding indicating open-channel block (Lysko et al., 1992). 
There is also evidence that tacrine can act as an open-channel blocker, but increasing the 
size of the molecule with the bis(7)-tacrine form resulted in a compound that was not 
thought to bind in the pore of the NMDA receptor as it lacked voltage-dependence (Liu 
et al., 2008). Therefore it may be that for carbacrine(3) and carbacrine(4) the carvedilol 
moiety of the MTDL was interacting with the channel, as block was voltage-dependent. 
The chain-dependent effects of the propyl and pentyl chains may have oriented the 
moieties in a similar way leading to similar properties. However, the potency of carvedilol 
is low and is not consistent with what was found for carbacrine(3), but it is possible it 
changes when it is placed within a larger backbone (Lysko et al., 1992). 
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For carbacrine(5) and carbacrine(6) it may have been that the tacrine moiety was 
preferentially interacting with the receptor as the compound would possibly have taken 
the properties of the non voltage-dependent bis(7) form due to its placement within the 
larger sized MTDL backbone. The carbacrine compounds could also have had a mixed 
mode of action which would depend on the orientation of the molecule as it docks with 
the receptor. Regardless, a threshold was reached with a propyl chain, and the decrease in 
IC, O may have been due to the constraint of the two functional moieties within the linker. 
These data formed part of an ongoing study measuring the ability of these compounds to 
show potential therapeutic effects when tested using in titm assays for AD. The 
carbacrine compounds were shown to retain AChEI activity, as would be expected due 
to its tacrine moiety (Rosini et al., 2008). Carbacrine had an IC50 for AChE in the 
nanomolar range and this effect was not altered through increasing chain length. Rather 
surprisingly the carbacrine compounds were shown to be a more potent than tacrine or 
the 6-chloro derivative alone when inhibiting AChE (Camps et al., 2008, Rosini et al., 
2008). The property may be due to their increased size compared to the originator 
molecules allowing them to inhibit both the catalytic and peripheral anionic site of 
AChE. Donepezil is similar, as when it was crystallised it was shown to inhibit both 
regions of AChE (Kryger et al., 1999). Binding at both sites has also been shown to allow 
donepezil to inhibit AChE induced aggregation of Aß (Bartolini et al., 2003). Bis-(7)- 
tacrine was also shown to bind to both sites with a minimum of five methylene groups 
linking the tacrine moieties (Carlier et al., 1999). Docking studies showed that 
carbacrine(3) could bind to both sites of AChE, with the tacrine moiety shown to interact 
with the catalytic pocket, while the carbazole interacted with the peripheral anionic site 
(Rosini et al., 2008). Such an ability may affect AChE induced AP 1,0 aggregation as the 
carbacrine compounds were shown to inhibit it in a manner that was not altered by chain 
201 
length. The same study did however also find that they were able to inhibit self-induced 
aggregation of Aß. Chain length influenced this as carbacrine(3) resulted in 36% 
inhibition, whereas carbacrine(6) only led to 23.7% inhibition of aggregation (Rosini et 
al., 2008). Furthermore, the same study also showed that the carbacrine compounds had 
an increased IC50 at BChE compared with AChE, possibly giving the group a favourable 
side effect profile. 
4.7.2 DoneDezil Derived Compounds I and 2 
2b and 2a have a similar structure to each other, with the methoxy group of the phenyl 
group located on the same carbon. The potency of these compounds was low, with 
inhibition of the control response being minimal at the highest concentrations tested. 
When the Hill equation was fitted to the data, it was either not possible, or the 
parameters obtained were not meaningful due to a poor fit. There was no effect of the 
linker region, as the pentyl linker of 2a and the hexyl linker of 2b had no effect on 
potency. 
Compounds la-e moved the methoxy group to a different carbon on the phenyl region 
which generally led to increased potency at the NMDA receptor, indicating it may have 
been involved in impairing block when it was in its previous position. However, a 
compound was not produced with an equivalently sized alkyl chain so the change in 
structure cannot be directly compared. The group had IC'O values around 50-100 µM 
which would limit their use as therapeutics. That with a butyl chain (1b) and that which 
had the largest (le, nonyl) had the lowest IC'O values. The octyl chain of ld seriously 
impaired the ability of the group to block the NMDA receptor. From 1d, which had 
eight carbons, the loss or gain of one carbon was shown to restore block similar to 
previous compounds that have been discussed. The voltage-dependence of the series was 
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not measured due to the limited quantities available. ICO values were calculated only at 
- 
100 mV and if these were acting as open channel blockers it would be expected to 
increase with an increase in voltage. The potential as therapeutics would be further 
reduced by the voltage-dependence as the membrane potential of neurones in vivo would 
not be as low. 
The low potency of 1 and 2 can be compared to that of carbacrine as both have the same 
carbazole pharmacophore derived from carvedilol. For the carbacrine compounds the 
tacrine moiety may have represented the region of the compound that interacted with the 
pore region with high affinity, as this group is lost with 1 and 2 possibly explaining their 
low potency. It may be that the carbacrine compound became constrained in such a way 
with a propyl linker that the tacrine moiety was the predominant area in which the 
compound interacted with the receptor, leaving a mixed mode of action with the larger 
chains. 1 and 2 also contain a group derived from donepezil (the methoxyphenyl and a 
piperazine group), but it is unknown if the small region added to the MTDL is that which 
is involved mediating its NMDA receptor activity, so may have been lost (Wang et al., 
1999). 
4.7.3 Dimebon Derived Compounds 
Compounds 3,4 and 5 took dimebon, removed the pyridine group and linked two 
dimebons producing a series that explored the effect of differing linker regions on 
potency. Of these, 4 had a 3,6 
- 
dioxa octyl chain and was found to be the most potent 
of the series at all voltages tested. However, modifications to PhTX-343 that included 
oxygen within the polyamine chain were shown to reduce potency at the NMDA 
receptor (Mellor et al., 2003). Such an effect may have been due to the electronegative 
oxygen of the modified PhTX-343 not being accommodated well within the negatively 
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charged pore region, and the IC_, of 4 found in the current study was similar to that of 
the PhTX-343 analogues with oxygen groups in the chain (Mellor et al., 2003). 
The remaining compounds had an alkyl chain (3a-c) or an aniline group within the chain 
(5), and these had similar potencies. Differing sizes of alkyl chain (3a-c) also had little 
effect on potency, apart from a small increase in ICS with the hexyl chain (3b). These 
data indicates that these substitutions within the chain region may not have been 
important for block, which as it acts mainly as a linker region would be desired. 
Antagonism by the dimebon derived compounds was found to be voltage-dependent, 
indicating open channel block of the NMDA receptor. When the alkyl chain length, the 
methoxy and the alinine substitutions were introduced in the linker region it did not alter 
voltage-dependence. Woodhull analysis suggests that block by these molecules was more 
extracellular than the N-site asparagine and the same comments can be made regarding 
the superficial memantine site that were discussed for the carbacrine series. Compound 5 
was shown to have aS value that was larger than the other compounds. The Woodhull 
results may indicate that the aniline substitution within the chain allowed block to occur 
deeper within the pore, or that the addition of the nitrogen atom within the chain caused 
more electrostatic interactions with other aromatic side chains within the pore. 
Compared to memantine dimebon was shown to be a weak blocker of NMDA receptor 
currents with an IC_, around 13 µM. Furthermore, the IC_, showed a non-linear voltage- 
dependence on a log-scale, which meant Woodhull analysis could not be carried out. It 
was shown that only when the voltage was increased to -50 mV could an increase in IC50 
be measured. 
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The compound has numerous targets in the nervous system; therefore a working 
hypothesis explaining why it could be beneficial in AD is difficult to produce. The 
current study has shown that this is probably unrelated to any memantine like effects, as 
the potency is too low to be considered a good therapeutic through similar mechanisms. 
The potency at NMDA receptors is what has previously described; however, NMDA 
activity is just one of the many targets of the compound and the current study has 
confirmed that most of its probable CNS targets (adrenergic, dopamine, histamine, 
imidazoline and 5-HT) have a much higher affinity to dimebon (Wu et al., 2008). Only L- 
type Ca2+ channels and CYP450 and 2C19 were in the same range. But it must be 
considered that taken as a whole low level activity at NMDA receptors is not undesirable 
from a drug-design perspective. Therefore blockers with low potency described in this 
chapter may still have potential as therapeutics, as the NMDA receptor is but one of their 
targets. 
4.7.4 Lipocrine 
Lipocrine took the 6-chloro tacrine AChEI moiety and combined it with the anti-oxidant 
lipoic acid within a chain containing an amide group. It was the most potent MTDL 
tested, as it had an IC50 that was significantly lower than memantine at all voltages tested. 
Woodhull analysis found that the compound blocked at 0.6 through the membrane 
which would suggest binding to the N-site of the NMDA receptor (Zhu and Auerbach, 
2001). The binding site could be confirmed by a mutation at the N-site. Comparing it to 
carbacrine(3), it may be that the smaller lipoic acid group or the amide in the chain 
allowed the tacrine moiety to bind within the pore deeper, increasing potency. 
Furthermore, it is not thought that lipocrine is fully-trapping as responses were obtained 
after wash-out (data not shown). If it can be shown to have a fast off-rate then the 
compound may have future use as a therapeutic. 
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Lipocrine has also been shown to act as an AChEI and was shown to be 10-fold more 
potent at doing so than the carbacrine compounds (Rosini et al., 2005). It also has around 
a 10-fold higher IC50 at BChE meaning the compound may have a more favourable side 
effect profile. Both cholinesterase effects were shown to be more potent than tacrine, 
possibly indicating binding to both sites due to its increased size within the MTDL 
backbone. The same study also showed it was a potent inhibitor of AChE induced AP 
aggregation, even though lipoic acid and tacrine do not posses this ability. Furthermore, 
as would be expected from its lipoic acid moiety it can block oxidative damage in SH- 
SY5Y cells, and may have a beneficial role in AD (Rosini et al., 2005). 
Compound 6 took the opposite approach to lipocrine, taking the carvedilol carbazole 
pharmacophore and adding to lipoic acid. The potency was severely impaired as it was 
shown to be a weak inhibitor of NMDA receptor current. It would therefore be mainly 
the tacrine moiety that allows the MTDL compounds to be potent NNMA receptor 
blockers, providing further evidence that it is this region that is involved in block by 
carbacrine(3). It may be that future MTDL combinations should use tacrine to retain the 
effect. 
Lipocrine and 6 contain anti-oxidant pharmacophores in order to target the proposed 
role that free radicals have in AD covered in the introduction. However, although 
diseases that seem to demand treatment with anti-oxidants remain plausible, they have 
proved disappointing in practice. In most cases systematic reviews have either found that 
there are no effects (e. g. gastrointestinal cancer (Bjelakovic et al., 2008b), pre-eclampsia 
(Rumbold et al., 2008) and aging (Bjelakovic et al., 2008a)) or that studies have been so 
poorly executed that no meaningful conclusion can be made. It is to the latter category 
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which lipoic acid (Kiugman et al., 2004) and vitamin E (Isaac et al., 2008) belong for 
dementia and AD. Until a rigorous study is carried out, no meaningful conclusion can be 
made regarding antioxidant activity in AD. Although the argument for the involvement 
of biometals and the production of ROS seems to lend plausibility, by the measure of 
previous disappointments it may be unlikely antioxidants have any real effect. 
4.7.5 Memantine-like Properties 
Memantine is the only currently approved drug for AD whose receptor target is the 
NMDA receptor. Its tolerability is due to a fast unblocking rates and its partial-trapping 
mechanism that means it does not have the same side effects that are found with high- 
affinity, fully-trapping blockers such as MK-801 (Chen and Lipton, 2006). Memantine 
was originally determined to have fast kinetics meaning that it did not accumulate in the 
channel like MK-801 (Chen et al., 1992). On and off-rates could be calculated for the 
MTDL compounds in order to determine if these properties were retained by lipocrine 
and carbacrine(3). Another important property of memantine was that there was 
increasing inhibition with increasing concentrations of agonist (Chen et al., 1992). Such a 
property was desirable as it meant that in excitotoxic conditions the potency of 
memantine was increased which would leave normal transmission less affected. Such an 
experiment could be carried out using the MTDL compounds by determining the level of 
inhibition with increasing concentrations of NMDA. Another property of memantine is 
that it is more potent at G1uN2A containing receptors than those containing GluN2D 
and the MTDL compounds could be tested to see if it is retained (Wrighton et al., 2007). 
Although this effect has not been directly implicated in AD it may represent a further 
mechanism that means memantine has a favourable side effect profile. 
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4.7.6 Neuroprotection 
In order to determine that there is not just block of recombinant NMDA receptors but 
that it led to neuroprotection, an excitotoxicity assay could be carried out. Neuronal 
cultures would be exposed to excitotoxic doses of L-glutamate, and the ability of these 
compounds to block cell death is measured using the trypan blue exclusion method. 
Memantine has been shown to block excitotoxicity in primary cultures of rat 
hippocampal neurones and would be desirable in the MTDL compounds (Krieglstein et 
al., 1996). 
However, clinical trials for NMDA receptor antagonists for use in stroke have failed, and 
the evidence for `slow excitotoxicity' in AD remains poor (Ikonomidou and Turski, 
2002). There are many possible reasons why memantine failed in stroke trials, one of 
which may be that downstream signalling proteins may in fact up-regulate the survival 
genes such as brain derived neurotrophic factor (BDNF), vasoactive intestinal peptide 
(VIP), bcl-2 and mcl-1 (Ikonomidou and Turski, 2002). In rat models of stroke there is a 
10 to 100-fold rapid increase in extracellular glutamate levels, but it only lasts 30 mins 
after insult (Benveniste et al., 1984). In humans, there seems to be a small but sustained 
increase in glutamate levels that lasts days. It may be that immediately following injury 
NMDA receptors are involved in apoptosis, but that in the long-term increased 
activation of these channels may actually form part of a survival mechanism. Therefore, 
application of NMDA antagonists such as memantine could be beneficial if applied 
before, and for a short time after stroke, which for an essentially random event is 
impossible. In relation to AD, BDNF is decreased in the hippocampus and parietal 
cortex of those with AD and A(3, 
_42 
down regulates bcl-2 in neuronal primary cultures 
(Phillips et al., 1991, Paradis et al., 1996, Holsinger et al., 2000). Therefore, as AD is a 
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progressive disease unrelated to an unpredictable event, blocking NMDA receptors may 
still have undesirable effects on neuronal survival. 
4.7.7 Modelling Alzheimer's Disease 
In vitro models of AD are used in the drug development process but these have been 
shown to have major limitations (see Bryan, 2009). It is possible to mimic A(3 expression 
without neuronal loss or impairment in some behavioural tasks. These transgenic animals 
produce Aß activity but may not be correctly modelling the disease. By this measure, it 
would appear that these animals are only acting as an expression system that also has the 
ability to measure behaviour. Transgenic invertebrates that produce Aß can now be 
produced and these also allow for pharmacological intervention in order to measure 
changes in behaviour and may be just as relevant to human disease as models using small 
mammals (see Link, 2005). 
Suitable human biomarkers for AD may be a better way to test new drugs rather than 
continuing to use flawed animal models. In humans treated with donepezil the 
cerebrospinal fluid showed an increase in the G4 from of AChE compared with controls 
(Amici et al., 2001). It has been shown that low levels of Aß1_42and high levels of tau in 
the cerebrospinal fluid (CSF) could predict post-mortem severity of AD (Tapiola et al., 
2009). The future of biomarkers will probably take into consideration the protein 
products from the newly associated genes in humans in CSF or blood of AD patients 
(Harold et al., 2009). If a group of biomarkers can be found then it is likely that 
combinations of these may accurately predict AD. The activity of these proteins could be 
a signature that could be measured in clinical trials directly in humans to determine drug 
efficacy. Moving into human subjects must be the next step for AD research due to the 
poor validity of animal models. 
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The pharmaceutical industry is close to producing viable biologics (e. g. bapineuzumab) 
that are human antibodies that can remove amyloid in vivo (Black et al., 2010). But 
another study that immunised patients against Aß formation to stop its free production 
found that patients had no plaques in the nervous post-mortem, but no improvement in 
the actual dementia was observed (Gilman et al., 2005). The fact that Aß can be removed 
without improving cognition has led researchers to believe that the disease causing 
process is not fully understood. By having a poorly understood mechanism it may mean 
that any biomarkers may not accurately represent the disease process, or be able to 
measure the efficacy of any drugs developed to treat it. There is a fear that Aß may not 
have anything to do with the disease, and if a drug was approved on the basis of a 
biomarker related to a mechanism that is not fully understood, then it would take years to 
become apparent due to the timescales involved. Furthermore, another disincentive to 
the pharmaceutical industry is the patent protection may be lost if compounds efficacy 
was determined at endpoint due to the timescales involved. 
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5 
General Discussion 
The current study has shown that the presence of G1uN3A and G1uN3B subunits of the 
NMDA receptor in a receptor assembly that originally contained G1uN1-la and G1uN2A 
generally caused a significant increase in the IC50 for open channel blockers tested. The 
N-site and N+1 site asparagines are known to play a role in the binding of these 
compounds, but the N mutations of GluN3A did not completely restore block. It may be 
that that the constricted threonine ring of the G1uN1/3 dimer becomes a more 
superficial binding site with lower affinity, or it may be restricting flux which has also 
been shown to affect affinity (Wada et al., 2006, Yang et al., 2009). When the N-site was 
restored partial recovery was found, but the ring was unaltered so flux may not have been 
restored. It may also be that the deep binding site and the threonine ring led to a situation 
where block was mediated by the mixed properties of both sites if the relative affinities 
were not far apart, leading to partial recovery (Chen and Upton, 2005). Or it could be 
that the double N mutant at N and N+1 was required to fully restore block. The study 
has also shown that the increased ICS found with PhTX-343 may be due to an inability 
to bind at a deep site at position +5 in the pore when G1uN3A and GluN3B were 
present. It has also been claimed that the differences found with MK-801 and 
methoctramine may be due to the aromatic groups interacting with the pore region in 
different ways, blocking entry to the N-site. 
The functional role of the G1uN3 subunits in vivo is currently unclear. G1uN3A 
expression peaks during the right period to suggest that it is related to synapse maturation 
in rat, but it is unknown if it acts as a brake by increasing threshold for activity, protects 
against excitotoxicity or as a tag for synapse removal (see Henson et al., 2010). The brake 
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theory is supported by the reduction in Ca2+ permeability found, but the reduced block 
by Mg2+ found in the current study tends to suggest that there would be more NMDA 
receptor mediated current at lower voltages. However, increasing the Mg 21 1C50 May 
encourage increased LTP and mature synapse development at a lower threshold, which 
may be required during development. It also may be that G1uN3 acts as a tag for receptor 
removal from the membrane. Strong synaptic activity could drive GluN3 containing 
receptors out of the synapse, and the weak synapses would retain G1uN3 and would be 
`tagged' for removal. These could then be removed by the PACSINI /syndapin1 complex 
which has been shown to interact with the C-terminus of G1uN3A and occurs at 
extrasynaptic regions (Perez-Otano et al., 2006). 
The current study has shown that there is a further significant increase in Mg2+ ICso with 
G1uN3B, but no difference in current through the channel. G1uN3B is expressed 
throughout development in adult rat and humans (Bendel et al., 2005). During 
development, G1uN2B and GluN2D are predominantly expressed; while in adulthood 
there is G1uN2A and GluN2C (see Henson et al., 2010). G1uN3B may play the same role 
as G1uN3A in adulthood, but due to the presence of mature NMDA receptor subunits, 
to have the same function it may require an increased loss of Mg2+ affinity, where only a 
lower level was required in the developing brain. It is currently unknown if G1uN3B 
interacts with PACSINI /syndapinl in the same way so these receptors may not undergo 
endocytosis, and any postulated role for the subunit in adults is further complicated by its 
common null allele in humans (Niemann et al., 2007). 
Determining the pharmacology of G1uN3 containing receptors is also not helped by 
conflicting in vitro studies, with some advocating glycine gated NMDA receptors and 
some advocating triheteromeric receptors (Madry et al., 2006, Tong et al., 2007). Until the 
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debate is solved it makes determining their physiological relevance difficult. The current 
study has shown that glycine did not open the channels alone, which is what would be 
expected if there was a glycine activated component (Ulbrich and Isacoff, 2008). By 
carrying out some of the experiments outlined in the discussion section, it is likely to be 
shown that these channels are being produced in oocytes with an endogenous 
XenGluN2B subunit, leading altered gating properties. If so, then it is unlikely these 
glycine gated channels have any relevance. 
The NMDA receptor is a fundamental ionotropic receptor of the nervous system and it 
is unsurprising that is has been linked to AD (see Chen and Lipton, 2006). The current 
study has shown that carbacrine(3) and lipocrine are potentially useful compounds that, 
not only have similar or better potency than memantine, have the ability to treat other 
aspects of the disease due to their MTDL composition. However, drugs cannot be 
designed without toxicity being considered thought the planning stage. One of the main 
reasons for candidates being refused a licence or being withdrawn is the prolongation of 
the QT interval, which can provoke torsade de pointer leading to fatal ventricular 
arrhythmias (van Noord et al., 2010). It is caused by block of the inwardly rectifying K+ 
channel encoded by the human Ether-ä-go-go Related Gene (hERG) in cardiomyocytes. 
If there is prolonged repolarisation, there can be early after depolarisations caused by the 
blocking of the rapid component responsible for repolarisation. The channel is very 
promiscuous in relation to binding small compounds, meaning that the production of 
new chemical entities has to include hERG activity profiling at the outset. Excessive 
hERG activity has stopped selective G1uN2B blockers from being used clinically (Kew 
and Kemp, 2005). The ICS for hERG channel activity should at an absolute minimum be 
30-fold greater than the maximum plasma concentration of the drug (Cm, x), but the safety 
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margin would also have to consider the possible benefits given to the severity of the 
disease (Redfern et al., 2003). 
Therefore, when designing drugs for use in humans it would be useful to screen for 
hERG activity early on in the drug design process. If a compound could be shown to 
have a very high IC50 at these channels then it would immediately give the compound 
hope of being developed further, regardless of large swathes of data on efficacy. It may 
be that the hugely reductionist approach to drug design is being tripped up by cardiac 
arrhythmias and regulation; therefore, it may be better to look at what drugs are safe and 
then determine if they are suitable for treating a disease. The effects of small compounds 
on hERG and other voltage gated channels is fast becoming a very important area of 
research in drug development as the brakes can be applied at a very early stage when the 
results from cheap in-vitro studies are known. 
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Appendix 
A 
Compound Memantine PhTX-343 Methoctramine MK-801 PhTX-12 
Mgz+ P<0.001 P<0.001 P=0.323 P<0.001 P<0.001 
Memantine P<0.001 P=0.010 P<O. 001 P<0.001 
PhTX-343 P<O. 001 P=0.133 P<O. 001 
Methoctramine P<0.001 P<0.001 
MK-801 P<0.001 
B 
Compound Memantine PhTX-343 Methoctramine MK-801 PhTX-12 
Mg 2+ P<0.001 P=0.243 P=0.005 P<0.001 P<0.001 
Memantine P=0.589 P=0.370 P<0.001 P<0.001 
PhTX-343 P=0.270 P<0.001 P<0.001 
Methoctramine P<O. 001 P<0.001 
MK-801 P<0.001 
C 
Compound Memantine PhTX-343 Methoctramine MK-801 PhTX-12 
Mg 2+ P<0.001 P=0.817 P<0.001 P<0.001 P<0.001 
Memantine P<0.001 P=0.122 P<0.001 P<0.001 
PhTX-343 P<0.001 P<0.001 P<0.001 
Methoctramine P<0.001 P<0.001 
MK-801 P<0.001 
Table 24: Comparison of fits for block of NMDAlglycine-evoked currents mediated by 1- 
1a/2A NMDA receptors. (A) 
-100 mV, (B) -75 mV and (C) -50 mV. 
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A 
B 
C 
Compound Memantine PhTX-343 Methoctramine MK-801 PhTX-12 
Mgt; P=0.003 P<0.001 P<0.001 P<0.001 P<0.001 
Memantine P=0.783 P=0.677 P<0.001 P<0.001 
PhTX-343 P=0.023 P=0.0001 P<0.001 
Methoctramine P<0.0001 P<0.001 
MK-801 P<0.001 
Compound Memantine PhTX-343 Methoctramine MK-801 PhTX-12 
Mg 21 P<0.001 P<0.001 P<0.001 PC0.001 PC0.001 
Memantine P=0.047 P<0.001 P<0.001 P<0.001 
PhTX-343 P=0.037 P<0.001 P<0.001 
Methoctramine P<0.001 P<0.001 
MK-801 P<0.001 
Compound Memantine PhTX-343 Methoctramine MK-801 PhTX-12 
Mg 2+ P=0.120 P=0.503 P<0.001 P<0.001 P<0.001 
Memantine P=0.815 P<0.001 P<0.001 P<0.001 
PhTX-343 P=0.002 P<0.001 P<0.001 
Methoctramine P<0.001 P<0.001 
MK-801 P<0.001 
Table 25: Comparison of fits for block of NMDA/glycine-evoked currents mediated by 
3A NMDA receptors. (A) 
-100 mV, (B) -75 mV and (C) -50 mV. 
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A 
Compound Memantine PhTX-343 Methoctramine MK-801 PhTX-12 
Mg 2+ P=0.754 P<0.001 P<0.001 P<0.001 P=0.001 
Memantine P<0.001 P<0.001 P<0.001 P=0.025 
PhTX-343 P<0.001 P=0.422 P<0.001 
Methoctramine P<0.001 P<0.001 
MK-801 P<0.001 
B 
Compound Memantine PhTX-343 Methoctramine MK-801 PhTX-12 
Mg2+ P=0.002 P<0.001 P<0.001 P<0.001 P<0.001 
Memantine P<0.001 P<0.001 P<0.001 P<0.001 
PhTX-343 P=0.492 P=0.031 P<0.001 
Methoctramine P=0.056 P<0.001 
MK-801 P<0.001 
C 
Compound Memantine PhTX-343 Methoctramine MK-801 PhTX-12 
Mgt' P<0.001 P=0.614 P<0.001 P<0.001 P=0.002 
Memantine P=0.001 P<0.001 P<0.001 P<0.001 
PhTX-343 P<0.001 P<0.001 P 0.006 
Methoctramine P=0.294 P<0.001 
MK-801 P<0.001 
Table 26: Comparison of fits for block of NMDAIglycine-evoked currents mediated by 1- 
3B NMDA receptors. (A) 
-100 mV, (B) -75 mV and (C) -50 mV. 
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A 
Compound Memantine PhTX-343 Methoctramine MK-801 
Mgt' P<0.001 P<0.001. P=0.010 P<0.001 
Memantine P<0.001 P=0.042 P<0.001 
PhTX-343 P<0.001 P<0.001 
Methoctramine P<0.001 
B 
Compound Memantine PhTX-343 Methoctramine MK-801 
Mg 2+ P=0.051 P=0.170 P<0.001 P<0.001 
Memantine P=0.992 P<0.001 P<0.001 
PhTX-343 P<0.001 P<0.001 
Methoctramine P<0.001 
C 
Compound Memantine PhTX-343 Methoctramine MK-801 
Mgt' P<0.001 P<0.001 P<0.001 P<0.001 
Memantine P<0.001 P<0.001 P<0.001 
PhTX-343 P<0.001 P<0.001 
Methoctramine P<0.001 
Table 27: Comparison of fits for block of NMDA/glycine-evoked currents mediated by 1- 
3AG703N MDA receptors. (A) 
-100 mV, (B) -75 mV and (C) -50 mV. 
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A 
Compound Memantine PhTX-343 Methoctramine MK-801 
Mgt` P=0.010 P<0.001 P=0.201 P<0.001 
Memantine P=0.002 P=0.156 P<0.001 
PhTX-343 P<0.001 P<0.001 
Methoctramine P<0.001 
B 
Compound Memantine PhTX-343 Methoctramine MK-801 
Mg 2+ P=0.022 P=0.045 P=0.084 P<0.001 
Memantine P=0.548 P=0.508 P<0.001 
PhTX-343 P=0.873 P<O. 001 
Methoctramine P<0.001 
C 
Compound Memantine PhTX-343 Methoctramine MK-801 
Mg 2+ P<0.001 P=0.781 P<0.001 P<0.001 
Memantine P<0.001 P=0.530 P<0.001 
PhTX-343 P<0.001 P<0.001 
Methoctramine P<0.001 
Table 28: Comparison of fits for block of NMDA/glycine-evoked currents mediated by 
3AR704N MDA receptors. (A) 
-100 mV, (B) -75 mV and (C) -50 mV. 
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A 
Compound Memantine PhTX-343 
Mgt' P<0.001 P<0.001 
Memantine P<O. 001 
C 
Compound Memanßne PhTX-343 
Mg 21 Pe0.001 P<O. 001 
Memantine P=0.197 
Compound Memantine PhTX-343 
Mgt' P<0.001 P<O. 001 
Memantine P<0.001 
Figure 96: Comparison of fits for block of NMDAlglycine-evoked currents mediated by 
34"m NMDA receptors. (A) 
-100 mV, (B) -75 mV and (C) -50 mV. 
Compound Ic lb le Memantine 
la P=0.882 P=0.076 P=0.433 P<0.001 
Ic P=0.004 P=0.123 P<0.001 
lb P=0.027 P<0.001 
le P<0.001 
Table 29: Comparison of fits for compound 1 block of NMDAlglycine-evoked currents 
mediated by 1-Ia/2ANMDA receptors at -100 mV 
B 
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A 
Compound Carbacrine(6) Carbacrine(4) Carbacrine(5) Memantine 
Carbacrine(3) P<0.001 P<0.001 P<0.001 P=0.773 
Carbacrine(6) P=0.043 P=0.549 P<0.001 
Carbacrine(4) P=0.255 P<0.001 
Carbacrine(5) P<0.001 
B 
Compound Carbacrine(6) Carbacrine(4) Carbacrine(5) Memantine 
Carbacrine(3) P<0.001 P<0.001 P<0.001 P=0.737 
Carbacrine(6) P=0.301 P=0.015 P<0.001 
Carbacrine(4) P=0.003 P<0.001 
Carbacrine(5) P<0.001 
C 
Compound Carbacrine(6) Carbacrine(4) Carbacrine(5) Memantine 
Carbacrine(3) P<0.001 P<0.001 P<0.001 P=0.485 
Carbacrine(6) P=0.346 P=0.871 P<0.001 
Carbacrine(4) P=0.293 P<0.001 
Carbacrine(5) P<0.001 
Figure 97: Comparison of fits for carbacrine block of NMDA/glycine-evoked currents 
mediated by 1-Ia/2ANMDA receptors. (A) at -100 mV, (B), -80 mV and (C) -50 mV. 
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A 
B 
C 
Compound 3b 3c 4 5 Memantine Dimebon 
3a P=0.526 P=0.189 P<0.001 P=0.275 P<0.001 P=0.772 
3b P=0.479 P<0.001 P=0.484 P<0.001 P=0.436 
3c P=0.001 P=0.737 P<0.001 P=0.200 
4 P=0.088 P<0.001 P<0.001 
5 P<0.001 P=0.298 
Memantne P<0.001 
Compound 3b 3c 4 5 Memantine Dimebon 
3a P=0.017 P=0.003 P<0.001 P=0.035 P<0.001 P=0.023 
3b P=0.290 P<0.001 P=0.549 P<0.001 P=0.232 
3c P=0.002 P=0.915 P<0.001 P=0.552 
4 P=0.033 P<0.001 P=0.258 
5 P<0.001 P=0.595 
Memantine P<0.001 
Compound 3b 3c 4 5 Memantine Dimebon 
3a P=0.004 P=0.037 P<0.001 P=0.245 P<0.001 P<0.001 
3b P=0.147 P=0.003 P=0.238 P<0.001 P<0.001 
3c P<0.001 P=0.793 P<0.001 P<0.001 
4 P=0.001 P<0.001 P<0.001 
5 P<0.001 P<O. 001 
Memandne P<0.001 
Figure 98: Comparison of fits for dimebon derived series. (A) at -100 mV, (B), -80 mV and (C) 
-50 mV. 
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